How many Durvalumab clinical trials are there?

732 Durvalumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 162 are actively recruiting participants. 189 are marked completed.

Are Durvalumab clinical trials recruiting in 2026?

Yes — 162 Durvalumab trials are actively recruiting in 2026, with 2298 U.S. sites across 49 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Durvalumab being studied for?

Durvalumab is being studied for Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Lung Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung and 1041 more. The trials are grouped by indication on this page.

What phase is Durvalumab in?

Durvalumab clinical trials span 5 Phase 4, 84 Phase 3, 397 Phase 2, 117 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Durvalumab clinical trials?

The lead sponsor across the most Durvalumab trials is AstraZeneca, with 303 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Durvalumab Clinical Trials (2026): 732 Studies for Hepatocellular Carcinoma & Non-small Cell Lung Cancer

Creator: Hipa.ai Research
Published: 2026-06-02T16:32:20.169Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

732 Durvalumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 363 indications (including Hepatocellular Carcinoma & Non-small Cell Lung Cancer) and 112,816 total planned enrollment. 84 Phase 3 Durvalumab trials and 397 Phase 2, 5 Phase 4 are listed. 185 Durvalumab clinical trials are actively recruiting at 2,298 U.S. sites across 49 states. Most recent activity: NCT05155189 (May 2041).

Where to Participate: All Durvalumab Trial Sites in the U.S. (2,298 sites across 49 states)

Every actively recruiting Durvalumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	The Kirklin Clinic at Acton Road	Birmingham35243	NCT05624996	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT04711824	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT01042379	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT06728410	Map
AL	University of Alabama at Birmingham Cancer Center	Birmingham35233	NCT05624996	Map
AL	University of Alabama at Birmingham Cancer Center	Birmingham35233	NCT06058377	Map
AL	Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis	Daphne36526	NCT05624996	Map
AL	Research Site	Daphne36526	NCT06103864	Map
AL	Southern Cancer Center	Daphne36526	NCT06773910	Map
AL	Southern Cancer Center Pc	Daphne36526	NCT07361497	Map
AL	Thomas Hospital	Fairhope36532	NCT05624996	Map
AL	Clearview Cancer Institute	Huntsville35805	NCT06890598	Map
AL	Mobile Infirmary Medical Center	Mobile36607	NCT05624996	Map
AL	Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland	Saraland36571	NCT05624996	Map
AZ	Pioneer Research Center, LLC	Bullhead City86442	NCT06463665	Map
AZ	Cancer and Blood Specialists of Arizona	Casa Grande85222	NCT07005128	Map
AZ	Research Site	Chandler85224	NCT05211895	Map
AZ	City of Hope Cancer Center Phoenix	Goodyear85338	NCT07005128	Map
AZ	CTCA at Western Regional Medical Center	Goodyear85338	NCT07288034	Map
AZ	Kingman Regional Medical Center	Kingman86401	NCT04628767	Map
AZ	Kingman Regional Medical Center	Kingman86401	NCT05624996	Map
AZ	Cancer Center at Saint Joseph's	Phoenix85004	NCT05624996	Map
AZ	Research Site	Scottsdale85259	NCT06467357	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT06058377	Map
AZ	The University of Arizona Cancer Center - North Campus	Tucson85719	NCT06890598	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT06058377	Map
AZ	University of Arizona Cancer Center-Orange Grove Campus	Tucson85704	NCT06058377	Map
AR	Mercy Hospital Fort Smith	Fort Smith72903	NCT06058377	Map
AR	NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro	Jonesboro72401	NCT05624996	Map
AR	NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro	Jonesboro72401	NCT06058377	Map
AR	NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro	Jonesboro72401	NCT06498635	Map
AR	Saint Bernards Medical Center	Jonesboro72401	NCT07005128	Map
AR	Research Site	Little Rock72205	NCT05061550	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT05624996	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT06058377	Map
AR	Highlands Oncology Group	Springdale72762	NCT06890598	Map
AR	Research Site	Springdale72762	NCT06103864	Map
CA	Sutter Auburn Faith Hospital	Auburn95602	NCT06058377	Map
CA	AIS Cancer Center at San Joaquin Community Hospital	Bakersfield93301	NCT05624996	Map
CA	AIS Cancer Center at San Joaquin Community Hospital	Bakersfield93301	NCT06058377	Map
CA	Alta Bates Summit Medical Center-Herrick Campus	Berkeley94704	NCT06058377	Map
CA	Alta Bates Summit Medical Center-Herrick Campus	Berkeley94704	NCT07166406	Map
CA	Beverly Hills Cancer Center	Beverly Hills90211	NCT05733598	Map
CA	Tower Cancer Research Foundation	Beverly Hills90211	NCT06058377	Map
CA	Tower Cancer Research Foundation	Beverly Hills90211	NCT06498635	Map
CA	Keck Medicine of USC Buena Park	Buena Park90621	NCT05198830	Map
CA	Mills-Peninsula Medical Center	Burlingame94010	NCT05624996	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Cameron Park	Cameron Park95682	NCT07166406	Map
CA	City of Hope Corona	Corona92882	NCT07288034	Map
CA	University of California - Davis, Comprehensive Cancer Center	Davis95817	NCT01042379	Map
CA	City of Hope	Duarte91010	NCT01042379	Map
CA	City of Hope	Duarte91010	NCT05136846	Map
CA	City of Hope /ID# 261468	Duarte91010	NCT06109272	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT04628767	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT05198830	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06058377	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06287775	Map
CA	City of Hope Medical Center	Duarte91010	NCT07288034	Map
CA	City of Hope(City of Hope National Medical Center, City of Hope Medical Center)	Duarte91010	NCT06282575	Map
CA	Research Site	Duarte91010	NCT07221253	Map
CA	Research Site	Fountain Valley92708	NCT05211895	Map
CA	Palo Alto Medical Foundation-Fremont	Fremont94538	NCT05624996	Map
CA	Palo Alto Medical Foundation-Fremont	Fremont94538	NCT06058377	Map
CA	Palo Alto Medical Foundation-Fremont	Fremont94538	NCT07166406	Map
CA	ClinRé 001-022 (Premier Cancer Care and Infusion Center)	Fresno93710	NCT07195695	Map
CA	Research Site	Fullerton92835	NCT06467357	Map
CA	OPN Healthcare, Inc.	Glendale91203	NCT07195695	Map
CA	Research Site	Glendale91204	NCT06103864	Map
CA	City of Hope Seacliff	Huntington Beach92648	NCT07288034	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT05198830	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT06058377	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT06287775	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT07288034	Map
CA	City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669	Irvine92618	NCT06109272	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT06050252	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT06058377	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT07166406	Map
CA	Research Site	La Jolla92093	NCT06467357	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT04628767	Map
CA	UC San Diego Moores Cancer Center	La Jolla92037	NCT05733598	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06287775	Map
CA	University of California San Diego	La Jolla92093-0698	NCT01042379	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT05198830	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT06058377	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT07288034	Map
CA	Loma Linda University Medical Center	Loma Linda92354	NCT06058377	Map
CA	Loma Linda University Medical Center	Loma Linda92354	NCT06769126	Map
CA	Veterans Affairs Loma Linda Healthcare System	Loma Linda92357	NCT06498635	Map
CA	City of Hope at Long Beach Elm	Long Beach90813	NCT06058377	Map
CA	City of Hope at Long Beach Elm	Long Beach90813	NCT07288034	Map
CA	Cancer and Blood Speciality Clinic - Los Alamitos	Los Alamitos90720	NCT06501625	Map
CA	Cedars Sinai	Los Angeles90048	NCT07489976	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06058377	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06498635	Map
CA	Los Angeles General Medical Center	Los Angeles90033	NCT05624996	Map
CA	Los Angeles General Medical Center	Los Angeles90033	NCT05198830	Map
CA	Research Site	Los Angeles90095	NCT05061550	Map
CA	Research Site	Los Angeles90017	NCT06467357	Map
CA	Research Site	Los Angeles90089	NCT06467357	Map
CA	The Angeles Clinic and Research Institute - West Los Angeles Office	Los Angeles90025	NCT06058377	Map
CA	Translational Research in Oncology US Inc, Trio Central Pharmacy	Los Angeles90095	NCT07005128	Map
CA	University of Southern California	Los Angeles90033	NCT01042379	Map
CA	USC / Norris Comprehensive Cancer Center	Los Angeles90033	NCT05624996	Map
CA	USC / Norris Comprehensive Cancer Center	Los Angeles90033	NCT05198830	Map
CA	Usc Norris Comprehensive Cancer Center	Los Angeles90033	NCT06501625	Map
CA	Fremont - Rideout Cancer Center	Marysville95901	NCT05624996	Map
CA	Memorial Medical Center	Modesto95355	NCT05624996	Map
CA	Memorial Medical Center	Modesto95355	NCT06058377	Map
CA	Palo Alto Medical Foundation-Camino Division	Mountain View94040	NCT05624996	Map
CA	Palo Alto Medical Foundation-Camino Division	Mountain View94040	NCT07166406	Map
CA	City of Hope at Newport Beach Fashion Island	Newport Beach92660	NCT07288034	Map
CA	City of Hope Newport Beach	Newport Beach92660	NCT06058377	Map
CA	HOAG Memorial Hospital Presbyterian	Newport Beach92663	NCT01042379	Map
CA	USC Norris Oncology/Hematology-Newport Beach	Newport Beach92663	NCT05198830	Map
CA	Profound Research LLC	Oceanside92056	NCT06890598	Map
CA	Chao Family Comprehensive Cancer Center, University	Orange92868	NCT05733689	Map
CA	Research Site	Orange92868	NCT04686305	Map
CA	Stern Center for Cancer Clinical Trials and Research	Orange92868	NCT04900818	Map
CA	UC Irvine /ID# 255673	Orange92868	NCT06109272	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT06050252	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT06058377	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT07166406	Map
CA	Desert Regional Medical Center	Palm Springs92262	NCT06058377	Map
CA	Palo Alto Medical Foundation Health Care	Palo Alto94301	NCT05624996	Map
CA	Palo Alto Medical Foundation Health Care	Palo Alto94301	NCT06058377	Map
CA	Palo Alto Medical Foundation Health Care	Palo Alto94301	NCT07166406	Map
CA	Stanford Cancer Center	Palo Alto94304	NCT06890598	Map
CA	Stanford Cancer Institute Palo Alto	Palo Alto94304	NCT04628767	Map
CA	Huntington Memorial Hospital	Pasadena91105	NCT06058377	Map
CA	Eisenhower Medical Center	Rancho Mirage92270	NCT06769126	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Roseville	Roseville95661	NCT05624996	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Roseville	Roseville95661	NCT07166406	Map
CA	Sutter Roseville Medical Center	Roseville95661	NCT05624996	Map
CA	Sutter Roseville Medical Center	Roseville95661	NCT06058377	Map
CA	Sutter Roseville Medical Center	Roseville95661	NCT07166406	Map
CA	Research Site	Sacramento95817	NCT06103864	Map
CA	Sutter Medical Center Sacramento	Sacramento95816	NCT05624996	Map
CA	Sutter Medical Center Sacramento	Sacramento95816	NCT06058377	Map
CA	Sutter Medical Center Sacramento	Sacramento95816	NCT07166406	Map
CA	SWOG	Sacramento95817	NCT06058377	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT05198830	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT06287775	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT06498635	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT06769126	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT07166406	Map
CA	Kaiser Permanente San Diego Mission Road	San Diego92108	NCT06890598	Map
CA	UC San Diego Medical Center - Hillcrest	San Diego92103	NCT04628767	Map
CA	University of California, San Diego	San Diego92093	NCT06710223	Map
CA	California Pacific Medical Center-Pacific Campus	San Francisco94115	NCT05624996	Map
CA	California Pacific Medical Center-Pacific Campus	San Francisco94115	NCT06058377	Map
CA	California Pacific Medical Center-Pacific Campus	San Francisco94115	NCT07166406	Map
CA	Research Site	San Francisco94143	NCT06467357	Map
CA	University of California San Francisco (UCSF)	San Francisco94115	NCT01042379	Map
CA	University of California, San Francisco	San Francisco94143	NCT04430452	Map
CA	Mills Health Center	San Mateo94401	NCT05624996	Map
CA	Mills Health Center	San Mateo94401	NCT06058377	Map
CA	Sansum Clinic	Santa Barbara93105	NCT06773910	Map
CA	Palo Alto Medical Foundation-Santa Cruz	Santa Cruz95065	NCT06058377	Map
CA	University of California Los Angeles	Santa Monica90404	NCT07005128	Map
CA	University of California Los Angeles	Santa Monica90404	NCT07195695	Map
CA	Providence Medical Foundation - Santa Rosa	Santa Rosa95403	NCT06058377	Map
CA	Providence Santa Rosa Memorial Hospital	Santa Rosa95405	NCT06058377	Map
CA	Research Site	Santa Rosa95403	NCT05211895	Map
CA	Sutter Pacific Medical Foundation	Santa Rosa95403	NCT05624996	Map
CA	Sutter Pacific Medical Foundation	Santa Rosa95403	NCT06058377	Map
CA	Sutter Pacific Medical Foundation	Santa Rosa95403	NCT07166406	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT05198830	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT06058377	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT07288034	Map
CA	GSK Investigational Site	Stanford94063	NCT06551142	Map
CA	Stanford University	Stanford94305	NCT04585477	Map
CA	Stanford University	Stanford94304	NCT04585490	Map
CA	Palo Alto Medical Foundation-Sunnyvale	Sunnyvale94086	NCT05624996	Map
CA	Palo Alto Medical Foundation-Sunnyvale	Sunnyvale94086	NCT06058377	Map
CA	Palo Alto Medical Foundation-Sunnyvale	Sunnyvale94086	NCT07166406	Map
CA	Cedars-Sinai Cancer - Tarzana	Tarzana91356	NCT06058377	Map
CA	City of Hope South Bay	Torrance90503	NCT06058377	Map
CA	City of Hope South Bay	Torrance90503	NCT07288034	Map
CA	Torrance Memorial Physician Network - Cancer Care	Torrance90505	NCT06058377	Map
CA	Torrance Memorial Physician Network - Cancer Care	Torrance90505	NCT06498635	Map
CA	City of Hope Upland	Upland91786	NCT05198830	Map
CA	City of Hope Upland	Upland91786	NCT06058377	Map
CA	City of Hope Upland	Upland91786	NCT07288034	Map
CA	Sutter Solano Medical Center/Cancer Center	Vallejo94589	NCT05624996	Map
CA	Sutter Solano Medical Center/Cancer Center	Vallejo94589	NCT06058377	Map
CA	BASS Cancer Center	Walnut Creek94598	NCT06890598	Map
CA	Presbyterian Intercommunity Hospital Health Whitter Hospital	Whittier90602	NCT07005128	Map
CA	UCI Health - Yorba Linda	Yorba Linda92886	NCT06058377	Map
CO	Research Site	Aurora80012	NCT06103864	Map
CO	UCHealth Cancer Care - Anschutz Medical Campus	Aurora80045	NCT04900818	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT04628767	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT05624996	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT03606967	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06050252	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06058377	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06769126	Map
CO	University of Colorado Anschutz Medical Campus ( Site 1110)	Aurora80045	NCT06780137	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT01042379	Map
CO	Memorial Hospital North	Colorado Springs80920	NCT05624996	Map
CO	Memorial Hospital North	Colorado Springs80920	NCT06769126	Map
CO	Rocky Mountain Cancer Centers-Penrose	Colorado Springs80907	NCT05624996	Map
CO	UCHealth Memorial Hospital Central	Colorado Springs80909	NCT05624996	Map
CO	UCHealth Memorial Hospital Central	Colorado Springs80909	NCT06769126	Map
CO	GSK Investigational Site	Denver80218	NCT06551142	Map
CO	Sarah Cannon Research Institute at HealthONE	Denver80218	NCT07174583	Map
CO	UCHealth - Cherry Creek	Denver80206	NCT04628767	Map
CO	UCHealth - Cherry Creek	Denver80206	NCT05624996	Map
CO	UCHealth - Cherry Creek	Denver80206	NCT06058377	Map
CO	Shaw Cancer Center	Edwards81632	NCT06058377	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT04628767	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT05624996	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT06058377	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT06769126	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT07166406	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT04628767	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT05624996	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT06058377	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT06769126	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT07166406	Map
CO	Lutheran Hospital - Cancer Centers of Colorado	Golden80401	NCT06769126	Map
CO	Colorado West Healthcare System dba Grand Valley Oncology	Grand Junction81505	NCT07005128	Map
CO	Saint Mary's Hospital and Regional Medical Center	Grand Junction81501	NCT06498635	Map
CO	Saint Mary's Hospital and Regional Medical Center	Grand Junction81501	NCT07166406	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT04628767	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT05624996	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT06058377	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT06769126	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT07166406	Map
CO	UCHealth Highlands Ranch Hospital	Highlands Ranch80129	NCT04628767	Map
CO	UCHealth Highlands Ranch Hospital	Highlands Ranch80129	NCT05624996	Map
CO	UCHealth Highlands Ranch Hospital	Highlands Ranch80129	NCT06058377	Map
CO	UCHealth Lone Tree Health Center	Lone Tree80124	NCT04628767	Map
CO	UCHealth Lone Tree Health Center	Lone Tree80124	NCT05624996	Map
CO	UCHealth Lone Tree Health Center	Lone Tree80124	NCT06058377	Map
CO	Medical Center of the Rockies	Loveland80538	NCT04628767	Map
CO	Medical Center of the Rockies	Loveland80538	NCT05624996	Map
CO	Medical Center of the Rockies	Loveland80538	NCT06058377	Map
CO	Medical Center of the Rockies	Loveland80538	NCT06769126	Map
CO	Medical Center of the Rockies	Loveland80538	NCT07166406	Map
CT	Hartford HealthCare - Avon	Avon06001	NCT06498635	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06050252	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06058377	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06769126	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT06769126	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT07166406	Map
CT	University of Connecticut Health Center	Farmington06030	NCT06667908	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06769126	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT07166406	Map
CT	Smilow Cancer Hospital-Hamden Care Center	Hamden06518	NCT07166406	Map
CT	Hartford Hospital	Hartford06102	NCT06498635	Map
CT	Hartford Hospital (HH)	Hartford06102	NCT06890598	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT07166406	Map
CT	Hartford HealthCare - Manchester	Manchester06042	NCT06498635	Map
CT	Midstate Medical Center	Meriden06451	NCT06498635	Map
CT	The Hospital of Central Connecticut	New Britain06050	NCT06498635	Map
CT	GSK Investigational Site	New Haven06511	NCT06551142	Map
CT	Research Site	New Haven06510	NCT05061550	Map
CT	Research Site	New Haven06510	NCT06103864	Map
CT	Smilow Cancer Center/Yale-New Haven Hospital	New Haven06510	NCT07166406	Map
CT	Yale Cancer Center	New Haven06510	NCT01042379	Map
CT	Yale New Haven Hospital	New Haven06510	NCT07005128	Map
CT	Yale University	New Haven06520	NCT06050252	Map
CT	Yale University	New Haven06520	NCT06058377	Map
CT	Yale University	New Haven06520	NCT06287775	Map
CT	Yale University	New Haven06519	NCT06667908	Map
CT	Yale University	New Haven06520	NCT06769126	Map
CT	Yale University	New Haven06520	NCT07166406	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06050252	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06058377	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06287775	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06769126	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT07166406	Map
CT	Eastern Connecticut Hematology and Oncology Associates	Norwich06360	NCT07005128	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT07166406	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT06050252	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT06058377	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT06769126	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06287775	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06769126	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT07166406	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT06050252	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT06058377	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT06769126	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT06050252	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT06058377	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT06769126	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT07166406	Map
DE	Beebe Medical Center	Lewes19958	NCT05624996	Map
DE	Beebe South Coastal Health Campus	Millville19967	NCT05624996	Map
DE	Beebe South Coastal Health Campus	Millville19967	NCT06058377	Map
DE	Beebe South Coastal Health Campus	Millville19967	NCT06498635	Map
DE	Christiana Care Health System-Christiana Hospital	Newark19718	NCT05624996	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT05624996	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT06058377	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT06498635	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT06769126	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT05624996	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT06058377	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT06498635	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT06769126	Map
DE	Medical Oncology Hematology Consultants, PA	Newark19713	NCT07361497	Map
DE	Beebe Health Campus	Rehoboth Beach19971	NCT05624996	Map
DE	Beebe Health Campus	Rehoboth Beach19971	NCT06058377	Map
DE	Beebe Health Campus	Rehoboth Beach19971	NCT06498635	Map
DE	Christiana Care Health System-Wilmington Hospital	Wilmington19801	NCT05624996	Map
DC	Georgetown Lombardi Comprehensive Cancer Center	Washington D.C.20007	NCT04499053	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT01042379	Map
DC	MedStar Georgetown University Hospital	Washington D.C.20007	NCT06287775	Map
DC	Medstar Washington Hospital Center	Washington D.C.20010	NCT04499053	Map
DC	MedStar Washington Hospital Center	Washington D.C.20010	NCT04628767	Map
DC	Research Site	Washington D.C.20016	NCT05211895	Map
DC	Sibley Memorial Hospital	Washington D.C.20016	NCT06058377	Map
FL	UM Sylvester Comprehensive Cancer Center at Aventura	Aventura33180	NCT03606967	Map
FL	Bay Pines VA Healthcare System	Bay Pines33744	NCT05624996	Map
FL	Boca Raton Regional Hospital	Boca Raton33486	NCT06890598	Map
FL	Schulze Family Foundation Cancer Clinic - Bonita Health Center	Bonita Springs34135	NCT06058377	Map
FL	Morton Plant Hospital	Clearwater33756	NCT05624996	Map
FL	Morton Plant Hospital	Clearwater33756	NCT06058377	Map
FL	Clermont Oncology Center	Clermont34711	NCT06463665	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT03606967	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT05198830	Map
FL	Oncology & Hematology Associates of West Broward	Coral Springs33065	NCT06463665	Map
FL	Halifax Health Medical Center-Centers for Oncology	Daytona Beach32114	NCT05624996	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT03606967	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT05198830	Map
FL	Helios Clinical Research	Fort Lauderdale33316	NCT06463665	Map
FL	Florida Cancer Specialists - South	Fort Myers33901	NCT06773910	Map
FL	Florida Cancer Specialists - South	Fort Myers33901	NCT06890598	Map
FL	Regional Cancer Center-Lee Memorial Health System	Fort Myers33905	NCT06058377	Map
FL	Research Site	Fort Myers33901	NCT06467357	Map
FL	UF Health Cancer Institute - Gainesville	Gainesville32610	NCT05198830	Map
FL	UF Health Cancer Institute - Gainesville	Gainesville32610	NCT06050252	Map
FL	UF Health Cancer Institute - Gainesville	Gainesville32610	NCT06287775	Map
FL	Bioresearch Partner	Hialeah33013	NCT06463665	Map
FL	Memorial Healthcare System	Hollywood33028	NCT04711824	Map
FL	Memorial Regional Hospital/Joe DiMaggio Children's Hospital	Hollywood33021	NCT05624996	Map
FL	Memorial Regional Hospital/Joe DiMaggio Children's Hospital	Hollywood33021	NCT06058377	Map
FL	Cancer Specialists of North Florida - Southpoint	Jacksonville32256	NCT07005128	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT05624996	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT06058663	Map
FL	Research Site	Jacksonville32224	NCT06467357	Map
FL	University of Florida - Jacksonville	Jacksonville32209	NCT06890598	Map
FL	Jupiter Medical Center	Jupiter33458	NCT05624996	Map
FL	Orlando Health Cancer Institute	Kissimmee34744	NCT07005128	Map
FL	Bioresearch Partner	Miami33155	NCT06463665	Map
FL	Miami Cancer Institute at Baptist Health, Inc.	Miami33176	NCT06890598	Map
FL	Research Site	Miami33176	NCT06103864	Map
FL	Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics)	Miami33136	NCT05733598	Map
FL	UM Sylvester Comprehensive Cancer Center at Kendall	Miami33176	NCT03606967	Map
FL	UM Sylvester Comprehensive Cancer Center at Kendall	Miami33176	NCT05198830	Map
FL	University of Miami	Miami33136	NCT06667908	Map
FL	University of Miami - Sylvester Comprehensive Cancer Center	Miami33136	NCT06463665	Map
FL	University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)	Miami33136	NCT06780137	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT03606967	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT05198830	Map
FL	Mount Sinai Medical Center	Miami Beach33140	NCT06058377	Map
FL	Ocala Oncology Center	Ocala34474	NCT06773910	Map
FL	Florida Cancer Specialists - North	Orange City32763	NCT06773910	Map
FL	Mid Florida Hematology and Oncology Center	Orange City32763	NCT06463665	Map
FL	Mid Florida Hematology and Oncology Center	Orange City32763	NCT07195695	Map
FL	AdventHealth Hematology and Oncology	Orlando32804	NCT06282575	Map
FL	Orlando Health Cancer Institute	Orlando32806	NCT05624996	Map
FL	Orlando Health Cancer Institute	Orlando32806	NCT06667908	Map
FL	Research Site	Orlando32804	NCT05211895	Map
FL	Cancer Care Centers of Brevard	Palm Bay32901	NCT06773910	Map
FL	Memorial Hospital West	Pembroke Pines33028	NCT05624996	Map
FL	Memorial Hospital West	Pembroke Pines33028	NCT06058377	Map
FL	BRCR Medical Center, Inc.	Plantation33322	NCT06463665	Map
FL	Research Site	Plantation33324	NCT06103864	Map
FL	UM Sylvester Comprehensive Cancer Center at Plantation	Plantation33324	NCT03606967	Map
FL	UM Sylvester Comprehensive Cancer Center at Plantation	Plantation33324	NCT05198830	Map
FL	Mease Countryside Hospital	Safety Harbor34695	NCT06058377	Map
FL	Research Site	Saint Augustine32086	NCT05211895	Map
FL	Comprehensive Hematology Oncology	St. Petersburg33709	NCT06890598	Map
FL	Florida Cancer Specialists North	St. Petersburg33701-4553	NCT06890598	Map
FL	Research Site	St. Petersburg33705	NCT06467357	Map
FL	St. Anthony's Hospital - BayCare Health System	St. Petersburg33705	NCT05742607	Map
FL	H. Lee Moffitt Cancer Center & Research Institute	Tampa33612	NCT05742607	Map
FL	H. Lee Moffitt Cancer Center and Research Institute	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05733598	Map
FL	Moffitt Cancer Center	Tampa33612	NCT03606967	Map
FL	Moffitt Cancer Center	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06503614	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06890598	Map
FL	Moffitt Cancer Center - McKinley Campus	Tampa33612	NCT03606967	Map
FL	Moffitt Cancer Center-International Plaza	Tampa33607	NCT03606967	Map
FL	Saint Joseph's Hospital/Children's Hospital-Tampa	Tampa33607	NCT05624996	Map
FL	Saint Joseph's Hospital/Children's Hospital-Tampa	Tampa33607	NCT06058377	Map
FL	Moffitt Cancer Center at Wesley Chapel	Wesley Chapel33544	NCT03606967	Map
FL	Florida Cancer Specialists - East	West Palm Beach33401	NCT06773910	Map
FL	Florida Cancer Specialists East	West Palm Beach33401	NCT06890598	Map
FL	Research Site	West Palm Beach33401	NCT06467357	Map
FL	Winter Haven Hospital	Winter Haven33881	NCT05624996	Map
FL	Winter Haven Hospital	Winter Haven33881	NCT06058377	Map
GA	Emory Proton Therapy Center	Atlanta30308	NCT05624996	Map
GA	Emory Proton Therapy Center	Atlanta30308	NCT07166406	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT04628767	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT05624996	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06050252	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06058377	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06287775	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06498635	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT07166406	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT07174570	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT04628767	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT05624996	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06050252	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06058377	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06287775	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06498635	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07166406	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07174570	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT04628767	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT05624996	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06050252	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06058377	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06287775	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06498635	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT07166406	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT07174570	Map
GA	Emory University Winship Cancer Institute	Atlanta30306	NCT06667908	Map
GA	Grady Health System	Atlanta30303	NCT05624996	Map
GA	Grady Health System	Atlanta30303	NCT06058377	Map
GA	Grady Health System	Atlanta30303	NCT07166406	Map
GA	Piedmont Cancer Institute	Atlanta30318	NCT07195695	Map
GA	Piedmont Healthcare - Atlanta	Atlanta30309	NCT06773910	Map
GA	Research Site	Atlanta30309	NCT06467357	Map
GA	Winship Cancer Institute	Atlanta30322	NCT06282575	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT01042379	Map
GA	Augusta University Medical Center	Augusta30912	NCT05624996	Map
GA	WellStar Cobb Hospital	Austell30106	NCT05624996	Map
GA	Hamilton Medical Center - Peeples Cancer Institute	Dalton30720	NCT05624996	Map
GA	Emory Decatur Hospital	Decatur30033	NCT04628767	Map
GA	Emory Decatur Hospital	Decatur30033	NCT06058377	Map
GA	Emory Decatur Hospital	Decatur30033	NCT06498635	Map
GA	Emory Johns Creek Hospital	Johns Creek30097	NCT06058377	Map
GA	Emory Johns Creek Hospital	Johns Creek30097	NCT06498635	Map
GA	Northwest Georgia Oncology Centers	Marietta30060	NCT07195695	Map
GA	Research Site	Marietta30060	NCT07221253	Map
GA	Wellstar Kennestone Hospital	Marietta30060	NCT05624996	Map
GA	City of Hope Atlanta	Newnan30265	NCT07005128	Map
GA	City of Hope Atlanta Cancer Center	Newnan30265	NCT07288034	Map
GA	CTCA at Southeastern Regional Medical Center	Newnan30265	NCT05624996	Map
GA	Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah31405	NCT05624996	Map
GA	Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah31405	NCT06058377	Map
GA	Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah31405	NCT06769126	Map
GA	Memorial Health University Medical Center	Savannah31404	NCT06058377	Map
HI	Hawaii Cancer Care - Westridge	‘Aiea96701	NCT05624996	Map
HI	Hawaii Cancer Care - Westridge	‘Aiea96701	NCT06498635	Map
HI	Pali Momi Medical Center	‘Aiea96701	NCT05624996	Map
HI	The Queen's Medical Center - West Oahu	‘Ewa Beach96706	NCT06498635	Map
HI	Hawaii Cancer Care Inc - Waterfront Plaza	Honolulu96813	NCT05624996	Map
HI	Hawaii Cancer Care Inc - Waterfront Plaza	Honolulu96813	NCT06498635	Map
HI	Kuakini Medical Center	Honolulu96817	NCT05624996	Map
HI	Queen's Cancer Cenrer - POB I	Honolulu96813	NCT05624996	Map
HI	Queen's Cancer Cenrer - POB I	Honolulu96813	NCT06498635	Map
HI	Queen's Cancer Center - Kuakini	Honolulu96817	NCT05624996	Map
HI	Queen's Cancer Center - Kuakini	Honolulu96817	NCT06498635	Map
HI	Queen's Medical Center	Honolulu96813	NCT05624996	Map
HI	Queen's Medical Center	Honolulu96813	NCT06498635	Map
HI	Straub Clinic and Hospital	Honolulu96813	NCT05624996	Map
HI	The Cancer Center of Hawaii-Liliha	Honolulu96817	NCT05624996	Map
HI	University of Hawaii Cancer Center	Honolulu96813	NCT05624996	Map
ID	Saint Alphonsus Cancer Care Center-Boise	Boise83706	NCT06058377	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT06058377	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT06498635	Map
ID	Saint Alphonsus Cancer Care Center-Caldwell	Caldwell83605	NCT06058377	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06058377	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06498635	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06769126	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT06058377	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT06498635	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT06058377	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT06498635	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT04628767	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT06058377	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT06498635	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT06769126	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT06058377	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT06498635	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06058377	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06498635	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06769126	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06058377	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06498635	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06769126	Map
IL	Illinois Cancer Specialists	Arlington Heights60005	NCT06773910	Map
IL	Advocate Outpatient Center - Aurora	Aurora60506	NCT05624996	Map
IL	Advocate Outpatient Center - Aurora	Aurora60506	NCT06058377	Map
IL	Rush-Copley Medical Center	Aurora60504	NCT05624996	Map
IL	Advocate Good Shepherd Hospital	Barrington60010	NCT04628767	Map
IL	Advocate Good Shepherd Hospital	Barrington60010	NCT05624996	Map
IL	Advocate Good Shepherd Hospital	Barrington60010	NCT06058377	Map
IL	Illinois CancerCare-Bloomington	Bloomington61704	NCT05624996	Map
IL	Illinois CancerCare-Bloomington	Bloomington61704	NCT06058377	Map
IL	OSF Saint Joseph Medical Center	Bloomington61701	NCT05624996	Map
IL	Illinois CancerCare-Canton	Canton61520	NCT05624996	Map
IL	Illinois CancerCare-Canton	Canton61520	NCT06058377	Map
IL	SIH Cancer Institute	Carterville62918	NCT04628767	Map
IL	SIH Cancer Institute	Carterville62918	NCT06058377	Map
IL	Illinois CancerCare-Carthage	Carthage62321	NCT05624996	Map
IL	Illinois CancerCare-Carthage	Carthage62321	NCT06058377	Map
IL	Centralia Oncology Clinic	Centralia62801	NCT05624996	Map
IL	Advocate Illinois Masonic Medical Center	Chicago60657	NCT04628767	Map
IL	Advocate Illinois Masonic Medical Center	Chicago60657	NCT05624996	Map
IL	Advocate Illinois Masonic Medical Center	Chicago60657	NCT06058377	Map
IL	Northwestern Medicine	Chicago60611	NCT06501625	Map
IL	Northwestern University	Chicago60611	NCT05624996	Map
IL	Northwestern University	Chicago60611	NCT06050252	Map
IL	Northwestern University	Chicago60611	NCT06058377	Map
IL	Northwestern University	Chicago60611	NCT06498635	Map
IL	Northwestern University	Chicago60611	NCT06769126	Map
IL	Research Site	Chicago60637	NCT05061550	Map
IL	Research Site	Chicago60637	NCT06103864	Map
IL	Research Site	Chicago60612	NCT06467357	Map
IL	The University of Chicago Medical Center	Chicago60637	NCT04918186	Map
IL	The University of Chicago Medical Center /ID# 255674	Chicago60637-1443	NCT06109272	Map
IL	University of Chicago	Chicago60453	NCT01042379	Map
IL	University of Chicago ( Site 1108)	Chicago60637	NCT06780137	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05198830	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT06287775	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT07166406	Map
IL	University of Chicago Medical Center	Chicago60637	NCT06890598	Map
IL	University of Chicago Medicine	Chicago60637	NCT05068232	Map
IL	University of Illinois	Chicago60612	NCT06058377	Map
IL	University of Illinois at Chicago	Chicago60612	NCT06890598	Map
IL	University of Illinois Chicago	Chicago60612	NCT07005128	Map
IL	University of Illinois Hospital and Health Sciences System	Chicago60612	NCT07195695	Map
IL	University of Illinois Medical Center	Chicago60612	NCT04699838	Map
IL	AMG Crystal Lake - Oncology	Crystal Lake60014	NCT04628767	Map
IL	AMG Crystal Lake - Oncology	Crystal Lake60014	NCT05624996	Map
IL	AMG Crystal Lake - Oncology	Crystal Lake60014	NCT06058377	Map
IL	Carle at The Riverfront	Danville61832	NCT04628767	Map
IL	Carle at The Riverfront	Danville61832	NCT05624996	Map
IL	Carle at The Riverfront	Danville61832	NCT06058377	Map
IL	Cancer Care Specialists of Illinois	Decatur62526	NCT07005128	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT04628767	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT05624996	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT06058377	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT05624996	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT06058377	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT05624996	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06058377	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06498635	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06769126	Map
IL	Illinois CancerCare-Dixon	Dixon61021	NCT06058377	Map
IL	Advocate Good Samaritan Hospital	Downers Grove60515	NCT04628767	Map
IL	Advocate Good Samaritan Hospital	Downers Grove60515	NCT05624996	Map
IL	Advocate Good Samaritan Hospital	Downers Grove60515	NCT06058377	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT04628767	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT05624996	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT06058377	Map
IL	Crossroads Cancer Center	Effingham62401	NCT04628767	Map
IL	Crossroads Cancer Center	Effingham62401	NCT05624996	Map
IL	Crossroads Cancer Center	Effingham62401	NCT06058377	Map
IL	Advocate Sherman Hospital	Elgin60123	NCT04628767	Map
IL	Advocate Sherman Hospital	Elgin60123	NCT05624996	Map
IL	Advocate Sherman Hospital	Elgin60123	NCT06058377	Map
IL	Illinois CancerCare-Eureka	Eureka61530	NCT05624996	Map
IL	Illinois CancerCare-Eureka	Eureka61530	NCT06058377	Map
IL	Illinois CancerCare-Galesburg	Galesburg61401	NCT05624996	Map
IL	Illinois CancerCare-Galesburg	Galesburg61401	NCT06058377	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT05624996	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06058377	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06498635	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06769126	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06058377	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06498635	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06769126	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06058377	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06498635	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06769126	Map
IL	Advocate South Suburban Hospital	Hazel Crest60429	NCT04628767	Map
IL	Advocate South Suburban Hospital	Hazel Crest60429	NCT05624996	Map
IL	Advocate South Suburban Hospital	Hazel Crest60429	NCT06058377	Map
IL	Northwestern Medicine Huntley Hospital	Huntley60142	NCT06498635	Map
IL	Illinois CancerCare-Kewanee Clinic	Kewanee61443	NCT05624996	Map
IL	Illinois CancerCare-Kewanee Clinic	Kewanee61443	NCT06058377	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06058377	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06498635	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06769126	Map
IL	AMG Libertyville - Oncology	Libertyville60048	NCT04628767	Map
IL	AMG Libertyville - Oncology	Libertyville60048	NCT05624996	Map
IL	AMG Libertyville - Oncology	Libertyville60048	NCT06058377	Map
IL	Condell Memorial Hospital	Libertyville60048	NCT05624996	Map
IL	Condell Memorial Hospital	Libertyville60048	NCT06058377	Map
IL	Illinois CancerCare-Macomb	Macomb61455	NCT05624996	Map
IL	Illinois CancerCare-Macomb	Macomb61455	NCT06058377	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT04628767	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT05624996	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT06058377	Map
IL	Loyola University	Maywood60153	NCT01042379	Map
IL	Loyola University Medical Center	Maywood60153	NCT06058377	Map
IL	Loyola University Medical Center	Maywood60153	NCT06498635	Map
IL	Loyola University Medical Center	Maywood60153	NCT06769126	Map
IL	Trinity Medical Center	Moline61265	NCT06058377	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT05198830	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT06287775	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT07166406	Map
IL	Research Site	Niles60714	NCT06467357	Map
IL	Carle BroMenn Medical Center	Normal61761	NCT06058377	Map
IL	Carle Cancer Institute Normal	Normal61761	NCT06058377	Map
IL	Captain James A. Lovell Federal Health Care Center	North Chicago60064	NCT06890598	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT04628767	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT05624996	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT06058377	Map
IL	HSHS Saint Elizabeth's Hospital	O'Fallon62269	NCT05624996	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT06058377	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT06498635	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT06769126	Map
IL	Advocate Christ Medical Center	Oak Lawn60453-2699	NCT04628767	Map
IL	Advocate Christ Medical Center	Oak Lawn60453-2699	NCT05624996	Map
IL	Advocate Christ Medical Center	Oak Lawn60453-2699	NCT06058377	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06058377	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06498635	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06769126	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT05198830	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT06287775	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT07166406	Map
IL	Illinois CancerCare-Ottawa Clinic	Ottawa61350	NCT05624996	Map
IL	Illinois CancerCare-Ottawa Clinic	Ottawa61350	NCT06058377	Map
IL	Advocate High Tech Medical Park	Palos Heights60463	NCT05624996	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT04628767	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT05624996	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT06058377	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT05624996	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT06058377	Map
IL	Illinois Cancer Care	Peoria61615	NCT06773910	Map
IL	Illinois Cancer Care	Peoria61615	NCT07361497	Map
IL	Illinois CancerCare-Peoria	Peoria61615	NCT05624996	Map
IL	Illinois CancerCare-Peoria	Peoria61615	NCT06058377	Map
IL	Methodist Medical Center of Illinois	Peoria61636	NCT05624996	Map
IL	OSF Saint Francis Medical Center	Peoria61637	NCT05624996	Map
IL	OSF Saint Francis Radiation Oncology at Peoria Cancer Center	Peoria61615	NCT05624996	Map
IL	Illinois CancerCare-Peru	Peru61354	NCT05624996	Map
IL	Illinois CancerCare-Peru	Peru61354	NCT06058377	Map
IL	Illinois CancerCare-Princeton	Princeton61356	NCT05624996	Map
IL	Illinois CancerCare-Princeton	Princeton61356	NCT06058377	Map
IL	Midwestern Regional Medical Center dba City of Hope Chicago	Rockford61108	NCT07005128	Map
IL	UW Health Carbone Cancer Center Rockford	Rockford61114	NCT05624996	Map
IL	UW Health Carbone Cancer Center Rockford	Rockford61114	NCT06058377	Map
IL	Memorial Hospital East	Shiloh62269	NCT06050252	Map
IL	Memorial Hospital East	Shiloh62269	NCT06058377	Map
IL	Memorial Hospital East	Shiloh62269	NCT07166406	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT04628767	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT05624996	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT06058377	Map
IL	Springfield Clinic	Springfield62702	NCT04628767	Map
IL	Springfield Clinic	Springfield62702	NCT05624996	Map
IL	Springfield Clinic	Springfield62702	NCT06058377	Map
IL	Springfield Clinic Main Campus	Springfield62703	NCT06890598	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT05624996	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT06058377	Map
IL	Carle Cancer Center	Urbana61801	NCT04628767	Map
IL	Carle Cancer Center	Urbana61801	NCT05624996	Map
IL	Carle Cancer Center	Urbana61801	NCT06058377	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT05624996	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06058377	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06498635	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06769126	Map
IL	Illinois CancerCare - Washington	Washington61571	NCT05624996	Map
IL	Illinois CancerCare - Washington	Washington61571	NCT06058377	Map
IL	City of Hope at Chicago	Zion60099	NCT07288034	Map
IL	Midwestern Regional Medical Center	Zion60099	NCT05624996	Map
IN	IU Health West Hospital	Avon46123	NCT06498635	Map
IN	IU Health North Hospital	Carmel46032	NCT06498635	Map
IN	Northwest Cancer Center - Main Campus	Crown Point46307	NCT05624996	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT05198830	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT06287775	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT07166406	Map
IN	Northwest Oncology LLC	Dyer46311	NCT05624996	Map
IN	Fort Wayne Medical Oncology and Hematology	Fort Wayne46804	NCT07361497	Map
IN	GSK Investigational Site	Fort Wayne46804	NCT06551142	Map
IN	Parkview Research Center at Parkview Regional Medical Center	Fort Wayne46845	NCT06890598	Map
IN	Northwest Cancer Center - Hobart	Hobart46342	NCT05624996	Map
IN	Northwest Cancer Center - Hobart	Hobart46342	NCT06058377	Map
IN	Saint Mary Medical Center	Hobart46342	NCT05624996	Map
IN	Franciscan Health	Indianapolis46237	NCT06890598	Map
IN	Hematology Oncology of Indiana	Indianapolis46260	NCT07005128	Map
IN	Indiana University Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT03317158	Map
IN	Indiana University Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT07005128	Map
IN	Indiana University Melvin and Bren Simon Comprehensive Cancer Center	Indianapolis46202	NCT04699838	Map
IN	Indiana University Melvin and Bren Simon Comprehensive Cancer Center	Indianapolis46202	NCT04711824	Map
IN	Indiana University Melvin and Bren Simon Comprehensive Cancer Center	Indianapolis46202	NCT05903092	Map
IN	Indiana University Simon Cancer Center	Indianapolis46202	NCT06773910	Map
IN	Indiana University/Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT06498635	Map
IN	Sidney and Lois Eskenazi Hospital	Indianapolis46202	NCT06498635	Map
IN	The Community Hospital	Munster46321	NCT05624996	Map
IN	Women's Diagnostic Center - Munster	Munster46321	NCT05624996	Map
IN	Northwest Cancer Center - Valparaiso	Valparaiso46383	NCT05624996	Map
IA	Mary Greeley Medical Center	Ames50010	NCT05624996	Map
IA	Mary Greeley Medical Center	Ames50010	NCT06498635	Map
IA	Mary Greeley Medical Center	Ames50010	NCT06769126	Map
IA	McFarland Clinic - Ames	Ames50010	NCT05624996	Map
IA	McFarland Clinic - Ames	Ames50010	NCT06498635	Map
IA	McFarland Clinic - Ames	Ames50010	NCT06769126	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT05624996	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT06058377	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT06498635	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT06769126	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT07166406	Map
IA	University of Iowa Healthcare Cancer Services Quad Cities	Bettendorf52722	NCT04628767	Map
IA	Saint Anthony Regional Hospital	Carroll51401	NCT06058377	Map
IA	Saint Anthony Regional Hospital	Carroll51401	NCT06498635	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT06058377	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT06769126	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT06058377	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT06769126	Map
IA	Saint Luke's Hospital	Cedar Rapids52402	NCT05624996	Map
IA	Mercy Cancer Center-West Lakes	Clive50325	NCT05624996	Map
IA	Mercy Cancer Center-West Lakes	Clive50325	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT05624996	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT06058377	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT06498635	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT06769126	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT07166406	Map
IA	Methodist Jennie Edmundson Hospital	Council Bluffs51503	NCT05624996	Map
IA	Greater Regional Medical Center	Creston50801	NCT05624996	Map
IA	Greater Regional Medical Center	Creston50801	NCT07166406	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT06058377	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT06498635	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT05624996	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT06058377	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT06498635	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT06769126	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT07166406	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT05624996	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT06058377	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT06498635	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT06769126	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT07166406	Map
IA	Research Site	Des Moines50309	NCT06103864	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT05624996	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT06058377	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT06498635	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT06769126	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT05624996	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT06058377	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT06498635	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT06769126	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT07166406	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT06498635	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT06769126	Map
IA	UI Healthcare Mission Cancer and Blood - Fort Dodge	Fort Dodge50501	NCT06058377	Map
IA	UI Healthcare Mission Cancer and Blood - Fort Dodge	Fort Dodge50501	NCT06498635	Map
IA	University of Iowa Hospitals and Clinics	Iowa City52242	NCT04699838	Map
IA	University of Iowa Hospitals and Clinics	Iowa City52242	NCT05903092	Map
IA	University of Iowa Hospitals and Clinics	Iowa City52242	NCT03317158	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT04628767	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT06498635	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT06769126	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT05624996	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT06058377	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT06498635	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT06769126	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT07166406	Map
IA	Mercy Medical Center-West Lakes	West Des Moines50266	NCT05624996	Map
IA	Mercy Medical Center-West Lakes	West Des Moines50266	NCT07166406	Map
IA	The Iowa Clinic PC	West Des Moines50266	NCT06769126	Map
IA	The Iowa Clinic PC	West Des Moines50266	NCT07166406	Map
KS	University of Kansas Clinical Research Center	Fairway66205	NCT06050252	Map
KS	University of Kansas Clinical Research Center	Fairway66205	NCT06287775	Map
KS	University of Kansas Clinical Research Center	Fairway66205	NCT06769126	Map
KS	HaysMed	Hays67601	NCT06058377	Map
KS	HaysMed	Hays67601	NCT06498635	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT05624996	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06050252	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06058377	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06287775	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06769126	Map
KS	Lawrence Memorial Hospital	Lawrence66044	NCT05624996	Map
KS	Lawrence Memorial Hospital	Lawrence66044	NCT06058377	Map
KS	Lawrence Memorial Hospital	Lawrence66044	NCT06498635	Map
KS	The University of Kansas Cancer Center - Olathe	Olathe66061	NCT05624996	Map
KS	The University of Kansas Cancer Center - Olathe	Olathe66061	NCT06058377	Map
KS	The University of Kansas Cancer Center - Olathe	Olathe66061	NCT06498635	Map
KS	The University of Kansas Cancer Center - Olathe	Olathe66061	NCT06769126	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT05624996	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT06050252	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT06058377	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT06769126	Map
KS	University of Kansas Hospital-Indian Creek Campus	Overland Park66211	NCT06058377	Map
KS	University of Kansas Hospital-Indian Creek Campus	Overland Park66211	NCT06287775	Map
KS	Salina Regional Health Center	Salina67401	NCT05624996	Map
KS	Salina Regional Health Center	Salina67401	NCT06058377	Map
KS	Salina Regional Health Center	Salina67401	NCT06498635	Map
KS	Salina Regional Health Center	Salina67401	NCT06769126	Map
KS	University of Kansas Health System Saint Francis Campus	Topeka66606	NCT05624996	Map
KS	University of Kansas Health System Saint Francis Campus	Topeka66606	NCT06058377	Map
KS	University of Kansas Health System Saint Francis Campus	Topeka66606	NCT06498635	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT05624996	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06050252	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06058377	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06287775	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06769126	Map
KS	Ascension Via Christi Hospitals Wichita	Wichita67214	NCT05624996	Map
KS	Cancer Center of Kansas, Heritage Plaza Medical Building	Wichita67214	NCT07005128	Map
KY	Baptist Health - Corbin	Corbin40701	NCT06773910	Map
KY	Baptist Health Corbin	Corbin40701	NCT06058377	Map
KY	Baptist Health Corbin	Corbin40701	NCT06769126	Map
KY	Baptist Health - Lexington	Lexington40503	NCT06773910	Map
KY	Baptist Health Hamburg	Lexington40509	NCT06769126	Map
KY	Baptist Health Hamburg	Lexington40509	NCT06890598	Map
KY	Baptist Health Lexington	Lexington40503	NCT06769126	Map
KY	Baptist Health Lexington	Lexington40503	NCT06890598	Map
KY	CHI Saint Joseph Cancer Center - East	Lexington40509	NCT06890598	Map
KY	Saint Joseph Hospital East	Lexington40509	NCT06058377	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT04628767	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT05624996	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT06058377	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT06287775	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT07166406	Map
KY	Baptist Health - Louisville	Louisville40207	NCT06773910	Map
KY	Norton Cancer Institute - Audubon	Louisville40217	NCT06282575	Map
KY	Norton Cancer Institute /ID# 260775	Louisville40217-1395	NCT06109272	Map
LA	Mary Bird Perkins Cancer Center	Baton Rouge70809	NCT04628767	Map
LA	Mary Bird Perkins Cancer Center	Baton Rouge70809	NCT06890598	Map
LA	Ochsner Health Ochsner Cancer Center - Baton Rouge	Baton Rouge70816	NCT06890598	Map
LA	Research Site	Baton Rouge70809	NCT06103864	Map
LA	East Jefferson General Hospital	Metairie70006	NCT04628767	Map
LA	LSU Healthcare Network / Metairie Multi-Specialty Clinic	Metairie70006	NCT04628767	Map
LA	Mary Bird Perkins Cancer Center - Metairie	Metairie70002	NCT04628767	Map
LA	Ochsner LSU Health Monroe Medical Center	Monroe71202	NCT06058377	Map
LA	Louisiana State University Health Science Center	New Orleans70112	NCT05624996	Map
LA	Ochsner Clinic Foundation	New Orleans70121	NCT06282575	Map
LA	Ochsner Clinic Foundation	New Orleans70121	NCT06890598	Map
LA	Ochsner Medical Center Jefferson	New Orleans70121	NCT06050252	Map
LA	Touro Infirmary	New Orleans70115	NCT05624996	Map
LA	University Medical Center New Orleans	New Orleans70112	NCT04628767	Map
LA	University Medical Center New Orleans	New Orleans70112	NCT05624996	Map
LA	University Medical Center New Orleans	New Orleans70112	NCT06058377	Map
LA	University Medical Center New Orleans	New Orleans70112	NCT06498635	Map
LA	LSU Health Sciences Center at Shreveport	Shreveport71103	NCT06058377	Map
ME	Harold Alfond Center for Cancer Care	Augusta04330	NCT04628767	Map
ME	Harold Alfond Center for Cancer Care	Augusta04330	NCT06498635	Map
ME	MaineHealth Maine Medical Center - Portland	Portland04102	NCT05624996	Map
ME	MaineHealth Cancer Care and IV Therapy - Sanford	Sanford04073	NCT04628767	Map
ME	MaineHealth Cancer Care Center of York County	Sanford04073	NCT04628767	Map
ME	MaineHealth Cancer Care Center of York County	Sanford04073	NCT05624996	Map
ME	MaineHealth Maine Medical Center- Scarborough	Scarborough04074	NCT04628767	Map
ME	MaineHealth Maine Medical Center- Scarborough	Scarborough04074	NCT05624996	Map
ME	MaineHealth Maine Medical Center- Scarborough	Scarborough04074	NCT06498635	Map
ME	MaineHealth Cancer Care and IV Therapy - South Portland	South Portland04106	NCT04628767	Map
ME	MaineHealth Cancer Care and IV Therapy - South Portland	South Portland04106	NCT05624996	Map
ME	MaineHealth Cancer Care and IV Therapy - South Portland	South Portland04106	NCT06498635	Map
ME	New England Cancer Specialists	Westbrook04092	NCT06890598	Map
ME	New England Cancer Specialists	Westbrook04092	NCT07005128	Map
MD	UM Upper Chesapeake Hematology and Oncology - Aberdeen	Aberdeen21001	NCT06058377	Map
MD	Greater Baltimore Medical Center	Baltimore21204	NCT05624996	Map
MD	Harry and Jeannette Weinberg Cancer Institute at Franklin Square	Baltimore21237	NCT04499053	Map
MD	Johns Hopkins	Baltimore21218	NCT07175441	Map
MD	Johns Hopkins SKCCC	Baltimore21231	NCT06027086	Map
MD	Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center	Baltimore21231	NCT03317158	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT04628767	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT03606967	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT06058377	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT06287775	Map
MD	Marlene and Stewart Greenebaum Comprehensive Cancer Center	Baltimore21201	NCT04499053	Map
MD	Maryland Proton Treatment Center	Baltimore21201	NCT06546969	Map
MD	Mercy Medical Center	Baltimore21202	NCT06058377	Map
MD	Research Site	Baltimore21224	NCT05211895	Map
MD	Research Site	Baltimore21287	NCT04686305	Map
MD	Research Site	Baltimore21287	NCT04379596	Map
MD	Research Site	Baltimore21231	NCT05061550	Map
MD	Sinai Hospital of Baltimore	Baltimore21215	NCT05624996	Map
MD	Sinai Hospital of Baltimore	Baltimore21215	NCT06058377	Map
MD	SKCCC Johns Hopkins Medical Institution	Baltimore21231	NCT06564623	Map
MD	University of Maryland	Baltimore21201	NCT04699838	Map
MD	University of Maryland	Baltimore21201	NCT06890598	Map
MD	University of Maryland Greenebaum Cancer Center	Baltimore21201	NCT06546969	Map
MD	University of Maryland Medical Center	Baltimore21201	NCT05733598	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT06050252	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT06058377	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT06287775	Map
MD	University of Maryland/Greenebaum Cancer Center	Baltimore21201	NCT06769126	Map
MD	UM Upper Chesapeake Medical Center	Bel Air21014	NCT06058377	Map
MD	National Cancer Institute Developmental Therapeutics Clinic	Bethesda20892	NCT03907475	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT06694454	Map
MD	Research Site	Columbia21044	NCT06103864	Map
MD	UPMC Western Maryland	Cumberland21502	NCT06058377	Map
MD	UPMC Western Maryland	Cumberland21502	NCT06498635	Map
MD	UM Baltimore Washington Medical Center/Tate Cancer Center	Glen Burnie21061	NCT06058377	Map
MD	TidalHealth Richard A Henson Cancer Institute	Ocean Pines21811	NCT05624996	Map
MD	TidalHealth Peninsula Regional	Salisbury21801	NCT05624996	Map
MD	Research Site	Towson21204	NCT06467357	Map
MD	William E Kahlert Regional Cancer Center/Sinai Hospital	Westminster21157	NCT05624996	Map
MD	William E Kahlert Regional Cancer Center/Sinai Hospital	Westminster21157	NCT06058377	Map
MA	Beverly Hospital	Beverly01915	NCT06058377	Map
MA	Beverly Hospital	Beverly01915	NCT06498635	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT05655949	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT05701488	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06667908	Map
MA	Brigham and Women's Hospital	Boston02215	NCT05795101	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05795101	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT07005128	Map
MA	Dana Farber Cancer Institute ( Site 1105)	Boston02215	NCT06780137	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05701488	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT07195695	Map
MA	GSK Investigational Site	Boston02114	NCT06551142	Map
MA	Mass General Hospital	Boston02114	NCT04900818	Map
MA	Research Site	Boston02215	NCT04379596	Map
MA	Research Site	Boston02215	NCT05061550	Map
MA	Tufts Medical Center	Boston02111	NCT06058377	Map
MA	Tufts Medical Center	Boston02111	NCT06769126	Map
MA	Lahey Hospital and Medical Center	Burlington01805	NCT06058377	Map
MA	Lahey Hospital and Medical Center	Burlington01805	NCT06498635	Map
MA	Lahey Hospital and Medical Center	Burlington01805	NCT06769126	Map
MA	Addison Gilbert Hospital	Gloucester01930	NCT06058377	Map
MA	Addison Gilbert Hospital	Gloucester01930	NCT06498635	Map
MA	Lahey Medical Center-Peabody	Peabody01960	NCT06058377	Map
MA	Lahey Medical Center-Peabody	Peabody01960	NCT06498635	Map
MA	Lahey Medical Center-Peabody	Peabody01960	NCT06769126	Map
MA	Baystate Medical Center	Springfield01199	NCT06498635	Map
MA	Reliant Medical Group	Worcester01606	NCT06890598	Map
MA	UMass Memorial Medical Center - University Campus	Worcester01655	NCT04628767	Map
MA	UMass Memorial Medical Center - University Campus	Worcester01655	NCT05624996	Map
MI	Research Site	Ann Arbor48106-0995	NCT05211895	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT04628767	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT05624996	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT06058377	Map
MI	University of Michigan Hospital	Ann Arbor48109	NCT06282575	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06058377	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06498635	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT06058377	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT06498635	Map
MI	McLaren Cancer Institute-Bay City	Bay City48706	NCT05624996	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT04628767	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT05624996	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06058377	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06498635	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06769126	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT04628767	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT05624996	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT06058377	Map
MI	University of Michigan - Brighton Center for Specialty Care	Brighton48116	NCT06058377	Map
MI	University of Michigan - Brighton Center for Specialty Care	Brighton48116	NCT06498635	Map
MI	Henry Ford Cancer Institute-Downriver	Brownstown48183	NCT05624996	—
MI	Henry Ford Cancer Institute-Downriver	Brownstown48183	NCT06058377	—
MI	Henry Ford Cancer Institute-Downriver	Brownstown48183	NCT07166406	—
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT04628767	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06058377	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06498635	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06769126	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT04628767	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT06058377	Map
MI	Chelsea Hospital	Chelsea48118	NCT04628767	Map
MI	Chelsea Hospital	Chelsea48118	NCT05624996	Map
MI	Chelsea Hospital	Chelsea48118	NCT06058377	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT04628767	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT05624996	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06058377	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06498635	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06769126	Map
MI	Hematology Oncology Consultants-Clarkston	Clarkston48346	NCT04628767	Map
MI	McLaren Cancer Institute-Clarkston	Clarkston48346	NCT05624996	Map
MI	Michigan Healthcare Professionals Clarkston	Clarkston48346	NCT05624996	Map
MI	Henry Ford Macomb Hospital-Clinton Township	Clinton Township48038	NCT05624996	Map
MI	Henry Ford Macomb Hospital-Clinton Township	Clinton Township48038	NCT06058377	Map
MI	Corewell Health Dearborn Hospital	Dearborn48124	NCT06058377	Map
MI	Henry Ford Medical Center-Fairlane	Dearborn48126	NCT05624996	Map
MI	Henry Ford Medical Center-Fairlane	Dearborn48126	NCT06058377	Map
MI	Henry Ford Medical Center-Fairlane	Dearborn48126	NCT07166406	Map
MI	Michigan Hematology and Oncology Consultants	Dearborn48126	NCT06463665	Map
MI	GSK Investigational Site	Detroit48201	NCT06551142	Map
MI	Henry Ford Cancer- Detroit	Detroit48202	NCT07339059	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT06058377	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT06498635	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT06769126	Map
MI	Henry Ford Health System	Detroit48202	NCT06282575	Map
MI	Henry Ford Hospital	Detroit48202	NCT05624996	Map
MI	Henry Ford Hospital	Detroit48202	NCT06058377	Map
MI	Henry Ford Hospital	Detroit48202	NCT06498635	Map
MI	Henry Ford Hospital	Detroit48202	NCT07166406	Map
MI	Henry Ford Hospital /ID# 255803	Detroit48202	NCT06109272	Map
MI	Karmanos Cancer Center (Wayne State University)	Detroit48201	NCT05903092	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06890598	Map
MI	Research Site	Detroit48201	NCT06103864	Map
MI	Wayne State University/Karmanos Cancer Institute	Detroit48201	NCT05624996	Map
MI	Wayne State University/Karmanos Cancer Institute	Detroit48201	NCT06058377	Map
MI	Henry Ford River District Hospital	East China Township48054	NCT06058377	—
MI	Henry Ford River District Hospital	East China Township48054	NCT06498635	—
MI	Henry Ford River District Hospital	East China Township48054	NCT06769126	—
MI	OSF Saint Francis Hospital and Medical Group	Escanaba49829	NCT06058377	Map
MI	OSF Saint Francis Hospital and Medical Group	Escanaba49829	NCT06498635	Map
MI	Corewell Health Farmington Hills Hospital	Farmington Hills48336	NCT05624996	Map
MI	Corewell Health Farmington Hills Hospital	Farmington Hills48336	NCT06058377	Map
MI	Michigan Healthcare Professionals Farmington	Farmington Hills48334	NCT05624996	Map
MI	Oakland Medical Group	Farmington Hills48336	NCT06463665	Map
MI	Weisberg Cancer Treatment Center	Farmington Hills48334	NCT05624996	Map
MI	Weisberg Cancer Treatment Center	Farmington Hills48334	NCT06058377	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT04628767	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT06058377	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT06498635	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT04628767	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT06058377	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT06498635	Map
MI	Hurley Medical Center	Flint48503	NCT04628767	Map
MI	Hurley Medical Center	Flint48503	NCT06058377	Map
MI	McLaren Cancer Institute-Flint	Flint48532	NCT05624996	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT06058377	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT06498635	Map
MI	Research Site	Grand Rapids49503	NCT06467357	Map
MI	The Cancer and Hematology Centers	Grand Rapids49546	NCT07174583	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT05624996	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT06058377	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT06498635	Map
MI	Henry Ford Saint John Hospital - Academic	Grosse Pointe Woods48236	NCT06498635	Map
MI	Henry Ford Saint John Hospital - Academic	Grosse Pointe Woods48236	NCT06769126	Map
MI	Henry Ford Saint John Hospital - Breast	Grosse Pointe Woods48236	NCT06498635	Map
MI	Henry Ford Saint John Hospital - Breast	Grosse Pointe Woods48236	NCT06769126	Map
MI	Henry Ford Saint John Hospital - Van Elslander	Grosse Pointe Woods48236	NCT06058377	Map
MI	Henry Ford Saint John Hospital - Van Elslander	Grosse Pointe Woods48236	NCT06498635	Map
MI	Henry Ford Saint John Hospital - Van Elslander	Grosse Pointe Woods48236	NCT06769126	Map
MI	Allegiance Health	Jackson49201	NCT05624996	Map
MI	Allegiance Health	Jackson49201	NCT06058377	Map
MI	Allegiance Health	Jackson49201	NCT07166406	Map
MI	Beacon Kalamazoo	Kalamazoo49048	NCT05624996	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT05624996	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT06058377	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT06498635	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT05624996	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT06058377	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT06498635	Map
MI	Herbert-Herman Cancer Center, Sparrow Hospital	Lansing48912	NCT01042379	Map
MI	Karmanos Cancer Institute at McLaren Greater Lansing	Lansing48910	NCT05624996	Map
MI	Karmanos Cancer Institute at McLaren Greater Lansing	Lansing48910	NCT06058377	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT05624996	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06058377	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06498635	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06769126	Map
MI	McLaren Cancer Institute-Lapeer Region	Lapeer48446	NCT05624996	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT04628767	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT05624996	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06058377	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06498635	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06769126	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT04628767	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT06058377	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT06498635	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT06769126	Map
MI	Henry Ford Warren Hospital - Breast Macomb	Macomb48044	NCT06498635	Map
MI	Henry Ford Warren Hospital - Breast Macomb	Macomb48044	NCT06769126	Map
MI	Michigan Healthcare Professionals Macomb	Macomb48044	NCT05624996	Map
MI	Michigan Healthcare Professionals Madison Heights	Madison Heights48071	NCT05624996	Map
MI	McLaren Cancer Institute-Macomb	Mount Clemens48043	NCT05624996	Map
MI	McLaren Cancer Institute-Central Michigan	Mount Pleasant48858	NCT05624996	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT06058377	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT06498635	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT06058377	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT06498635	Map
MI	Cancer and Hematology Centers of Western Michigan - Norton Shores	Norton Shores49444	NCT06058377	Map
MI	Cancer and Hematology Centers of Western Michigan - Norton Shores	Norton Shores49444	NCT06498635	Map
MI	Henry Ford Health Providence Novi Hospital	Novi48374	NCT06058377	Map
MI	Henry Ford Health Providence Novi Hospital	Novi48374	NCT06498635	Map
MI	Henry Ford Medical Center-Columbus	Novi48377	NCT05624996	Map
MI	Henry Ford Medical Center-Columbus	Novi48377	NCT06058377	Map
MI	Henry Ford Medical Center-Columbus	Novi48377	NCT07166406	Map
MI	McLaren Cancer Institute-Northern Michigan	Petoskey49770	NCT05624996	Map
MI	Michigan Healthcare Professionals Pontiac	Pontiac48341	NCT04628767	Map
MI	Michigan Healthcare Professionals Pontiac	Pontiac48341	NCT05624996	Map
MI	Newland Medical Associates-Pontiac	Pontiac48341	NCT04628767	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT04628767	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT05624996	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06058377	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06498635	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06769126	Map
MI	McLaren-Port Huron	Port Huron48060	NCT05624996	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT06058377	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT06498635	Map
MI	Corewell Health William Beaumont University Hospital	Royal Oak48073	NCT05624996	Map
MI	Corewell Health William Beaumont University Hospital	Royal Oak48073	NCT06058377	Map
MI	Corewell Health William Beaumont University Hospital	Royal Oak48073	NCT06498635	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT04628767	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT06058377	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT06058377	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT06498635	Map
MI	Corewell Health Lakeland Hospitals - Saint Joseph Hospital	Saint Joseph49085	NCT06058377	Map
MI	Corewell Health Lakeland Hospitals - Saint Joseph Hospital	Saint Joseph49085	NCT06498635	Map
MI	Henry Ford Health Providence Southfield Hospital	Southfield48075	NCT06058377	Map
MI	Henry Ford Health Providence Southfield Hospital	Southfield48075	NCT06498635	Map
MI	MyMichigan Medical Center Tawas	Tawas City48764	NCT04628767	Map
MI	MyMichigan Medical Center Tawas	Tawas City48764	NCT06058377	Map
MI	Munson Medical Center	Traverse City49684	NCT05624996	Map
MI	Munson Medical Center	Traverse City49684	NCT06058377	Map
MI	Munson Medical Center	Traverse City49684	NCT06498635	Map
MI	Corewell Health Beaumont Troy Hospital	Troy48085	NCT05624996	Map
MI	Corewell Health Beaumont Troy Hospital	Troy48085	NCT06058377	Map
MI	Corewell Health Beaumont Troy Hospital	Troy48085	NCT06498635	Map
MI	Michigan Healthcare Professionals Troy	Troy48098	NCT05624996	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT05624996	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT06058377	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT06498635	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT06769126	Map
MI	Henry Ford Madison Heights Hospital - Breast	Warren48093	NCT06498635	Map
MI	Henry Ford Madison Heights Hospital - Breast	Warren48093	NCT06769126	Map
MI	Henry Ford Warren Hospital - GLCMS	Warren48093	NCT06058377	Map
MI	Henry Ford Warren Hospital - GLCMS	Warren48093	NCT06498635	Map
MI	Henry Ford Warren Hospital - GLCMS	Warren48093	NCT06769126	Map
MI	Henry Ford West Bloomfield Hospital	West Bloomfield48322	NCT05624996	Map
MI	Henry Ford West Bloomfield Hospital	West Bloomfield48322	NCT06058377	Map
MI	Henry Ford West Bloomfield Hospital	West Bloomfield48322	NCT07166406	Map
MI	Henry Ford Wyandotte Hospital	Wyandotte48192	NCT06058377	Map
MI	Henry Ford Wyandotte Hospital	Wyandotte48192	NCT07166406	Map
MI	University of Michigan Health - West	Wyoming49519	NCT05624996	Map
MI	University of Michigan Health - West	Wyoming49519	NCT06058377	Map
MI	University of Michigan Health - West	Wyoming49519	NCT06498635	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT04628767	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT06058377	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT04628767	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT05624996	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06058377	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06498635	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06769126	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT05624996	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT06498635	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT06769126	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT05624996	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT06058377	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT06498635	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT06769126	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT07166406	Map
MN	MNCCTN Essentia Health St. Joseph's Brainerd Medical Center	Brainerd56401	NCT04105270	Map
MN	Minnesota Oncology - Burnsville	Burnsville55337	NCT06058377	Map
MN	Minnesota Oncology Hematology PA-Chaska	Chaska55318	NCT06058377	Map
MN	Mercy Hospital	Coon Rapids55433	NCT04628767	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06058377	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06498635	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06769126	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT05624996	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT06058377	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT06498635	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT06769126	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT07166406	Map
MN	MNCCTN Essentia Health Deer River	Deer River56636	NCT04105270	Map
MN	MNCCTN Essentia Health St. Mary's Detroit Lakes Clinic	Detroit Lakes56501	NCT04105270	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT05624996	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT06058377	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT06498635	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT06769126	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT07166406	Map
MN	Essentia Health Saint Mary's Medical Center	Duluth55805	NCT05624996	Map
MN	Essentia Health Saint Mary's Medical Center	Duluth55805	NCT07166406	Map
MN	Miller-Dwan Hospital	Duluth55805	NCT05624996	Map
MN	Miller-Dwan Hospital	Duluth55805	NCT07166406	Map
MN	MNCCTN Essentia Health Duluth	Duluth55805	NCT04105270	Map
MN	Saint Luke's Hospital of Duluth	Duluth55805	NCT06058377	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06058377	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06498635	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06769126	Map
MN	Minnesota Oncology Hematology PA	Edina55435	NCT07005128	Map
MN	MNCCTN Essentia Health Fosston	Fosston56542	NCT04105270	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT05624996	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT06058377	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT06498635	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT06769126	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT07166406	Map
MN	MNCCTN Essentia Health Hibbing Clinic	Hibbing55746	NCT04105270	Map
MN	Minnesota Oncology Hematology	Maple Grove55369	NCT06773910	Map
MN	Minnesota Oncology Hematology	Maple Grove55369	NCT07361497	Map
MN	Minnesota Oncology Hematology PA-Maplewood	Maplewood55109	NCT04628767	Map
MN	Saint John's Hospital - Healtheast	Maplewood55109	NCT06058377	Map
MN	Saint John's Hospital - Healtheast	Maplewood55109	NCT06769126	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06058377	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06498635	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06769126	Map
MN	Allina Health System dba Allina Health Cancer Institute	Minneapolis55407	NCT07005128	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT06058377	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT06769126	Map
MN	Masonic Cancer Center, University of Minnesota	Minneapolis55455	NCT04105270	Map
MN	Minneapolis VA Medical Center	Minneapolis55417	NCT06498635	Map
MN	Research Site	Minneapolis55407	NCT05211895	Map
MN	University of Minnesota	Minneapolis55455	NCT01042379	Map
MN	New Ulm Medical Center	New Ulm56073	NCT06769126	Map
MN	North Memorial Medical Health Center	Robbinsdale55422	NCT06058377	Map
MN	Mayo Clinic	Rochester55905	NCT01042379	Map
MN	Mayo Clinic	Rochester55905	NCT07005128	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT05388006	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT04628767	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT05624996	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT03942328	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06078709	Map
MN	Research Site	Rochester55905	NCT06467357	Map
MN	Coborn Cancer Center at Saint Cloud Hospital	Saint Cloud56303	NCT05624996	Map
MN	Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041	Saint Louis Park55416	NCT06109272	Map
MN	Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center	Saint Louis Park55416	NCT01042379	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT04628767	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06058377	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06498635	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06769126	Map
MN	Regions Hospital	Saint Paul55101	NCT04628767	Map
MN	Regions Hospital	Saint Paul55101	NCT06058377	Map
MN	Regions Hospital	Saint Paul55101	NCT06498635	Map
MN	Regions Hospital	Saint Paul55101	NCT06769126	Map
MN	Research Site	Saint Paul55109	NCT06103864	Map
MN	United Hospital	Saint Paul55102	NCT06058377	Map
MN	United Hospital	Saint Paul55102	NCT06498635	Map
MN	United Hospital	Saint Paul55102	NCT06769126	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT05624996	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT06058377	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT06498635	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT06769126	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT07166406	Map
MN	MNCCTN Essentia Health Sandstone	Sandstone550723	NCT04105270	Map
MN	Saint Francis Regional Medical Center	Shakopee55379	NCT06058377	Map
MN	Lakeview Hospital	Stillwater55082	NCT04628767	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT05624996	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT06058377	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT06498635	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT06769126	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT07166406	Map
MN	MNCCTN Essentia Health Virginia Clinic	Virginia55792	NCT04105270	Map
MN	Ridgeview Medical Center	Waconia55387	NCT06058377	Map
MN	Minnesota Oncology Hematology PA-Woodbury	Woodbury55125	NCT06058377	Map
MS	Baptist Memorial Hospital and Cancer Center-Golden Triangle	Columbus39705	NCT06058377	Map
MS	Baptist Memorial Hospital and Cancer Center-Golden Triangle	Columbus39705	NCT06498635	Map
MS	Baptist Cancer Center-Grenada	Grenada38901	NCT06058377	Map
MS	Baptist Cancer Center-Grenada	Grenada38901	NCT06498635	Map
MS	Baptist Memorial Hospital and Cancer Center-Union County	New Albany38652	NCT06058377	Map
MS	Baptist Memorial Hospital and Cancer Center-Union County	New Albany38652	NCT06498635	Map
MS	Baptist Memorial Hospital and Cancer Center-Oxford	Oxford38655	NCT06058377	Map
MS	Baptist Memorial Hospital and Cancer Center-Oxford	Oxford38655	NCT06498635	Map
MS	Baptist Memorial Hospital and Cancer Center-Desoto	Southhaven38671	NCT05624996	Map
MS	Baptist Memorial Hospital and Cancer Center-Desoto	Southhaven38671	NCT06058377	Map
MS	Baptist Memorial Hospital and Cancer Center-Desoto	Southhaven38671	NCT06498635	Map
MO	Mercy Oncology and Hematology - Clayton-Clarkson	Ballwin63011	NCT06058377	Map
MO	Mercy Oncology and Hematology - Clayton-Clarkson	Ballwin63011	NCT06498635	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT04628767	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT05624996	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT06058377	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT03606967	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06050252	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06058377	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT07166406	Map
MO	Missouri Cancer Associates	Columbia65201	NCT06773910	Map
MO	Missouri Cancer Associates	Columbia65201	NCT07361497	Map
MO	MU Health - University Hospital/Ellis Fischel Cancer Center	Columbia65212	NCT05624996	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT03606967	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06050252	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06058377	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT07166406	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT04628767	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT05624996	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT06058377	Map
MO	Freeman Health System	Joplin64804	NCT05624996	Map
MO	Research Site	Kansas City64132	NCT06467357	Map
MO	University Health Truman Medical Center	Kansas City64108	NCT06058377	Map
MO	University Health Truman Medical Center	Kansas City64108	NCT06498635	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT05624996	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT06050252	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT06058377	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT06769126	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT05624996	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT06050252	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT06058377	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT06769126	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT05624996	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT06050252	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT06058377	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT06769126	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT04628767	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT05624996	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT06058377	Map
MO	CoxHealth South Hospital	Springfield65807	NCT06058377	Map
MO	Mercy Hospital Springfield	Springfield65804	NCT05624996	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT04628767	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT05624996	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT06058377	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT06498635	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT06769126	Map
MO	Mercy Hospital South	St Louis63128	NCT04628767	Map
MO	Mercy Hospital South	St Louis63128	NCT05624996	Map
MO	Mercy Hospital South	St Louis63128	NCT06058377	Map
MO	Mercy Hospital South	St Louis63128	NCT06498635	Map
MO	Mercy Hospital South	St Louis63128	NCT06769126	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT04628767	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT05624996	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT06058377	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT06890598	Map
MO	Research Site	St Louis63129	NCT06103864	Map
MO	Research Site	St Louis63110	NCT06467357	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT03606967	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06050252	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06058377	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT07166406	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT03606967	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06050252	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06058377	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT07166406	Map
MO	Washington University School of Medicine	St Louis63110	NCT03317158	Map
MO	Washington University School of Medicine	St Louis63110	NCT03606967	Map
MO	Washington University School of Medicine	St Louis63110	NCT06050252	Map
MO	Washington University School of Medicine	St Louis63110	NCT06058377	Map
MO	Washington University School of Medicine	St Louis63110	NCT07107750	Map
MO	Washington University School of Medicine	St Louis63110	NCT07166406	Map
MO	Washington University-School of Medicine /ID# 255720	St Louis63110	NCT06109272	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT04628767	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT05624996	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT06058377	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT04628767	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT05624996	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT06058377	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06058377	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06498635	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06769126	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT05624996	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06058377	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06498635	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06769126	Map
MT	Saint Vincent Frontier Cancer Center	Billings59102	NCT06498635	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT05624996	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06058377	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06498635	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06769126	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT05624996	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06058377	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06498635	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06769126	Map
MT	Logan Health Medical Center	Kalispell59901	NCT06498635	Map
MT	Community Medical Center	Missoula59804	NCT06058377	Map
MT	Community Medical Center	Missoula59804	NCT06498635	Map
MT	Community Medical Center	Missoula59804	NCT06769126	Map
NE	Cancer Partners of Nebraska	Lincoln68516	NCT07005128	Map
NE	NHO Revive Research Institute LLC ( Site 0118)	Lincoln68506	NCT07554339	Map
NE	Nebraska Cancer Specialists	Omaha68130	NCT07005128	Map
NE	Nebraska Cancer Specialists/Oncology Hematology West PC - MECC	Omaha68114	NCT05624996	Map
NE	Nebraska Methodist Hospital	Omaha68114	NCT05624996	Map
NE	Research Site	Omaha68124	NCT05061550	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT03317158	Map
NV	OptumCare Cancer Care at Charleston	Las Vegas89102	NCT04628767	Map
NV	OptumCare Cancer Care at Fort Apache	Las Vegas89183	NCT04628767	Map
NV	Cancer Care Specialists	Reno89511	NCT07195695	Map
NV	Renown Regional Medical Center	Reno89502	NCT05624996	Map
NV	Renown Regional Medical Center	Reno89502	NCT06058377	Map
NV	Research Site	Reno89511	NCT05211895	Map
NH	Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center	Lebanon03756	NCT05624996	Map
NH	Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center	Lebanon03756	NCT06058377	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT05624996	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT06287775	Map
NJ	Cooper Hospital University Medical Center	Camden08103	NCT05624996	Map
NJ	Jefferson Cherry Hill Hospital	Cherry Hill08002	NCT05624996	Map
NJ	Jefferson Health - Cherry Hill	Cherry Hill08002	NCT06890598	Map
NJ	Research Site	East Brunswick08816	NCT05211895	Map
NJ	Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus	Elizabeth07207	NCT06058377	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103)	Hackensack07601	NCT06780137	Map
NJ	Hackettstown Medical Center	Hackettstown07840	NCT06058377	Map
NJ	The Cancer Institute of New Jersey Hamilton	Hamilton08690	NCT05624996	Map
NJ	The Cancer Institute of New Jersey Hamilton	Hamilton08690	NCT06058377	Map
NJ	Jersey City Medical Center	Jersey City07302	NCT05624996	Map
NJ	Jersey City Medical Center	Jersey City07302	NCT05198830	Map
NJ	Jersey City Medical Center	Jersey City07302	NCT06058377	Map
NJ	Monmouth Medical Center Southern Campus	Lakewood08701	NCT05624996	Map
NJ	Monmouth Medical Center Southern Campus	Lakewood08701	NCT06058377	Map
NJ	Saint Barnabas Medical Center	Livingston07039	NCT04628767	Map
NJ	Saint Barnabas Medical Center	Livingston07039	NCT05624996	Map
NJ	Saint Barnabas Medical Center	Livingston07039	NCT05198830	Map
NJ	Monmouth Medical Center	Long Branch07740	NCT05624996	Map
NJ	Monmouth Medical Center	Long Branch07740	NCT05198830	Map
NJ	Monmouth Medical Center	Long Branch07740	NCT06058377	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT05624996	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT06287775	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT05624996	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT06287775	Map
NJ	Morristown Medical Center	Morristown07960	NCT06058377	Map
NJ	Inspira Medical Center Mullica Hill	Mullica Hill08062	NCT06463665	Map
NJ	GSK Investigational Site	New Brunswick08903	NCT06551142	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT04628767	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT05624996	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT01042379	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT05198830	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT06058377	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT06503614	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06667908	Map
NJ	Newark Beth Israel Medical Center	Newark07112	NCT05198830	Map
NJ	Newark Beth Israel Medical Center	Newark07112	NCT06058377	Map
NJ	Rutgers New Jersey Medical School	Newark07101	NCT05624996	Map
NJ	Rutgers New Jersey Medical School	Newark07101	NCT06058377	Map
NJ	Newton Medical Center	Newton07860	NCT06058377	Map
NJ	Chilton Medical Center	Pompton07444	NCT06058377	Map
NJ	Sidney Kimmel Cancer Center - Washington Township	Sewell08080	NCT06890598	Map
NJ	Sidney Kimmel Cancer Center Washington Township	Sewell08080	NCT05624996	Map
NJ	Robert Wood Johnson University Hospital Somerset	Somerville08876	NCT05624996	Map
NJ	Robert Wood Johnson University Hospital Somerset	Somerville08876	NCT05198830	Map
NJ	Robert Wood Johnson University Hospital Somerset	Somerville08876	NCT06058377	Map
NJ	Overlook Hospital	Summit07902	NCT06058377	Map
NJ	Community Medical Center	Toms River08755	NCT04628767	Map
NJ	Community Medical Center	Toms River08755	NCT05624996	Map
NJ	Community Medical Center	Toms River08755	NCT05198830	Map
NJ	Community Medical Center	Toms River08755	NCT06058377	Map
NM	Presbyterian Kaseman Hospital	Albuquerque87110	NCT05624996	Map
NM	Research Site	Albuquerque87109	NCT06103864	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT04628767	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT05624996	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT06498635	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT07166406	Map
NM	Memorial Medical Center-Las Cruces	Las Cruces88011	NCT05624996	Map
NM	Presbyterian Rust Medical Center/Jorgensen Cancer Center	Rio Rancho87124	NCT05624996	Map
NM	Research Site	Santa Fe87505	NCT07221253	Map
NY	New York Oncology Hematology PC	Albany12206	NCT07005128	Map
NY	Northwell Health Imbert Cancer Center	Bay Shore11706	NCT05624996	Map
NY	NYU Langone Hospital - Brooklyn	Brooklyn11220	NCT06058377	Map
NY	Research Site	Buffalo14263	NCT05061550	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT01042379	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT06498635	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT06728410	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT06769126	Map
NY	Roswell Park Cancer Institute ( Site 1107)	Buffalo14263	NCT06780137	Map
NY	Roswell Park Comprehensive Cancer Center	Buffalo14236	NCT05733598	Map
NY	Sands Cancer Center	Canandiaqua14424	NCT05624996	—
NY	Memorial Sloan Kettering Commack	Commack11725	NCT05624996	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT06287775	Map
NY	The Cancer Institute at Saint Francis Hospital	East Hills11548	NCT06058377	Map
NY	Memorial Sloan Kettering Westchester	East White Plains10604	NCT05624996	Map
NY	Glens Falls Hospital	Glens Falls12801	NCT05624996	Map
NY	Glens Falls Hospital	Glens Falls12801	NCT06058377	Map
NY	Northwell Health Cancer Institute at Huntington	Greenlawn11740	NCT05624996	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT06287775	Map
NY	Northwell Health/Center for Advanced Medicine	Lake Success11042	NCT05624996	Map
NY	NYU Langone Hospital - Long Island	Mineola11501	NCT06058377	Map
NY	Northern Westchester Hospital	Mount Kisco10549	NCT06058377	Map
NY	Columbia University Irving Medical Center	New York10032	NCT03317158	Map
NY	Columbia University Irving Medical Center	New York10032	NCT06890598	Map
NY	Columbia University Medical Center	New York10032	NCT01042379	Map
NY	Columbia University Medical Center - Herbert Irving Pavilion	New York10032	NCT07174583	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06503614	Map
NY	Laura & Isaac Perlmutter Cancer Center at NYU Langone Health	New York10016	NCT07195695	Map
NY	Laura and Isaac Perlmutter Cancer Center / NYU Langone Health	New York10016	NCT01042379	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York10016	NCT06058377	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center	New York10016	NCT06282575	Map
NY	Lenox Hill Hospital	New York10075	NCT05624996	Map
NY	Lenox Hill Hospital	New York10075	NCT06058377	Map
NY	Manhattan Eye Ear and Throat Hospital	New York10065	NCT05624996	Map
NY	Manhattan Eye Ear and Throat Hospital	New York10065	NCT06058377	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04711824	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04900818	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05624996	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06287775	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06501625	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06667908	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06890598	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07361497	Map
NY	Memorial Sloan Kettering Cancer Centers	New York10022	NCT06282575	Map
NY	Memorial Sloan-Kettering Cancer Center	New York10065	NCT07195695	Map
NY	Mount Sinai Chelsea	New York10011	NCT06058377	Map
NY	Mount Sinai Hospital	New York10029	NCT06058377	Map
NY	Mount Sinai Hospital	New York10029	NCT07166406	Map
NY	Mount Sinai West	New York10019	NCT06058377	Map
NY	New York Proton Center	New York10035	NCT05624996	Map
NY	New York University Cancer Institute	New York10016	NCT07531095	Map
NY	NYP/Weill Cornell Medical Center	New York10065	NCT03606967	Map
NY	NYP/Weill Cornell Medical Center	New York10065	NCT06050252	Map
NY	NYU Langone	New York10016	NCT04900818	Map
NY	NYU Langone Health	New York10016	NCT06667908	Map
NY	Research Site	New York10065	NCT04379596	Map
NY	Research Site	New York10065	NCT06103864	Map
NY	Weill Cornell Medical Center	New York10065	NCT06503614	Map
NY	Upstate Cancer Center at Oswego	Oswego13126	NCT06058377	Map
NY	Highland Hospital	Rochester14620	NCT05624996	Map
NY	University of Rochester	Rochester14642	NCT05624996	Map
NY	University of Rochester	Rochester14642	NCT06769126	Map
NY	University of Rochester Wilmot Cancer Institute	Rochester14642	NCT01042379	Map
NY	Wilmot Cancer Institute Radiation Oncology at Greece	Rochester14606	NCT05624996	Map
NY	New York Cancer and Blood Specialists	Shirley11967	NCT07005128	Map
NY	Phelps Memorial Hospital Center	Sleepy Hollow10591	NCT06058377	Map
NY	The Philips Family Cancer Center	Southampton11968	NCT06058377	Map
NY	Staten Island University Hospital	Staten Island10305	NCT05624996	Map
NY	Staten Island University Hospital	Staten Island10305	NCT06058377	Map
NY	Research Site	Stony Brook11794-7263	NCT06103864	Map
NY	Stony Brook University Medical Center	Stony Brook11794	NCT05624996	Map
NY	Stony Brook University Medical Center	Stony Brook11794	NCT06058377	Map
NY	State University of New York Upstate Medical University	Syracuse13210	NCT05624996	Map
NY	State University of New York Upstate Medical University	Syracuse13210	NCT06058377	Map
NY	SUNY Upstate Medical Center-Community Campus	Syracuse13215	NCT06058377	Map
NY	James J Peters VA Medical Center	The Bronx10468	NCT06498635	Map
NY	Montefiore Medical Center	The Bronx10467	NCT01042379	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT05624996	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT06498635	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT07166406	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT05624996	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT06498635	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT07166406	Map
NY	Montefiore Medical Center-Weiler Hospital	The Bronx10461	NCT05624996	Map
NY	Montefiore Medical Center-Weiler Hospital	The Bronx10461	NCT06498635	Map
NY	Montefiore Medical CenterMontefiore Medical Park	The Bronx10461	NCT05733598	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT05624996	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT06287775	Map
NY	Westchester Medical Center	Valhalla10595	NCT05624996	Map
NY	Upstate Cancer Center at Verona	Verona13478	NCT06058377	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT05624996	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT06769126	Map
NY	Dickstein Cancer Treatment Center	White Plains10601	NCT06058377	Map
NY	Research Site	White Plains10601	NCT06467357	Map
NY	White Plains Hospital Physician Associates	White Plains10601	NCT06773910	Map
NC	Atrium Health Stanly/LCI-Albemarle	Albemarle28002	NCT05624996	Map
NC	Duke Cancer Center Cary	Cary27518	NCT05624996	Map
NC	Duke Cancer Center Cary	Cary27518	NCT06498635	Map
NC	UNC Health Cancer Care Cary	Cary27518	NCT06058377	Map
NC	UNC Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT05624996	Map
NC	UNC Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT06058377	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27899	NCT04711824	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27514	NCT06667908	Map
NC	Atrium Health Pineville/LCI-Pineville	Charlotte28210	NCT05624996	Map
NC	Atrium Health University City/LCI-University	Charlotte28262	NCT05624996	Map
NC	Carolinas Medical Center/Levine Cancer Institute	Charlotte28203	NCT05624996	Map
NC	Carolinas Medical Center/Levine Cancer Institute	Charlotte28203	NCT06287775	Map
NC	Levine Cancer Institute-Ballantyne	Charlotte28277	NCT05624996	Map
NC	Novant Health Presbyterian Medical Center	Charlotte28204	NCT05624996	Map
NC	Wake Forest University at Clemmons	Clemmons27012	NCT05624996	Map
NC	Wake Forest University at Clemmons	Clemmons27012	NCT03606967	Map
NC	Southeastern Medical Oncology Center-Clinton	Clinton28328	NCT04628767	Map
NC	Southeastern Medical Oncology Center-Clinton	Clinton28328	NCT06058377	Map
NC	Atrium Health Cabarrus/LCI-Concord	Concord28025	NCT05624996	Map
NC	Atrium Health Cabarrus/LCI-Concord	Concord28025	NCT06287775	Map
NC	Duke Cancer Institute	Durham27710	NCT04711824	Map
NC	Duke University	Durham27708	NCT06501625	Map
NC	Duke University Medical Center	Durham27710	NCT05624996	Map
NC	Duke University Medical Center	Durham27710	NCT06498635	Map
NC	Levine Cancer Institute - Rutherford	Forest City28043	NCT05624996	Map
NC	UNC Health Cancer Care Garner	Garner27529	NCT06058377	Map
NC	CaroMont Regional Medical Center	Gastonia28054	NCT05624996	Map
NC	Southeastern Medical Oncology Center-Goldsboro	Goldsboro27534	NCT04628767	Map
NC	Southeastern Medical Oncology Center-Goldsboro	Goldsboro27534	NCT06058377	Map
NC	Novant Health Breast Surgery - Greensboro	Greensboro27403	NCT05624996	Map
NC	Hayworth Cancer Center	High Point27262	NCT05624996	Map
NC	Novant Health Cancer Institute - Huntersville	Huntersville28078	NCT05624996	Map
NC	Novant Health Presbyterian Medical Center Huntersville	Huntersville28078	NCT05624996	Map
NC	Southeastern Medical Oncology Center-Jacksonville	Jacksonville28546	NCT04628767	Map
NC	Southeastern Medical Oncology Center-Jacksonville	Jacksonville28546	NCT06058377	Map
NC	Novant Health Cancer Institute - Kernersville	Kernersville27284	NCT05624996	Map
NC	Levine Cancer Institute - Union West	Matthews28104	NCT05624996	Map
NC	Matthews Radiation Oncology Center	Matthews28105	NCT05624996	Map
NC	Novant Health Cancer Institute - Matthews	Matthews28105	NCT05624996	Map
NC	Atrium Health Union/LCI-Union	Monroe28112	NCT05624996	Map
NC	Novant Health Cancer Institute - Mooresville	Mooresville28117	NCT05624996	Map
NC	Novant Health Cancer Institute - Mount Airy	Mount Airy27030	NCT05624996	Map
NC	Novant Health Cancer Institute - Wilkesboro	North Wilkesboro28659	NCT05624996	Map
NC	FirstHealth of the Carolinas	Pinehurst28374	NCT06667908	Map
NC	FirstHealth of the Carolinas-Moore Regional Hospital	Pinehurst28374	NCT06498635	Map
NC	FirstHealth of the Carolinas-Moore Regional Hospital	Pinehurst28374	NCT06769126	Map
NC	Duke Cancer Center Raleigh	Raleigh27609	NCT05624996	Map
NC	Duke Cancer Center Raleigh	Raleigh27609	NCT06498635	Map
NC	UNC Health Cancer Care Raleigh	Raleigh27607	NCT06058377	Map
NC	UNC Health Cancer Care Wakefield	Raleigh27614	NCT06058377	Map
NC	Novant Health Cancer Institute - Rowan	Salisbury28144	NCT05624996	Map
NC	Rowan Regional Medical Center	Salisbury28144	NCT05624996	Map
NC	Atrium Health Cleveland/LCI-Cleveland	Shelby28150	NCT05624996	Map
NC	Wake Forest Baptist Health - Hematology Oncology - Statesville	Statesville28677	NCT05624996	Map
NC	Novant Health Cancer Institute - Statesville	Stateville28625	NCT05624996	—
NC	Novant Cancer Institute Radiation Oncology - Supply	Supply28462	NCT05624996	Map
NC	Novant Health Cancer Institute - Thomasville	Thomasville27360	NCT05624996	Map
NC	Wake Forest Baptist Health - Wilkes Medical Center	Wilkesboro28659	NCT05624996	Map
NC	Novant Health Cancer Institute Radiation Oncology - Wilmington	Wilmington28401	NCT05624996	Map
NC	Novant Health New Hanover Regional Medical Center	Wilmington28401	NCT05624996	Map
NC	Carolina Cancer Research Center	Wilson27896	NCT06773910	Map
NC	Novant Health Forsyth Medical Center	Winston-Salem27103	NCT05624996	Map
NC	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT05696782	Map
NC	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT01042379	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05624996	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT03606967	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05198830	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT06050252	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT06287775	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT05624996	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT06498635	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT06769126	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT06058377	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT06498635	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT06769126	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT05624996	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT06498635	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT06769126	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT05624996	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT06498635	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT06769126	Map
ND	Altru Cancer Center	Grand Forks58201	NCT05624996	Map
OH	Cleveland Clinic Akron General	Akron44307	NCT05624996	Map
OH	UH Seidman Cancer Center at UH Avon Health Center	Avon44011	NCT05624996	Map
OH	UHHS-Chagrin Highlands Medical Center	Beachwood44122	NCT05624996	Map
OH	Aultman Health Foundation	Canton44710	NCT05624996	Map
OH	Aultman Health Foundation	Canton44710	NCT06498635	Map
OH	Aultman Health Foundation	Canton44710	NCT06769126	Map
OH	Cleveland Clinic Mercy Hospital	Canton44708	NCT05624996	Map
OH	Gabrail Cancer and Research Center	Canton44718	NCT06463665	Map
OH	Miami Valley Hospital South	Centerville45459	NCT04628767	Map
OH	Miami Valley Hospital South	Centerville45459	NCT05624996	Map
OH	Miami Valley Hospital South	Centerville45459	NCT06058377	Map
OH	Miami Valley Hospital South	Centerville45459	NCT06498635	Map
OH	Miami Valley Hospital South	Centerville45459	NCT06769126	Map
OH	Oncology Hematology Care	Cincinnati45242	NCT06773910	Map
OH	Oncology Hematology Care, Inc	Cincinnati45242	NCT07005128	Map
OH	Research Site	Cincinnati45219	NCT06103864	Map
OH	Research Site	Cincinnati45245	NCT06103864	Map
OH	University of Cincinnati Cancer Center-UC Medical Center	Cincinnati45219	NCT06050252	Map
OH	Case Western Reserve University	Cleveland44106	NCT05624996	Map
OH	Case Western Reserve University	Cleveland44106	NCT05198830	Map
OH	Case Western Reserve University	Cleveland44106	NCT06287775	Map
OH	Cleveland Clinic	Cleveland44195	NCT04711824	Map
OH	Cleveland Clinic	Cleveland44106	NCT01042379	Map
OH	Cleveland Clinic	Cleveland44195	NCT06890598	Map
OH	Cleveland Clinic Taussig Cancer Center	Cleveland44195	NCT06263153	Map
OH	MetroHealth Medical Center	Cleveland44109	NCT05198830	Map
OH	MetroHealth Medical Center	Cleveland44109	NCT06058377	Map
OH	Research Site	Cleveland44195	NCT05061550	Map
OH	Research Site	Cleveland44195	NCT06103864	Map
OH	Research Site	Cleveland44195	NCT06467357	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT06667908	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT07005128	Map
OH	Columbus Oncology and Hematology Associates Inc	Columbus43214	NCT06058377	Map
OH	Doctors Hospital	Columbus43228	NCT05624996	Map
OH	Doctors Hospital	Columbus43228	NCT06058377	Map
OH	Grant Medical Center	Columbus43215	NCT05624996	Map
OH	Grant Medical Center	Columbus43215	NCT06058377	Map
OH	Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center	Columbus43219	NCT06773910	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT04699838	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT03606967	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05136846	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06050252	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06058377	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06263153	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06287775	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06498635	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT07166406	Map
OH	Research Site	Columbus43214	NCT05211895	Map
OH	Research Site	Columbus43210	NCT06467357	Map
OH	Riverside Methodist Hospital	Columbus43214	NCT05624996	Map
OH	Riverside Methodist Hospital	Columbus43214	NCT06058377	Map
OH	The Ohio State University, Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT01042379	Map
OH	Miami Valley Hospital	Dayton45409	NCT04628767	Map
OH	Miami Valley Hospital	Dayton45409	NCT05624996	Map
OH	Miami Valley Hospital	Dayton45409	NCT06058377	Map
OH	Miami Valley Hospital	Dayton45409	NCT06498635	Map
OH	Miami Valley Hospital	Dayton45409	NCT06769126	Map
OH	Miami Valley Hospital North	Dayton45415	NCT04628767	Map
OH	Miami Valley Hospital North	Dayton45415	NCT05624996	Map
OH	Miami Valley Hospital North	Dayton45415	NCT06058377	Map
OH	Miami Valley Hospital North	Dayton45415	NCT06498635	Map
OH	Miami Valley Hospital North	Dayton45415	NCT06769126	Map
OH	Premier Blood and Cancer Center	Dayton45409	NCT04628767	Map
OH	Premier Blood and Cancer Center	Dayton45409	NCT05624996	Map
OH	Premier Blood and Cancer Center	Dayton45409	NCT06058377	Map
OH	Premier Blood and Cancer Center	Dayton45409	NCT06769126	Map
OH	Delaware Health Center-Grady Cancer Center	Delaware43015	NCT05624996	Map
OH	Delaware Health Center-Grady Cancer Center	Delaware43015	NCT06058377	Map
OH	Grady Memorial Hospital	Delaware43015	NCT05624996	Map
OH	Grady Memorial Hospital	Delaware43015	NCT06058377	Map
OH	Columbus Oncology and Hematology Associates	Dublin43016	NCT06058377	Map
OH	Dublin Methodist Hospital	Dublin43016	NCT05624996	Map
OH	Dublin Methodist Hospital	Dublin43016	NCT06058377	Map
OH	Atrium Medical Center-Middletown Regional Hospital	Franklin45005-1066	NCT04628767	Map
OH	Atrium Medical Center-Middletown Regional Hospital	Franklin45005-1066	NCT05624996	Map
OH	Atrium Medical Center-Middletown Regional Hospital	Franklin45005-1066	NCT06058377	Map
OH	Atrium Medical Center-Middletown Regional Hospital	Franklin45005-1066	NCT06498635	Map
OH	Atrium Medical Center-Middletown Regional Hospital	Franklin45005-1066	NCT06769126	Map
OH	Miami Valley Cancer Care and Infusion	Greenville45331	NCT04628767	Map
OH	Miami Valley Cancer Care and Infusion	Greenville45331	NCT05624996	Map
OH	Miami Valley Cancer Care and Infusion	Greenville45331	NCT06058377	Map
OH	Miami Valley Cancer Care and Infusion	Greenville45331	NCT06498635	Map
OH	Miami Valley Cancer Care and Infusion	Greenville45331	NCT06769126	Map
OH	OhioHealth Mansfield Hospital	Mansfield44903	NCT05624996	Map
OH	OhioHealth Mansfield Hospital	Mansfield44903	NCT06058377	Map
OH	OhioHealth Marion General Hospital	Marion43302	NCT05624996	Map
OH	OhioHealth Marion General Hospital	Marion43302	NCT06058377	Map
OH	Research Site	Maumee43537	NCT05211895	Map
OH	UH Seidman Cancer Center at Lake Health Mentor Campus	Mentor44060	NCT05624996	Map
OH	Mercy Health - Perrysburg Hospital	Perrysburg43551	NCT05624996	Map
OH	OhioHealth Pickerington Methodist Hospital	Pickerington43147	NCT06058377	Map
OH	ProMedica Flower Hospital	Sylvania43560	NCT04628767	Map
OH	ProMedica Flower Hospital	Sylvania43560	NCT06058377	Map
OH	Upper Valley Medical Center	Troy45373	NCT04628767	Map
OH	Upper Valley Medical Center	Troy45373	NCT05624996	Map
OH	Upper Valley Medical Center	Troy45373	NCT06058377	Map
OH	Upper Valley Medical Center	Troy45373	NCT06498635	Map
OH	Upper Valley Medical Center	Troy45373	NCT06769126	Map
OH	University of Cincinnati Cancer Center-West Chester	West Chester45069	NCT06050252	Map
OH	OhioHealth Westerville Medical Campus/Westerville Cancer Center	Westerville43082	NCT06058377	Map
OK	Cancer Centers of Southwest Oklahoma Research	Lawton73505	NCT04628767	Map
OK	Mercy Hospital Oklahoma City	Oklahoma City73120	NCT06058377	Map
OK	Research Site	Oklahoma City73102	NCT05211895	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT04628767	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05624996	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06050252	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06058377	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06498635	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06769126	Map
OR	Saint Charles Health System	Bend97701	NCT06058377	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT07166406	Map
OR	Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center)	Eugene97401	NCT06773910	Map
OR	Oncology Associates Of Oregon, Pc	Eugene97401	NCT07361497	Map
OR	Willamette Valley Cancer Institute and Research Center - Eugene	Eugene97401	NCT07005128	Map
OR	Legacy Mount Hood Medical Center	Gresham97030	NCT05624996	Map
OR	Legacy Mount Hood Medical Center	Gresham97030	NCT06058377	Map
OR	Northwest Cancer Specialists, P.C.	Happy Valley97015	NCT07361497	Map
OR	Providence Hood River Memorial Hospital	Hood River97031	NCT06058377	Map
OR	Providence Hood River Memorial Hospital	Hood River97031	NCT06498635	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06058377	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06498635	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06769126	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT07166406	Map
OR	Saint Alphonsus Cancer Care Center-Ontario	Ontario97914	NCT06058377	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06058377	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06498635	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06769126	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT07166406	Map
OR	Kaiser Permanente Interstate Medical Office Central	Portland97227	NCT06890598	Map
OR	Kaiser Permanente Medical Center	Portland97227	NCT07005128	Map
OR	Legacy Good Samaritan Hospital and Medical Center	Portland97210	NCT05624996	Map
OR	Legacy Good Samaritan Hospital and Medical Center	Portland97210	NCT06058377	Map
OR	Oregon Health & Science Institute (OHSU)	Portland97239	NCT01042379	Map
OR	Oregon Health and Science University	Portland97239	NCT06498635	Map
OR	Oregon Health and Science University	Portland97239	NCT06890598	Map
OR	Oregon Health And Science University	Portland97239	NCT06667908	Map
OR	Providence Cancer Institute	Portland97213	NCT07195695	Map
OR	Providence Portland Medical Center	Portland97213	NCT06058377	Map
OR	Providence Portland Medical Center	Portland97213	NCT06498635	Map
OR	Providence Portland Medical Center	Portland97213	NCT06769126	Map
OR	Providence Portland Medical Center	Portland97213	NCT06890598	Map
OR	Providence Portland Medical Center	Portland97213	NCT07166406	Map
OR	Providence Portland Medical Center ( Site 1101)	Portland97213	NCT06780137	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06058377	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06498635	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06769126	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT07166406	Map
OR	Providence St. Vincent Medical Center	Portland97225	NCT06890598	Map
OR	Legacy Meridian Park Hospital	Tualatin97062	NCT05624996	Map
OR	Legacy Meridian Park Hospital	Tualatin97062	NCT06058377	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT06058377	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT06498635	Map
PA	Saint Luke's Cancer Center - Allentown	Allentown18104	NCT06058377	Map
PA	UPMC-Heritage Valley Health System Beaver	Beaver15009	NCT06058377	Map
PA	Lehigh Valley Hospital - Muhlenberg	Bethlehem18017	NCT06058377	Map
PA	Lehigh Valley Hospital - Muhlenberg	Bethlehem18017	NCT06498635	Map
PA	Saint Luke's University Hospital-Bethlehem Campus	Bethlehem18015	NCT06058377	Map
PA	Bryn Mawr Hospital	Bryn Mawr19010	NCT06058377	Map
PA	Bryn Mawr Hospital	Bryn Mawr19010	NCT06498635	Map
PA	UPMC Hillman Cancer Center at Butler Health System	Butler16001	NCT06058377	Map
PA	Christiana Care Health System-Concord Health Center	Chadds Ford19317	NCT05624996	Map
PA	Chambersburg Hospital	Chambersburg17201	NCT05624996	Map
PA	UPMC Hillman Cancer Center - Passavant - Cranberry	Cranberry Township16066	NCT06058377	Map
PA	Geisinger Medical Center	Danville17822	NCT05624996	Map
PA	Geisinger Medical Center	Danville17822	NCT06058377	Map
PA	Geisinger Medical Center	Danville17822	NCT07166406	Map
PA	Geisinger Cancer Center Dickson City	Dickson City18519	NCT06058377	Map
PA	Pocono Medical Center	East Stroudsburg18301	NCT06058377	Map
PA	Pocono Medical Center	East Stroudsburg18301	NCT06498635	Map
PA	Saint Luke's Hospital-Anderson Campus	Easton18045	NCT06058377	Map
PA	Ephrata Cancer Center	Ephrata17522	NCT05624996	Map
PA	Saint Vincent Hospital	Erie16544	NCT06058377	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT04628767	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT06058377	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT06498635	Map
PA	Adams Cancer Center	Gettysburg17325	NCT05624996	Map
PA	UPMC Cancer Centers - Arnold Palmer Pavilion	Greensburg15601	NCT04628767	Map
PA	UPMC Cancer Centers - Arnold Palmer Pavilion	Greensburg15601	NCT06058377	Map
PA	UPMC Cancer Centers - Arnold Palmer Pavilion	Greensburg15601	NCT06498635	Map
PA	UPMC Pinnacle Cancer Center/Community Osteopathic Campus	Harrisburg17109	NCT06058377	Map
PA	UPMC Pinnacle Cancer Center/Community Osteopathic Campus	Harrisburg17109	NCT06498635	Map
PA	Lehigh Valley Hospital-Hazleton	Hazleton18201	NCT06058377	Map
PA	Lehigh Valley Hospital-Hazleton	Hazleton18201	NCT06498635	Map
PA	Penn State Milton S Hershey Medical Center	Hershey17033-0850	NCT04628767	Map
PA	Penn State Milton S Hershey Medical Center	Hershey17033-0850	NCT05624996	Map
PA	IRMC Cancer Center	Indiana15701	NCT06058377	Map
PA	Jefferson Hospital	Jefferson Hills15025	NCT06058377	Map
PA	UPMC-Johnstown/John P. Murtha Regional Cancer Center	Johnstown15901	NCT06058377	Map
PA	Lancaster General Ann B Barshinger Cancer Institute	Lancaster17601	NCT05624996	Map
PA	Sechler Family Cancer Center	Lebanon17042	NCT05624996	Map
PA	Geisinger Medical Oncology-Lewisburg	Lewisburg17837	NCT05624996	Map
PA	Geisinger Medical Oncology-Lewisburg	Lewisburg17837	NCT06058377	Map
PA	Geisinger Medical Oncology-Lewisburg	Lewisburg17837	NCT07166406	Map
PA	Yolanda G Barco Oncology Institute	Meadville16335	NCT06058377	Map
PA	UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion	Mechanicsburg17050	NCT06058377	Map
PA	UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion	Mechanicsburg17050	NCT06498635	Map
PA	Riddle Memorial Hospital	Media19063	NCT06058377	Map
PA	Riddle Memorial Hospital	Media19063	NCT06498635	Map
PA	Forbes Hospital	Monroeville15146	NCT06058377	Map
PA	UPMC Hillman Cancer Center - Monroeville	Monroeville15146	NCT04628767	Map
PA	UPMC Hillman Cancer Center - Monroeville	Monroeville15146	NCT06058377	Map
PA	UPMC Hillman Cancer Center - Monroeville	Monroeville15146	NCT06498635	Map
PA	UPMC Hillman Cancer Center in Coraopolis	Moon Township15108	NCT06058377	Map
PA	Arnold Palmer Cancer Center Medical Oncology Norwin	N. Huntingdon15642	NCT06058377	—
PA	UPMC Cancer Center-Natrona Heights	Natrona Heights15065	NCT06058377	Map
PA	Paoli Memorial Hospital	Paoli19301	NCT06058377	Map
PA	Paoli Memorial Hospital	Paoli19301	NCT06498635	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT05624996	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT03317158	Map
PA	Jefferson Hospital Northeast	Philadelphia19114	NCT06890598	Map
PA	Jefferson Torresdale Hospital	Philadelphia19114	NCT06498635	Map
PA	Sidney Kimmel Cancer Center at Thomas Jefferson University	Philadelphia19107	NCT07174583	Map
PA	Temple University Hospital	Philadelphia19140	NCT05624996	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT04628767	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT05624996	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT06498635	Map
PA	Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office	Philadelphia19107	NCT06890598	Map
PA	University of Pennsylvania	Philadelphia19104	NCT06667908	Map
PA	University of Pennsylvania (U Penn)	Philadelphia19104	NCT01042379	Map
PA	University of Pennsylvania, Abramson Cancer Center	Philadelphia19104	NCT05733598	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT04628767	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT05624996	Map
PA	AHN Allegheny General Hospital	Pittsburgh15212	NCT06890598	Map
PA	Allegheny General Hospital	Pittsburgh15212	NCT06058377	Map
PA	Research Site	Pittsburgh15212	NCT05211895	Map
PA	Research Site	Pittsburgh15212	NCT05061550	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT04628767	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT03606967	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT05198830	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06050252	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06058377	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06287775	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06498635	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT05733598	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT03539822	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT06698250	Map
PA	UPMC-Magee Womens Hospital	Pittsburgh15213	NCT06058377	Map
PA	UPMC-Passavant Hospital	Pittsburgh15237	NCT04628767	Map
PA	UPMC-Passavant Hospital	Pittsburgh15237	NCT06058377	Map
PA	UPMC-Saint Clair Hospital Cancer Center	Pittsburgh15243	NCT04628767	Map
PA	UPMC-Saint Clair Hospital Cancer Center	Pittsburgh15243	NCT06058377	Map
PA	UPMC-Saint Margaret	Pittsburgh15215	NCT06058377	Map
PA	Saint Luke's Hospital - Upper Bucks Campus	Quakertown18951	NCT06058377	Map
PA	Community Medical Center	Scranton18510	NCT06058377	Map
PA	UPMC Cancer Center at UPMC Northwest	Seneca16346	NCT06058377	Map
PA	Saint Luke's Hospital - Monroe Campus	Stroudsburg18360	NCT06058377	Map
PA	UPMC Cancer Center-Washington	Washington15301	NCT04628767	Map
PA	UPMC Cancer Center-Washington	Washington15301	NCT06058377	Map
PA	UPMC West Mifflin-Cancer Center Jefferson	West Mifflin15122	NCT06058377	Map
PA	Reading Hospital	West Reading19611	NCT04628767	Map
PA	Reading Hospital	West Reading19611	NCT05624996	Map
PA	Reading Hospital	West Reading19611	NCT06498635	Map
PA	Wexford Health and Wellness Pavilion	Wexford15090	NCT06058377	Map
PA	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre18711	NCT05624996	Map
PA	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre18711	NCT06058377	Map
PA	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre18711	NCT07166406	Map
PA	Divine Providence Hospital	Williamsport17754	NCT06058377	Map
PA	Asplundh Cancer Pavilion	Willow Grove19090	NCT05624996	Map
PA	Lankenau Medical Center	Wynnewood19096	NCT05624996	Map
PA	Lankenau Medical Center	Wynnewood19096	NCT06058377	Map
PA	Lankenau Medical Center	Wynnewood19096	NCT06498635	Map
PA	UPMC Memorial	York17408	NCT06058377	Map
PA	WellSpan Health-York Cancer Center	York17403	NCT05624996	Map
PA	WellSpan Health-York Hospital	York17403	NCT05624996	Map
RI	Research Site	Providence02903	NCT06103864	Map
RI	Women and Infants Hospital	Providence02905	NCT06058377	Map
RI	Smilow Cancer Hospital Care Center - Westerly	Westerly02891	NCT06050252	Map
RI	Smilow Cancer Hospital Care Center - Westerly	Westerly02891	NCT06058377	Map
SC	Saint Joseph's/Candler - Bluffton Campus	Bluffton29910	NCT05624996	Map
SC	Saint Joseph's/Candler - Bluffton Campus	Bluffton29910	NCT06058377	Map
SC	Saint Joseph's/Candler - Bluffton Campus	Bluffton29910	NCT06769126	Map
SC	Prisma Health Cancer Institute - Spartanburg	Boiling Springs29316	NCT06058377	Map
SC	Prisma Health Cancer Institute - Spartanburg	Boiling Springs29316	NCT06498635	Map
SC	Prisma Health Cancer Institute - Spartanburg	Boiling Springs29316	NCT06769126	Map
SC	Bon Secours Saint Francis Hospital	Charleston29414	NCT06058377	Map
SC	Charleston Oncology - Roper	Charleston29403	NCT06058377	Map
SC	Charleston Oncology - Saint Francis	Charleston29414	NCT06058377	Map
SC	Medical University of South Carolina	Charleston29425	NCT06058377	Map
SC	Roper Hospital	Charleston29401	NCT06058377	Map
SC	Prisma Health Cancer Institute - Easley	Easley29640	NCT06058377	Map
SC	Prisma Health Cancer Institute - Easley	Easley29640	NCT06498635	Map
SC	Prisma Health Cancer Institute - Easley	Easley29640	NCT06769126	Map
SC	Gibbs Cancer Center-Gaffney	Gaffney29341	NCT05624996	Map
SC	Gibbs Cancer Center-Gaffney	Gaffney29341	NCT06498635	Map
SC	Tidelands Georgetown Memorial Hospital	Georgetown29440	NCT06058377	Map
SC	Tidelands Georgetown Memorial Hospital	Georgetown29440	NCT06498635	Map
SC	Tidelands Georgetown Memorial Hospital	Georgetown29440	NCT06769126	Map
SC	Prisma Health Cancer Institute - Butternut	Greenville29605	NCT06058377	Map
SC	Prisma Health Cancer Institute - Butternut	Greenville29605	NCT06498635	Map
SC	Prisma Health Cancer Institute - Butternut	Greenville29605	NCT06769126	Map
SC	Prisma Health Cancer Institute - Eastside	Greenville29615	NCT06058377	Map
SC	Prisma Health Cancer Institute - Eastside	Greenville29615	NCT06498635	Map
SC	Prisma Health Cancer Institute - Eastside	Greenville29615	NCT06769126	Map
SC	Prisma Health Cancer Institute - Faris	Greenville29605	NCT06058377	Map
SC	Prisma Health Cancer Institute - Faris	Greenville29605	NCT06498635	Map
SC	Prisma Health Cancer Institute - Faris	Greenville29605	NCT06769126	Map
SC	Prisma Health Greenville Memorial Hospital	Greenville29605	NCT06058377	Map
SC	Research Site	Greenville29605	NCT06467357	Map
SC	Saint Francis Cancer Center	Greenville29607	NCT05624996	Map
SC	Saint Francis Cancer Center	Greenville29607	NCT06282575	Map
SC	Saint Francis Hospital	Greenville29601	NCT05624996	Map
SC	Gibbs Cancer Center-Pelham	Greer29651	NCT05624996	Map
SC	Gibbs Cancer Center-Pelham	Greer29651	NCT06498635	Map
SC	Prisma Health Cancer Institute - Greer	Greer29650	NCT06058377	Map
SC	Prisma Health Cancer Institute - Greer	Greer29650	NCT06498635	Map
SC	Prisma Health Cancer Institute - Greer	Greer29650	NCT06769126	Map
SC	South Carolina Cancer Specialists PC	Hilton Head Island29926-3827	NCT06058377	Map
SC	Lancaster Radiation Therapy Center	Lancaster29720	NCT05624996	Map
SC	GSK Investigational Site	Myrtle Beach29572	NCT06551142	Map
SC	Levine Cancer Institute-Rock Hill	Rock Hill29732	NCT05624996	Map
SC	Rock Hill Radiation Therapy Center	Rock Hill29730	NCT05624996	Map
SC	Prisma Health Cancer Institute - Seneca	Seneca29672	NCT06058377	Map
SC	Prisma Health Cancer Institute - Seneca	Seneca29672	NCT06498635	Map
SC	Prisma Health Cancer Institute - Seneca	Seneca29672	NCT06769126	Map
SC	Gibbs Cancer Center	Spartanburg29303	NCT06501625	Map
SC	Spartanburg Medical Center	Spartanburg29303	NCT05624996	Map
SC	Spartanburg Medical Center	Spartanburg29303	NCT06498635	Map
SC	SMC Center for Hematology Oncology Union	Union29379	NCT05624996	Map
SC	SMC Center for Hematology Oncology Union	Union29379	NCT06498635	Map
SC	Lexington Medical Center	West Columbia29169	NCT05624996	Map
SC	Lexington Medical Center	West Columbia29169	NCT06890598	Map
SD	Research Site	Sioux Falls57105	NCT07221253	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT05624996	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT06498635	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT06769126	Map
SD	Sanford Clinical Research	Sioux Falls57104	NCT01042379	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT05624996	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT06498635	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT06769126	Map
TN	Research Site	Chattanooga37404	NCT05211895	Map
TN	Research Site	Chattanooga37404	NCT05061550	Map
TN	Research Site	Chattanooga37404	NCT06103864	Map
TN	Tennessee Oncology Chattanooga	Chattanooga37404	NCT06890598	Map
TN	Baptist Memorial Hospital and Cancer Center-Collierville	Collierville38017	NCT05624996	Map
TN	Baptist Memorial Hospital and Cancer Center-Collierville	Collierville38017	NCT06058377	Map
TN	Baptist Memorial Hospital and Cancer Center-Collierville	Collierville38017	NCT06498635	Map
TN	The West Clinic	Germantown38138	NCT05733598	Map
TN	Covenant Health Cancer Centers	Knoxville37916	NCT06058377	Map
TN	Covenant Health Cancer Centers - West	Knoxville37932	NCT06058377	Map
TN	Tennessee Cancer Specialists	Knoxville37909	NCT06773910	Map
TN	University of Tennessee - Knoxville	Knoxville37920	NCT05624996	Map
TN	University of Tennessee Medical Center	Knoxville37920	NCT05733598	Map
TN	University of Tennessee Medical Center	Knoxville37920	NCT06890598	Map
TN	Baptist Cancer Center	Memphis38120	NCT07005128	Map
TN	Baptist Cancer Center	Memphis38120	NCT07531095	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT05624996	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT06058377	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT06498635	Map
TN	Research Site	Memphis38120	NCT05061550	Map
TN	GSK Investigational Site	Nashville37203	NCT06551142	Map
TN	Research Site	Nashville37203	NCT05211895	Map
TN	Research Site	Nashville37232	NCT05211895	Map
TN	Research Site	Nashville37203	NCT05061550	Map
TN	Research Site	Nashville37232	NCT05061550	Map
TN	Research Site	Nashville37203	NCT06103864	Map
TN	Sarah Cannon Research Institute	Nashville37203	NCT06890598	Map
TN	Sarah Cannon Research Institute - Oncology Partners	Nashville37203	NCT07174583	Map
TN	Sarah Cannon Research Institute ( Site 7001)	Nashville37203	NCT06780137	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06773910	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06890598	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07361497	Map
TN	Tennesse Oncology - Elliston Place Plaza	Nashville37203	NCT06501625	Map
TN	Tennessee Oncology	Nashville37203	NCT06890598	Map
TN	United States Oncology Regulatory Affairs Corporate Office	Nashville37203	NCT07005128	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT06050252	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT07175441	Map
TN	Covenant Health Oncology Group - Oak Ridge	Oak Ridge37830	NCT06058377	Map
TX	Hendrick Health	Abilene79601	NCT07195695	Map
TX	Texas Oncology - Abilene - Antilley Road /ID# 265820	Abilene79606	NCT06109272	Map
TX	Texas Oncology - Amarillo Cancer Center	Amarillo79124	NCT07361497	Map
TX	Texas Oncology - West Texas	Amarillo79124	NCT06773910	Map
TX	GSK Investigational Site	Austin78705	NCT06551142	Map
TX	Texas Oncology - Austin Central	Austin78745	NCT06463665	Map
TX	Texas Oncology- Austin	Austin78705	NCT06773910	Map
TX	Texas Oncology-Austin Central	Austin78731	NCT07361497	Map
TX	World Research Link	Baytown77521	NCT06463665	Map
TX	Texas Oncology - Gulf Coast	Beaumont77702	NCT06773910	Map
TX	MD Anderson in The Woodlands	Conroe77384	NCT05624996	Map
TX	MD Anderson in The Woodlands	Conroe77384	NCT06050252	Map
TX	MD Anderson in The Woodlands	Conroe77384	NCT06058377	Map
TX	Baylor Scott and White Research Institute /ID# 260853	Dallas76508-0001	NCT06109272	Map
TX	GSK Investigational Site	Dallas75230	NCT06551142	Map
TX	Parkland Memorial Hospital	Dallas75235	NCT04628767	Map
TX	Research Site	Dallas75246	NCT06103864	Map
TX	Research Site	Dallas75246	NCT06467357	Map
TX	Texas Oncology - Dallas - Worth Street /ID# 265806	Dallas75246	NCT06109272	Map
TX	Texas Oncology - Dallas Fort Worth	Dallas75246	NCT07005128	Map
TX	Texas Oncology - DFW	Dallas75246	NCT06773910	Map
TX	University of Texas Southwestern	Dallas75390	NCT07175441	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT06282575	Map
TX	UT Southwestern/Simmons Cancer Center-Dallas	Dallas75390	NCT04628767	Map
TX	Texas Oncology - Northeast Texas	Denison75020	NCT06773910	Map
TX	Texas Oncology	Denton76210	NCT07361497	Map
TX	Research Site	El Paso79902	NCT06103864	Map
TX	Research Site	Fort Sam Houston78234	NCT05211895	Map
TX	Research Site	Fort Worth76104	NCT06467357	Map
TX	START Dallas Fort Worth	Fort Worth76104	NCT07175441	Map
TX	The Center for Cancer and Blood Disorders	Fort Worth76104	NCT06890598	Map
TX	UT Southwestern/Simmons Cancer Center-Fort Worth	Fort Worth76104	NCT04628767	Map
TX	University of Texas Medical Branch	Galveston77555-0565	NCT03606967	Map
TX	Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	Houston77030	NCT05624996	Map
TX	Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	Houston77030	NCT06058377	Map
TX	Baylor St Lukes	Houston77030	NCT05932199	Map
TX	Ben Taub General Hospital	Houston77030	NCT05624996	Map
TX	Ben Taub General Hospital	Houston77030	NCT06058377	Map
TX	Houston Methodist Hospital	Houston77030	NCT06890598	Map
TX	Houston Methodist Hospital Cancer Center	Houston77030	NCT05733598	Map
TX	M D Anderson Cancer Center	Houston77030	NCT04892953	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05624996	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05632809	Map
TX	M D Anderson Cancer Center	Houston77030	NCT06050252	Map
TX	M D Anderson Cancer Center	Houston77030	NCT06058377	Map
TX	M D Anderson Cancer Center	Houston77030	NCT06769126	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06548412	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06667908	Map
TX	MD Anderson West Houston	Houston77079	NCT05624996	Map
TX	MD Anderson West Houston	Houston77079	NCT06050252	Map
TX	MD Anderson West Houston	Houston77079	NCT06058377	Map
TX	Millennium Research & Clinical Development	Houston77090	NCT05742607	Map
TX	Oncology Consultants	Houston77030	NCT07005128	Map
TX	Research Site	Houston77030	NCT04686305	Map
TX	Research Site	Houston77090	NCT04379596	Map
TX	Research Site	Houston77030	NCT05061550	Map
TX	Research Site	Houston77090	NCT05061550	Map
TX	Research Site	Houston77030	NCT06467357	Map
TX	The Univerrsity of Texas MD Anderson Cancer Center	Houston77030	NCT06282575	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06858735	Map
TX	The University of Texas Md Anderson Cancer Center	Houston77030	NCT06501625	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT05795101	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT06890598	Map
TX	Next Oncology Dallas	Irving75039	NCT07174583	Map
TX	US Oncology Research Investigational Products Center	Irving75063	NCT07005128	Map
TX	MD Anderson League City	League City77573	NCT05624996	Map
TX	MD Anderson League City	League City77573	NCT06050252	Map
TX	MD Anderson League City	League City77573	NCT06058377	Map
TX	UT Southwestern Clinical Center at Richardson/Plano	Richardson75080	NCT04628767	Map
TX	GSK Investigational Site	San Antonio78229	NCT06551142	Map
TX	Texas Oncology - San Antonio	San Antonio78240	NCT06773910	Map
TX	Texas Oncology - San Antonio Medical Center	San Antonio78229	NCT07361497	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06058377	Map
TX	USO - Texas Oncology - San Antonio	San Antonio78240	NCT06890598	Map
TX	UT Health San Antonio	San Antonio78229	NCT06526104	Map
TX	MD Anderson in Sugar Land	Sugar Land77478	NCT05624996	Map
TX	MD Anderson in Sugar Land	Sugar Land77478	NCT06050252	Map
TX	MD Anderson in Sugar Land	Sugar Land77478	NCT06058377	Map
TX	Research Site	Sugar Land77479	NCT06103864	Map
TX	USO - Texas Oncology Gulf Coast	Sugar Land77479	NCT06890598	Map
TX	USO - US Oncology Research Network	The Woodlands77380	NCT06890598	Map
TX	GSK Investigational Site	Tyler75702	NCT06551142	Map
TX	Texas Oncology - Northeast Texas	Tyler75702	NCT07361497	Map
TX	Texas Oncology Northeast Texas	Tyler75702	NCT07005128	Map
TX	University of Texas Health Science Center at Tyler	Tyler75701	NCT07005128	Map
UT	Community Cancer Trials of Utah	Ogden84405	NCT07195695	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT06124118	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT01042379	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT06050252	Map
UT	GSK Investigational Site	West Valley City84119	NCT06551142	Map
VT	Central Vermont Medical Center/National Life Cancer Treatment	Berlin Corners05602	NCT05624996	Map
VT	The University of Vermont Medical Center Inc.	Burlington05405	NCT06890598	Map
VT	University of Vermont and State Agricultural College	Burlington05405	NCT05624996	Map
VT	University of Vermont Medical Center	Burlington05401	NCT05624996	Map
VT	University of Vermont Medical Center	Burlington05401	NCT06667908	Map
VT	Dartmouth Cancer Center - North	Saint Johnsbury05819	NCT05624996	Map
VA	Inova Alexandria Hospital	Alexandria22304	NCT07166406	Map
VA	Research Site	Arlington22205	NCT05211895	Map
VA	Research Site	Charlottesville22903	NCT06103864	Map
VA	University of Virginia	Charlottesville22903	NCT03161223	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06050252	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06287775	Map
VA	University of Virginia Comprehensive Cancer Center	Charlottesville22908	NCT07149363	Map
VA	University of Virginia Health System	Charlottesville22908	NCT05903092	Map
VA	University of Virginia Health System	Charlottesville22903	NCT06890598	Map
VA	Blue Ridge Cancer Care	Christiansburg24073	NCT07361497	Map
VA	Inova Fair Oaks Hospital	Fairfax22033	NCT07166406	Map
VA	Inova Schar Cancer Institute	Fairfax22031	NCT07166406	Map
VA	NEXT Oncology Virginia	Fairfax22031	NCT07174583	Map
VA	Next Virginia	Fairfax22031	NCT07531095	Map
VA	Research Site	Fairfax22031	NCT04686305	Map
VA	Research Site	Fairfax22031	NCT05061550	Map
VA	Research Site	Fairfax22031	NCT06103864	Map
VA	Research Site	Fairfax22031	NCT06467357	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT06773910	Map
VA	Virginia Cancer Specialists PC	Fairfax22031	NCT07005128	Map
VA	Inova Fairfax Hospital	Falls Church22042	NCT07166406	Map
VA	Research Site	Fort Belvoir22060	NCT05211895	Map
VA	Hematology Oncology Associates of Fredericksburg Inc	Fredericksburg22408	NCT06058377	Map
VA	Hematology Oncology Associates of Fredericksburg Inc	Fredericksburg22408	NCT06498635	Map
VA	Inova Loudoun Hospital	Leesburg20176	NCT07166406	Map
VA	Centra Alan B Pearson Regional Cancer Center	Lynchburg24501	NCT06498635	Map
VA	Bon Secours Memorial Regional Medical Center	Mechanicsville23116	NCT06058377	Map
VA	Bon Secours Saint Francis Medical Center	Midlothian23114	NCT06058377	Map
VA	Research Site	Midlothian23114	NCT06103864	Map
VA	GSK Investigational Site	Norfolk23502	NCT06551142	Map
VA	Research Site	Norfolk23502	NCT06103864	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT06773910	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT07005128	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT07361497	Map
VA	Bon Secours Saint Mary's Hospital	Richmond23226	NCT06058377	Map
VA	VCU Health Adult Outpatient Pavillion	Richmond23219	NCT06890598	Map
VA	VCU Massey Cancer Center at Stony Point	Richmond23235	NCT06058377	Map
VA	VCU Massey Cancer Center at Stony Point	Richmond23235	NCT06769126	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT03606967	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06050252	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06058377	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06287775	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06769126	Map
VA	Virginia Cancer Institute	Richmond23229	NCT06058377	Map
VA	Virginia Cancer Institute	Richmond23229	NCT06498635	Map
VA	Virginia Commonwealth University, VCU Health	Richmond23219	NCT06282575	Map
VA	Oncology and Hematology Associates of Southwest Virginia /ID# 265834	Roanoke98684	NCT06109272	Map
VA	Research Site	Roanoke24014	NCT06103864	Map
VA	Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA)	Salem24153	NCT06773910	Map
VA	VCU Community Memorial Health Center	South Hill23970	NCT06058377	Map
VA	VCU Community Memorial Health Center	South Hill23970	NCT06498635	Map
VA	VCU Community Memorial Health Center	South Hill23970	NCT06769126	Map
VA	VCU Health Tappahannock Hospital	Tappahannock22560	NCT06769126	Map
WA	Research Site	Edmonds98026	NCT05061550	Map
WA	Swedish Cancer Institute - Edmonds	Edmonds98026	NCT06890598	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT06058377	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT06498635	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT06058377	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT06498635	Map
WA	Kadlec Clinic Hematology and Oncology	Kennewick99336	NCT06058377	Map
WA	Providence Regional Cancer System-Lacey	Lacey98503	NCT06058377	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT04628767	Map
WA	Research Site	Seattle98104	NCT05061550	Map
WA	Swedish Cancer Institute	Seattle98104	NCT07174583	Map
WA	Swedish Cancer Institute Medical Oncology	Seattle98104	NCT07005128	Map
WA	Swedish Medical Center	Seattle98104	NCT06890598	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT06058377	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT06498635	Map
WA	University of Washington Medical Center - Montlake	Seattle98195	NCT04628767	Map
WA	Virginia Mason Medical Center	Seattle98101	NCT05624996	Map
WA	Cancer Care Northwest - Vercler	Spokane Valley99216	NCT06890598	Map
WA	Research Site	Spokane Valley99216	NCT05211895	Map
WA	Northwest Medical Specialties PLLC	Tacoma98405	NCT06058377	Map
WA	Northwest Medical Specialties, PLLC	Tacoma98405	NCT07005128	Map
WA	Research Site	Tacoma98405	NCT06103864	Map
WA	Legacy Cancer Institute Medical Oncology and Day Treatment	Vancouver98684	NCT05624996	Map
WA	Legacy Cancer Institute Medical Oncology and Day Treatment	Vancouver98684	NCT06058377	Map
WA	Legacy Salmon Creek Hospital	Vancouver98686	NCT05624996	Map
WA	Legacy Salmon Creek Hospital	Vancouver98686	NCT06058377	Map
WA	Northwest Cancer Specialists PC	Vancouver98684	NCT06890598	Map
WV	West Virginia University Charleston Division	Charleston25304	NCT04628767	Map
WV	West Virginia University Charleston Division	Charleston25304	NCT06058377	Map
WV	Edwards Comprehensive Cancer Center	Huntington25701	NCT05624996	Map
WV	Edwards Comprehensive Cancer Center	Huntington25701	NCT06498635	Map
WV	West Virginia University Health Sciences Center	Morgantown26506	NCT07005128	Map
WV	West Virginia University Healthcare	Morgantown26506	NCT05624996	Map
WV	West Virginia University Healthcare	Morgantown26506	NCT06058377	Map
WI	Langlade Hospital and Cancer Center	Antigo54409	NCT05624996	Map
WI	Langlade Hospital and Cancer Center	Antigo54409	NCT06498635	Map
WI	Research Site	Appleton54911	NCT05211895	Map
WI	ThedaCare Regional Cancer Center	Appleton54911	NCT04628767	Map
WI	ThedaCare Regional Cancer Center	Appleton54911	NCT06058377	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT05624996	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT06058377	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT06498635	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT06769126	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT07166406	Map
WI	Northwest Wisconsin Cancer Center	Ashland54806	NCT05624996	Map
WI	Northwest Wisconsin Cancer Center	Ashland54806	NCT07166406	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT04628767	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT05624996	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT06058377	Map
WI	Aurora Saint Luke's South Shore	Cudahy53110	NCT06058377	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT04628767	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT05624996	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT06058377	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT06498635	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT07166406	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT04628767	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT05624996	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT06058377	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT04628767	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT05624996	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT06058377	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT04628767	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT05624996	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT06058377	Map
WI	Bellin Memorial Hospital	Green Bay54301	NCT06058377	Map
WI	Saint Vincent Hospital Cancer Center at Saint Mary's	Green Bay54303	NCT06058377	Map
WI	Saint Vincent Hospital Cancer Center at Saint Mary's	Green Bay54303	NCT06498635	Map
WI	Saint Vincent Hospital Cancer Center Green Bay	Green Bay54301	NCT05624996	Map
WI	Saint Vincent Hospital Cancer Center Green Bay	Green Bay54301	NCT06058377	Map
WI	Saint Vincent Hospital Cancer Center Green Bay	Green Bay54301	NCT06498635	Map
WI	Essentia Health-Hayward Clinic	Hayward54843	NCT05624996	Map
WI	Essentia Health-Hayward Clinic	Hayward54843	NCT07166406	Map
WI	Mercyhealth Hospital and Cancer Center - Janesville	Janesville53548	NCT06058377	Map
WI	University of Wisconsin Carbone Cancer Center - Johnson Creek	Johnson Creek53038	NCT05624996	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT04628767	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT05624996	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT06058377	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT06498635	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT06769126	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT05624996	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT06050252	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT06058377	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT05624996	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT06050252	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT06058377	Map
WI	UW Carbone Cancer Center	Madison53705	NCT04900818	Map
WI	UW Carbone Cancer Center - Cancer Connect	Madison53792	NCT05742607	Map
WI	William S Middleton VA Medical Center	Madison53705	NCT05624996	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT04628767	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT05624996	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT06058377	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT04628767	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT05624996	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT06058377	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT07166406	Map
WI	Aspirus Medford Hospital	Medford54451	NCT06498635	Map
WI	Froedtert Menomonee Falls Hospital	Menomonee Falls53051	NCT05624996	Map
WI	Froedtert Menomonee Falls Hospital	Menomonee Falls53051	NCT06058377	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT04628767	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT05624996	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT06058377	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT04628767	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT05624996	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT06058377	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT04628767	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT05624996	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT06058377	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT05624996	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06058377	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06890598	Map
WI	Medical College of Wisconsin ( Site 1112)	Milwaukee53226	NCT06780137	Map
WI	Zablocki Veterans Administration Medical Center	Milwaukee53295	NCT05624996	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT04628767	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT05624996	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT06058377	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT04628767	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT05624996	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT06498635	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT07166406	Map
WI	ThedaCare Regional Medical Center - Neenah	Neenah54956	NCT06058377	Map
WI	Drexel Town Square Health Center	Oak Creek53154	NCT05624996	Map
WI	Drexel Town Square Health Center	Oak Creek53154	NCT06058377	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT04628767	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT05624996	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT06498635	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT07166406	Map
WI	Saint Vincent Hospital Cancer Center at Oconto Falls	Oconto Falls54154	NCT06058377	Map
WI	Saint Vincent Hospital Cancer Center at Oconto Falls	Oconto Falls54154	NCT06498635	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT04628767	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT05624996	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT06058377	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT04628767	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT05624996	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT06058377	Map
WI	Aspirus Cancer Care - James Beck Cancer Center	Rhinelander54501	NCT05624996	Map
WI	Aspirus Cancer Care - James Beck Cancer Center	Rhinelander54501	NCT06498635	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT04628767	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT05624996	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT06058377	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT07166406	Map
WI	Saint Vincent Hospital Cancer Center at Sheboygan	Sheboygan53081	NCT05624996	Map
WI	Saint Vincent Hospital Cancer Center at Sheboygan	Sheboygan53081	NCT06058377	Map
WI	Saint Vincent Hospital Cancer Center at Sheboygan	Sheboygan53081	NCT06498635	Map
WI	Sheboygan Physicians Group	Sheboygan53081	NCT06498635	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT04628767	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT05624996	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT06058377	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT05624996	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT06058377	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT07166406	Map
WI	Aspirus Cancer Care - Stevens Point	Stevens Point54481	NCT05624996	Map
WI	Aspirus Cancer Care - Stevens Point	Stevens Point54481	NCT06498635	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT04628767	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT05624996	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT06058377	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT07166406	Map
WI	Saint Vincent Hospital Cancer Center at Sturgeon Bay	Sturgeon Bay54235-1495	NCT05624996	Map
WI	Saint Vincent Hospital Cancer Center at Sturgeon Bay	Sturgeon Bay54235-1495	NCT06058377	Map
WI	Saint Vincent Hospital Cancer Center at Sturgeon Bay	Sturgeon Bay54235-1495	NCT06498635	Map
WI	Aurora Medical Center in Summit	Summit53066	NCT04628767	—
WI	Aurora Medical Center in Summit	Summit53066	NCT05624996	—
WI	Aurora Medical Center in Summit	Summit53066	NCT06058377	—
WI	Essentia Health Saint Mary's Hospital - Superior	Superior54880	NCT05624996	Map
WI	Essentia Health Saint Mary's Hospital - Superior	Superior54880	NCT07166406	Map
WI	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers54241	NCT04628767	Map
WI	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers54241	NCT06058377	Map
WI	ProHealth Waukesha Memorial Hospital	Waukesha53188	NCT04628767	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT04628767	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT05624996	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT06498635	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT07166406	Map
WI	ThedaCare Cancer Care - Waupaca	Waupaca54981	NCT04628767	Map
WI	Aspirus Regional Cancer Center	Wausau54401	NCT05624996	Map
WI	Aspirus Regional Cancer Center	Wausau54401	NCT06498635	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT04628767	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT05624996	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT06058377	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT04628767	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT05624996	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT06058377	Map
WI	Froedtert West Bend Hospital/Kraemer Cancer Center	West Bend53095	NCT05624996	Map
WI	Froedtert West Bend Hospital/Kraemer Cancer Center	West Bend53095	NCT06058377	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT04628767	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT05624996	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT06058377	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT07166406	Map
WI	Aspirus Cancer Care - Wisconsin Rapids	Wisconsin Rapids54494	NCT05624996	Map
WI	Aspirus Cancer Care - Wisconsin Rapids	Wisconsin Rapids54494	NCT06498635	Map

Durvalumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	approved for marketing	Total
Early P1		2		3	2	3		1			11
P1	19	19		45	20	7	3	1	3		117
P1/P2	20	17		29	14	1		1	8		90
P2	90	84	1	88	31	35		18	50		397
P2/P3	5			2							7
P3	21	45	1	13	1	1		2			84
P4	2			2					1		5
N/A	3	2		7					8	1	21

Recruiting Durvalumab clinical trials (185)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT05155189	A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma	P1	Hepatocellular Carcinoma	72	Feb 2022
NCT06498635	Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial	P3	Lung Non-Small Cell Carcinoma	306	Apr 2025
NCT07554339	MK-1084A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)	P3	Non-small Cell Lung Cancer	310	Jun 2026
NCT07195695	Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations	P3	Non-small Cell Lung Cancer	400	Jan 2026
NCT06492421	Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.	P2	Lung Cancer	90	Jul 2024
NCT06482801	Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT	P2	Liver Cancer	90	Jun 2024
NCT05187338	Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors	P1/P2	Lung Cancer	100	Nov 2021
NCT06694454	MEDI4736Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)	P1/P2	Non-small Cell Lung Cancer (NSCLC)	60	Jun 2026
NCT03288532	RAMPARTRenal Adjuvant MultiPle Arm Randomised Trial	P3	Renal Cell Carcinoma	1,750	Jul 2018
NCT07361497	NSCLCA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)	P3	Non-small Cell Lung Cancer (NSCLC)	850	Mar 2026
NCT06492408	Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.	P2	Hepatic Cancer	90	Jul 2024
NCT06483347	Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT	P2	Lung Cancer	90	Apr 2024
NCT06027086	FLCDRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)	P1/P2	Fibrolamellar Hepatocellular Carcinoma	27	Feb 2024
NCT06999694	Proton-STRIDEProton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	HCC - Hepatocellular Carcinoma	45	May 2025
NCT06999707	Photon-STRIDEPhoton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	HCC - Hepatocellular Carcinoma	45	May 2025
NCT06503614	ENHANCEA Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer	P2	Non-muscle Invasive Bladder Cancer	60	Feb 2025
NCT05795101	TRUDITRUDI: TDXD+Durva in HER2+/Low IBC	P2	Invasive Breast Cancer	63	May 2023
NCT06773910	TIGOS-LSBMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)	P2	Limited Stage Small Cell Lung Cancer	250	Mar 2025
NCT04106115	DURANCEDURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr	P1/P2	Bladder Cancer	52	Mar 2022
NCT06680739	SERPENTINESingle cEll pRofiling PErsistaNce To ImmuNothErapy	P2	Colorectal Cancer	60	Mar 2022
NCT07107750	CA-4948Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer	P1	Metastatic Biliary Tract Cancer	48	Mar 2026
NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	P3	Anatomic Stage II Breast Cancer AJCC v8	3,680	Nov 2023
NCT05253131	Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas	P2	MPNST	41	May 2026
NCT06890598	SUNRAY-02Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer	P3	Carcinoma, Non-Small-Cell Lung	700	Mar 2025
NCT01042379	I-SPYI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	Breast Neoplasms	5,000	Mar 2010
NCT07247786	MIGRANTStudy for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)	P2	Non Small Cell Lung Cancer	68	Sep 2026
NCT05624996	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer	P3	Locally Advanced Lung Non-Small Cell Carcinoma	474	Jul 2023
NCT07531095	DeLLphi-313Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)	P1	Small Cell Lung Cancer	160	Apr 2026
NCT03847649	A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	P2	Cancer	60	Mar 2020
NCT07149363	Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer	P2	Small Cell Lung Cancer (SCLC)	65	Feb 2026
NCT05255653	RAINBORefining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features	P2/P3	Endometrial Cancer	1,615	Nov 2021
NCT07489976	IIT2025-03-YANG-LIFT-HCC	P2	Hepato Cellular Carcinoma	41	Apr 2026
NCT06274879	AblatioSafety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer	P2	Bile Duct Cancer	36	May 2026
NCT06858735	HYPERION CCAHYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma	P2	Advanced Intrahepatic Cholangiocarcinoma	60	Jun 2025
NCT05903092	MOZARTMOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer	P2	Small Cell Lung Cancer	84	Sep 2023
NCT05211895	PACIFIC-8A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC	P3	Non-Small Cell Lung Cancer	860	Feb 2022
NCT06904170	ALICEDurvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma	P2/P3	Hepatocellular Carcinoma	196	Nov 2025
NCT06109272	LIVIGNO-2A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)	P2/P3	Hepatocellular Carcinoma	660	Jan 2024
NCT06103864	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	P3	Breast Cancer	625	Nov 2023
NCT04465968	DEEP_OCEANEfficacy and Safety of CRT, Durvalumab and Surgery for SST	P3	Superior Sulcus Tumor	84	Sep 2020
NCT07603856	REVIVEA Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer	P2	Non-Small Cell Lung Cancer	39	Dec 2026
NCT05061550	NeoCOAST-2Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer	P2	Non-small Cell Lung Cancer	630	Apr 2022
NCT06282575	Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer	P3	Biliary Tract Cancer	286	Jul 2024
NCT06284317	ADOPT-lungA Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.	P3	Non Small Cell Lung Cancer	290	Jan 2025
NCT06954480	DIAMONDInvestigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	P2	Triple Negative Breast Cancer	140	Oct 2025
NCT07507968	TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma	P2	Esophagogastric Adenocarcinoma	101	Jul 2026
NCT06780137	MK-6070A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)	P1/P2	Small Cell Lung Cancer	262	Feb 2025
NCT07122089	IOSPHEREEvaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis	P2	Hepatocellular Carcinoma Non-resectable	80	Feb 2026
NCT07229625	BTCA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)	P3	Advanced Biliary Tract Cancer	604	Jan 2026
NCT06769126	Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study	P2	Extensive Stage Lung Small Cell Carcinoma	900	Nov 2025
NCT06692491	SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS	P2	Rare Tumour	200	Jan 2025
NCT05582538	ATRiBRAVERestoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel	P2	Triple Negative Breast Cancer Metastatic	37	Dec 2022
NCT07339059	Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	P2	Small Cell Lung Cancer ( SCLC )	35	Jun 2026
NCT07036380	TACTICMP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma	P2	Advanced Biliary Tract Carcinoma	75	Dec 2025
NCT05451043	BLOCKEDDurvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)	P2	Pancreatic Cancer	62	Jul 2023
NCT07269158	A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer	P1/P2	Biliary Tract Neoplasms	160	Dec 2025
NCT06393816	FIRST-NECFIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum	P2	Large Cell Neuroendocrine Carcinoma of the Lung	80	Jun 2024
NCT03942328	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	P1/P2	Stage III Hepatocellular Carcinoma AJCC v8	85	Sep 2019
NCT07055581	Durvalumab as Consolidation for Patients LS-SCLC	P2	Small Cell Lung Cancer Limited Stage	100	Feb 2026
NCT06463665	VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer	P2	Advanced Non-squamous Non-small-cell Lung Cancer	142	Sep 2024
NCT04430452	Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma	P2	Advanced Hepatocellular Carcinoma	21	Feb 2022
NCT06290505	PALEOA Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study	P2	Esophageal Cancer	54	Dec 2021
NCT06287775	Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer	P1/P2	Extensive Stage Lung Small Cell Carcinoma	45	Apr 2025
NCT06214572	RUGBRadiation Therapy in Unresectable Gall Bladder Cancer	P2/P3	Gall Bladder Cancer	249	Mar 2024
NCT07005128	DeLLphi-312A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)	P3	Small-cell Lung Cancer	330	Aug 2025
NCT07221253	AB02A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)	P3	Biliary Tract Cancer	1,100	Dec 2025
NCT06992609	ALBORANDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.	P3	Small Cell Lung Carcinoma	70	Sep 2025
NCT03740893	PHOENIXPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer	P2	Breast Neoplasm	119	Oct 2019
NCT03539822	CAMILLACabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies	P1/P2	Gastric Cancer	117	Oct 2018
NCT06551142	PanTumor-101A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)	P1	Neoplasms	845	Sep 2024
NCT07174583	A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer	P1/P2	Small-cell Lung Cancer	208	Oct 2025
NCT06467357	DESTINY-BTC01Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer	P3	Biliary Tract Cancer	620	Aug 2024
NCT06548412	CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers	P1/P2	Metastatic Biliary Tract Cancer	50	Jan 2025
NCT06564623	BTCTargeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)	P1	Biliary Tract Cancers	25	May 2025
NCT07166406	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	P3	Advanced Hepatocellular Carcinoma	226	Feb 2026
NCT07146230	SPRINT 2The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2	P2	Non-small Cell Lung Cancer	52	Sep 2026
NCT06680050	AUSTRALPhase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen	P2	Non Small Cell Lung Cancer NSCLC	21	Aug 2025
NCT07172412	Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer	P2	Extensive Stage Lung Small Cell Cancer	165	Nov 2025
NCT06880523	SLIDE-HCCSTRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	140	Oct 2025
NCT06667908	CONVERGEA Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)	P2	Carcinoma, Non-Small-Cell Lung	130	Dec 2024
NCT06546969	Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer	P1	Biliary Tract Cancer	15	Oct 2024
NCT06031233	MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	P4	Oncology	776	Sep 2023
NCT05713838	Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery	P2	Esophagus Adenocarcinoma	32	Aug 2023
NCT06908070	CROWDChemoradiotherapy With Surgery Followed by Consolidation Durvalumab	P4	Non-small Cell Lung Cancer Stage III	38	Dec 2024
NCT06719336	STONE-001Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)	P3	Extensive-stage Small Cell Lung Cancer	182	Dec 2024
NCT06058663	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma	P1	Locally Advanced Intrahepatic Cholangiocarcinoma	16	Jun 2024
NCT06650709	NEOCATSNEoadjuvant Olaparib Combination OvArian Cancer Targeted Study	P2	Ovarian Cancer Stage IV	40	Nov 2024
NCT06960577	NIAGARA-2Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)	P3	Urinary Bladder Neoplasms	150	May 2025
NCT07288034	LImmunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial	P2	Lung Non-Small Cell Carcinoma	535	Apr 2026
NCT06484491	HyDoseIMPT Dose Escalation for NSCLC (HyDose)	N/A	Carcinoma, Non-Small-Cell Lung	87	Sep 2025
NCT07226063	Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer	P2	Hepatocellular Carcinoma	16	May 2026
NCT06441747	MEDI4736Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)	P2	Cholangiocarcinoma	40	Sep 2024
NCT06530823	Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma	P2	Biliary Tract Carcinoma	38	Aug 2024
NCT06824363	ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu	Early P1	Solid Tumor, Adult	34	Apr 2026
NCT05733598	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	P2	Hepatocellular Carcinoma	60	Aug 2024
NCT06911255	MEDI4736Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma	P1/P2	Hepatocellular Carcinoma (HCC)	24	Apr 2025
NCT06502080	RADITOPConsolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)	P2	Biliary Tract Cancer	128	Jul 2024
NCT04644289	WoOWoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC	P2	Epithelial Ovarian Cancer	60	May 2022
NCT06470256	Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma	P1	Advanced Hepatocellular Carcinoma	50	Jun 2024
NCT06855225	A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma	P2	Combined Hepatocellular and Cholangiocarcinoma	29	May 2026
NCT05932199	Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma	P1/P2	Mesothelioma	52	Jul 2024
NCT05845450	UNICORNPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)	P2	Colorectal Cancer	197	May 2023
NCT07168668	EXEPECTPartial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment	P2	HCC	90	Sep 2025
NCT05886439	LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer	P1/P2	Lung Cancer	60	May 2023
NCT07459634	A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC	P2	Extensive-stage Small-cell Lung Cancer	50	Jun 2026
NCT06440993	ID-RFADurvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma	P2	Extrahepatic Cholangiocarcinoma	42	Aug 2024
NCT04585490	Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	P3	Non Small Cell Lung Cancer	48	Aug 2021
NCT04550104	CONCORDEA Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC	P1	Non Small Cell Lung Cancer	200	Mar 2021
NCT04105270	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	P2	Adenocarcinoma of Lung	82	Nov 2022
NCT06464068	DURVASCCAGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA	P2	Extrapulmonary Small Cell Carcinoma	66	Jan 2024
NCT06998719	ACCESSNeoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC	P2	Non-small Cell Lung Cancer Stage III	80	Jul 2025
NCT06223711	Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC	P2	Extensive-stage Small-cell Lung Cancer	43	Oct 2023
NCT06371482	Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)	P2	SCLC, Limited Stage	58	Jun 2023
NCT05632809	RESCUEREStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)	P2	Lung Cancer	39	Jan 2023
NCT04900818	Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors	P1	Solid Tumor	330	Jun 2021
NCT04522544	Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC	P2	Hepatocellular Carcinoma Non-resectable	55	Dec 2020
NCT04499053	Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer	P2	Carcinoma, Non-Small Cell Lung	18	Dec 2020
NCT03317158	ADAPT-BLADDERModern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder	P1/P2	Urothelial Carcinoma	55	Nov 2017
NCT02925234	DRUPThe Drug Rediscovery Protocol (DRUP Trial)	P2	Cancer	1,550	Aug 2016
NCT06508216	COMPASS-TNBCA Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer	P1/P2	Breast Cancer	50	Jul 2024
NCT06526104	MEDI4736Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis	P2	Hepatocellular Carcinoma	32	Dec 2024
NCT05655949	Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio	P2	Bile Duct Cancer	30	Feb 2024
NCT06124118	NOVOCURETumor Treating Fields for Locally Advanced NSCLC	P1	Non Small Cell Lung Cancer	30	Apr 2024
NCT07174570	Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer	P2	Advanced Hepatocellular Carcinoma	39	Jan 2026
NCT06634199	SIENNAStudy of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients	—	Non-small Cell Lung Cancer Stage III	50	Oct 2024
NCT02029001	MOST plusAdapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment	P2	Malignant Solid Neoplasms	900	Mar 2014
NCT06591650	GCNDGemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer	P2	Gallbladder Cancer Unresectable	33	Oct 2024
NCT05068232	DARESDurvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)	P2	Small-cell Lung Cancer	49	Aug 2022
NCT04628767	Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer	P2/P3	Renal Pelvis and Ureter Urothelial Carcinoma	131	Nov 2021
NCT06501625	Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation	P1/P2	Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	52	Dec 2024
NCT07175441	Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma	P2	Advanced Unresectable Hepatocellular Carcinoma	220	Apr 2026
NCT07391670	IMFINZI-subQA Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab	P1	Solid Tumours	40	Mar 2026
NCT07511504	Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma	P2	Locally Advanced Hepatocellular Carcinoma	40	Apr 2026
NCT05484583	Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases	P2	Lung Cancer	58	Aug 2022
NCT06728410	A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement	P2	Intrahepatic Cholangiocarcinoma	38	Jan 2026
NCT06708858	Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer	P2	Advanced Biliary Tract Cancer	35	Aug 2024
NCT05733689	Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)	P1	Gastroesophageal Adenocarcinoma	20	Jun 2025
NCT06710223	Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab	P1	Hepatocellular Carcinoma	20	Jan 2025
NCT05620628	MEDI4736Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)	P2	Stomach Cancer, Adenocarcinoma	25	Jan 2023
NCT05198830	Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer	P2	Lung Adenocarcinoma	42	Dec 2022
NCT04686305	DL03Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	P1	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	304	Mar 2021
NCT04379596	DG-03Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)	P2	Gastric Cancer	450	Jun 2020
NCT03907475	Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial	P2	Locally Advanced Malignant Solid Neoplasm	115	Jul 2019
NCT05568212	NSCLCRandomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab	P2	Non-small-cell Lung Cancer Patients	176	May 2022
NCT03694236	MEDI4736Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC	P1/P2	Potentially Resectable Stage II/IIIa NSCLC	39	Feb 2019
NCT06078709	PHOXPreoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma	P2	Clinical Stage I Esophageal Adenocarcinoma AJCC v8	99	Nov 2023
NCT06698250	ZENOBIAZanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)	P2	Hepatocellular Carcinoma	40	Dec 2024
NCT05927142	DURIPANCCombining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy	P1/P2	Metastatic Pancreatic Cancer	43	Jan 2024
NCT05696782	Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer	P2	Nonsmall Cell Lung Cancer Stage III	28	Jul 2023
NCT06611345	A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers	N/A	Biliary Tract Cancers (BTC)	60	Oct 2024
NCT06302426	Trial of INI-4001 in Patients With Advanced Solid Tumours	P1	Advanced Solid Tumor	50	Jul 2024
NCT06859684	HAIC-quadHepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)	P2	Intrahepatic Cholangiocarcinoma (Icc)	25	Mar 2025
NCT05388006	Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P2	Chronic Lymphocytic Leukemia	27	Jan 2023
NCT06050252	Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery	P2	Resectable Intrahepatic Cholangiocarcinoma	27	Jul 2024
NCT07332351	TRIFECTANeoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial	P2	Muscle Invasive Bladder Urothelial Carcinoma	33	Sep 2026
NCT05720260	Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC	P2	Premenopausal Breast Cancer	42	Jan 2023
NCT07012798	MEDI4736FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma (HCC)	30	Sep 2025
NCT06263153	Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy	P2	Bladder Urothelial Carcinoma	24	Dec 2024
NCT06419179	GUIDANCEMaintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)	P2	Small Cell Lung Carcinoma	29	Oct 2024
NCT06070740	First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma	P2	Gastrointestinal Neuroendocrine Carcinoma	22	Nov 2023
NCT05844046	MONTBLANCSequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients	P2	Hepatocellular Carcinoma	83	Apr 2023
NCT06418087	DUPLEDurvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)	P2	Pulmonary Large-cell Neuroendocrine Carcinoma	49	May 2022
NCT04918186	IPROCImmunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer	P2	Ovarian Cancer	60	May 2022
NCT05303532	ROSY-DRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab	P3	Cancer	214	Apr 2022
NCT05136846	Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer	P1	Locally Advanced Lung Non-Small Cell Carcinoma	28	Dec 2021
NCT03772561	MEDIPACPhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies	P1	Solid Tumor, Adult	40	Dec 2018
NCT07196384	GLOWOptical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW	P1	Esophageal Cancer	15	Dec 2025
NCT05222971	OPTIMUMOlaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy	P2	Biliary Tract Cancer	62	Apr 2022
NCT03606967	Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	P2	Anatomic Stage IV Breast Cancer AJCC v8	70	Apr 2021
NCT04585477	ADAPT-EAdjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)	P2	Non-small Cell Lung Cancer	80	Apr 2021
NCT04988945	TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma	P2	HCC	33	Dec 2020
NCT04711824	SOLARAStudy of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases	P1/P2	Breast Cancer	41	Mar 2022
NCT04699838	Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer	P2	Extensive Stage Small Cell Lung Cancer	30	Apr 2021
NCT06060405	DORADurvalumab and Oleclumab in Resectable PDAC	P2	Pancreatic Ductal Adenocarcinoma	22	Nov 2023
NCT05701488	SIRT With Tremelimumab and Durvalumab for Resectable HCC	P1	Resectable Hepatocellular Carcinoma	20	Apr 2023
NCT05742607	MATISSEIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)	P2	Non Small Cell Lung Cancer	70	Jun 2023
NCT04892953	Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy	P2	Stage III Lung Cancer AJCC v8	51	Jul 2021
NCT05809869	Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	25	Feb 2023
NCT05215106	POP-DURVAShort-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)	P2	Early Small (cT1N0) Triple Negative Breast Cancer	200	Dec 2021
NCT06331455	SUPERTreatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection	P2	Lung Cancer Patients	12	May 2024
NCT03899428	Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC	P2	Hepatocellular Carcinoma	30	May 2019
NCT06341764	Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma	P2	Cholangiocarcinoma	38	Sep 2023
NCT05557838	TREMENDOUSStudy of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma	P3	Hepatocellular Carcinoma	210	Feb 2023
NCT03991832	SOLIDStudy of Olaparib and Durvalumab in IDH-Mutated Solid Tumors	P2	Glioma	58	Dec 2019
NCT03161223	Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma	P1/P2	Lymphoma, T-Cell	148	May 2018

Durvalumab clinical trials by indication

Hepatocellular Carcinoma (30)

NCT	Acronym	Phase	Status	Title
NCT05155189	—	P1	recruiting	A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
NCT06904170	ALICE	P2/P3	recruiting	Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
NCT06109272	LIVIGNO-2	P2/P3	recruiting	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06880523	SLIDE-HCC	P2	recruiting	STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
NCT07081633	TREMENDOUS-2	P2	active not recruiting	Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07226063	—	P2	not yet recruiting	Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
NCT05733598	—	P2	recruiting	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
NCT06526104	MEDI4736	P2	recruiting	Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
+ 22 more, see All trials below.

Non-small Cell Lung Cancer (21)

NCT	Acronym	Phase	Status	Title
NCT07554339	MK-1084	P3	recruiting	A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07195695	—	P3	recruiting	Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT04245514	NSCLC	P2	active not recruiting	Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT05061550	NeoCOAST-2	P2	recruiting	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT07146230	SPRINT 2	P2	not yet recruiting	The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
NCT05925530	MDT-BRIDGE	P2	active not recruiting	Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT03965468	CHESS	P2	active not recruiting	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
NCT04585477	ADAPT-E	P2	recruiting	Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
+ 13 more, see All trials below.

Non-Small Cell Lung Cancer (18)

NCT	Acronym	Phase	Status	Title
NCT03228667	—	P2	active not recruiting	QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT05211895	PACIFIC-8	P3	recruiting	A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05221840	PACIFIC-9	P3	active not recruiting	A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT07603856	REVIVE	P2	not yet recruiting	A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
NCT05170204	HORIZON 1	P3	active not recruiting	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT03800134	AEGEAN	P3	active not recruiting	A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT06606847	LADOGA	P2	active not recruiting	A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
NCT03334617	HUDSON	P2	active not recruiting	Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
+ 10 more, see All trials below.

Carcinoma, Non-Small-Cell Lung (17)

NCT	Acronym	Phase	Status	Title
NCT04597671	NVALT28	P3	active not recruiting	Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)
NCT06890598	SUNRAY-02	P3	recruiting	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06667908	CONVERGE	P2	recruiting	A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT03833154	PACIFIC-4	P3	active not recruiting	Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT06484491	HyDose	N/A	recruiting	IMPT Dose Escalation for NSCLC (HyDose)
NCT06008093	TRITON	P2	active not recruiting	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT03148327	—	P1/P2	active not recruiting	Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
NCT03706690	PACIFIC-5	P3	active not recruiting	A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
+ 9 more, see All trials below.

Non Small Cell Lung Cancer (16)

NCT	Acronym	Phase	Status	Title
NCT07247786	MIGRANT	P2	not yet recruiting	Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
NCT06284317	ADOPT-lung	P3	recruiting	A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT05206812	MEDI4736	P2	active not recruiting	Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)
NCT04585490	—	P3	recruiting	Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
NCT04550104	CONCORDE	P1	recruiting	A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
NCT06124118	NOVOCURE	P1	recruiting	Tumor Treating Fields for Locally Advanced NSCLC
NCT04944173	SCION	P2	withdrawn	SCION: SABR and Checkpoint Inhibition of NSCLC
NCT05742607	MATISSE	P2	recruiting	IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
+ 8 more, see All trials below.

Breast Cancer (16)

NCT	Acronym	Phase	Status	Title
NCT06112379	—	P3	active not recruiting	A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06103864	—	P3	recruiting	A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT05629585	—	P3	active not recruiting	A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT03820141	DTP	P2	active not recruiting	Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT06508216	COMPASS-TNBC	P1/P2	recruiting	A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
NCT02826434	—	P1	active not recruiting	Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
NCT03872505	PANDoRA	P2	withdrawn	Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
NCT05498155	OlympiaN	P2	active not recruiting	Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
+ 8 more, see All trials below.

Lung Cancer (14)

NCT	Acronym	Phase	Status	Title
NCT06492421	—	P2	recruiting	Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
NCT05187338	—	P1/P2	recruiting	Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT06483347	—	P2	recruiting	Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
NCT05886439	—	P1/P2	recruiting	LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
NCT05632809	RESCUE	P2	recruiting	REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
NCT05484583	—	P2	not yet recruiting	Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
NCT05092412	EP	P2	active not recruiting	Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05374603	SOUND	P2	active not recruiting	Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
+ 6 more, see All trials below.

Biliary Tract Cancer (10)

NCT	Acronym	Phase	Status	Title
NCT06282575	—	P3	recruiting	Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT07221253	AB02	P3	recruiting	A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT06467357	DESTINY-BTC01	P3	recruiting	Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06546969	—	P1	recruiting	Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
NCT06502080	RADITOP	P2	not yet recruiting	Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
NCT06591520	—	P3	active not recruiting	AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
NCT06490107	—	P2	active not recruiting	Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
NCT05222971	OPTIMUM	P2	recruiting	Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
+ 2 more, see All trials below.

Bladder Cancer (10)

NCT	Acronym	Phase	Status	Title
NCT04106115	DURANCE	P1/P2	recruiting	DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
NCT06963346	—	P1	suspended	Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
NCT03768570	—	P2	active not recruiting	Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT04073160	TRIO Bladder	P1	withdrawn	TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
NCT04543110	RADIANT	P2	unknown	Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
NCT03150836	—	P2	withdrawn	Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
NCT03472274	DUTRENEO	P2	completed	Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
NCT03759496	—	P2	unknown	Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
+ 2 more, see All trials below.

Small Cell Lung Cancer (9)

NCT	Acronym	Phase	Status	Title
NCT06898957	(DeLLphi-310)	P1	active not recruiting	Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT07531095	DeLLphi-313	P1	recruiting	Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT05903092	MOZART	P2	recruiting	MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
NCT06780137	MK-6070	P1/P2	recruiting	A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT04472949	ED-SCLC	P2	active not recruiting	Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
NCT03703297	ADRIATIC	P3	active not recruiting	Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT05572476	LURBIMUNE	P2	withdrawn	Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
NCT04361825	SUKSES-N4	P2	completed	Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects
+ 1 more, see All trials below.

Colorectal Cancer (9)

NCT	Acronym	Phase	Status	Title
NCT06680739	SERPENTINE	P2	recruiting	Single cEll pRofiling PErsistaNce To ImmuNothErapy
NCT05845450	UNICORN	P2	recruiting	Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
NCT03802747	—	P1	withdrawn	Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
NCT04696848	—	P1/P2	terminated	The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
NCT03206073	—	P1/P2	completed	A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
NCT02963831	—	P1/P2	completed	A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
NCT02870920	—	P2	completed	Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
NCT03101475	ILOC	P2	completed	Synergism of Immunomodulation and Tumor Ablation
+ 1 more, see All trials below.

Advanced Solid Tumors (8)

NCT	Acronym	Phase	Status	Title
NCT02671435	MEDI4736	P1/P2	active not recruiting	A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
NCT03889275	—	P1	completed	A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
NCT04261075	—	P1	completed	IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
NCT03665129	STELLAR-001	P1	terminated	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
NCT03089645	—	P1	completed	MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
NCT02900157	—	P1	completed	Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
NCT02301130	—	P1	completed	Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
NCT02205333	MEDI6469	P1/P2	terminated	A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

Small Cell Lung Carcinoma (7)

NCT	Acronym	Phase	Status	Title
NCT05617963	DURVALUNG	P2	active not recruiting	Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
NCT06992609	ALBORAN	P3	recruiting	Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
NCT05683977	ARSENAL	N/A	active not recruiting	A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
NCT06419179	GUIDANCE	P2	enrolling by invitation	Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
NCT06826677	ARAL	N/A	completed	REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
NCT03963414	—	P1	terminated	A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
NCT02658214	—	P1	completed	Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Ovarian Cancer (7)

NCT	Acronym	Phase	Status	Title
NCT04742075	DOVACC	P2	active not recruiting	Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
NCT04918186	IPROC	P2	recruiting	Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT03249142	INeOV	P1/P2	completed	Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
NCT03267589	—	P2	completed	Trial in Patients With Relapsed Ovarian Cancer
NCT02431559	—	P1/P2	completed	Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
NCT02764333	—	P2	completed	TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
NCT03283943	—	P1	unknown	PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Lung Non-Small Cell Carcinoma (6)

NCT	Acronym	Phase	Status	Title
NCT06498635	—	P3	recruiting	Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT07288034	L	P2	recruiting	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
NCT06732401	—	P3	active not recruiting	Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT05443971	—	P1	terminated	Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen
NCT04348292	—	P1	terminated	Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
NCT04262869	—	P2	withdrawn	Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Advanced Hepatocellular Carcinoma (6)

NCT	Acronym	Phase	Status	Title
NCT04430452	—	P2	recruiting	Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
NCT07166406	—	P3	recruiting	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT06470256	—	P1	recruiting	Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
NCT07174570	—	P2	recruiting	Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
NCT05883644	SIERRA	P3	active not recruiting	Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT04294498	—	P2	active not recruiting	Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

Biliary Tract Neoplasms (6)

NCT	Acronym	Phase	Status	Title
NCT07269158	—	P1/P2	not yet recruiting	A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
NCT03875235	TOPAZ-1	P3	active not recruiting	Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT04308174	DEBATE	P2	active not recruiting	Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
NCT03046862	MEDI4736	P2	unknown	Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
NCT05935579	—	P2	unknown	Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT02821754	HCC	P2	completed	A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Esophageal Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT06290505	PALEO	P2	recruiting	A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
NCT07196384	GLOW	P1	not yet recruiting	Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW
NCT05450484	OPTIC	P1	completed	Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer
NCT02735239	—	P1/P2	completed	Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
NCT02520453	—	P2	unknown	Adjuvant Durvalumab for Esophageal Cancer
NCT02639065	MEDI4736	P2	completed	A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Solid Tumor (6)

NCT	Acronym	Phase	Status	Title
NCT04900818	—	P1	recruiting	Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04078152	WAVE	P4	completed	Durvalumab Long-Term Safety and Efficacy Study
NCT02793466	—	P1	completed	Durvalumab in Pediatric and Adolescent Patients
NCT03238027	—	P1	completed	A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
NCT02718911	—	P1	completed	A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
NCT02737072	—	P1	terminated	A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Metastatic Breast Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT04538742	DB-07	P1/P2	active not recruiting	A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
NCT04556773	DB-08	P1	active not recruiting	A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
NCT03608865	MEDI4736	P2	completed	Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing
NCT02563925	—	N/A	completed	Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
NCT02649686	—	P1	completed	Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
NCT02802098	—	Early P1	completed	Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Cholangiocarcinoma (5)

NCT	Acronym	Phase	Status	Title
NCT06441747	MEDI4736	P2	recruiting	Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
NCT04521686	—	P1	active not recruiting	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
NCT05712356	BOLSTER	P2	terminated	A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT06341764	—	P2	recruiting	Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
NCT03473574	IMMUCHEC	P2	completed	Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

NSCLC, Stage III (5)

NCT	Acronym	Phase	Status	Title
NCT04351256	TRADE-hypo	P2	completed	Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy
NCT05757843	—	P2	withdrawn	Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
NCT05128630	DEDALUS	P2	unknown	Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.
NCT04202809	ESPADURVA	P2	unknown	Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.
NCT05718297	BOUNCE	P2	withdrawn	Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Pancreatic Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT05451043	BLOCKED	P2	recruiting	Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
NCT06094140	NEO-IMPACT	P2	active not recruiting	NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
NCT03572400	MEDI4736	P2	unknown	Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
NCT05327582	—	P1/P2	unknown	An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
NCT03038477	—	P2	withdrawn	A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT04392505	DART	P2	active not recruiting	Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
NCT03847649	—	P2	recruiting	A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
NCT02925234	DRUP	P2	recruiting	The Drug Rediscovery Protocol (DRUP Trial)
NCT05303532	ROSY-D	P3	enrolling by invitation	Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
NCT02938793	—	P2	terminated	Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Esophageal Squamous Cell Carcinoma (5)

NCT	Acronym	Phase	Status	Title
NCT04550260	KUNLUN	P3	active not recruiting	Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
NCT04568200	—	P2	completed	Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT04851132	—	N/A	unknown	Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma
NCT04054518	DESC	P2	unknown	Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma
NCT03377400	—	P2	unknown	Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Head and Neck Squamous Cell Carcinoma (5)

NCT	Acronym	Phase	Status	Title
NCT03212469	ABIMMUNE	P1/P2	completed	A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
NCT03283605	—	P1/P2	active not recruiting	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
NCT03618654	—	Early P1	completed	Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
NCT03450967	—	P2	unknown	Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
NCT02643303	—	P1/P2	completed	A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Multiple Myeloma (5)

NCT	Acronym	Phase	Status	Title
NCT02616640	—	P1	completed	A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
NCT02685826	—	P1/P2	completed	A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
NCT02807454	FUSIONMM-003	P2	terminated	A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
NCT02716805	—	P1	terminated	Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
NCT03000452	FUSION-MM-005	P2	completed	A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Non-small Cell Lung Cancer (NSCLC) (4)

NCT	Acronym	Phase	Status	Title
NCT06694454	MEDI4736	P1/P2	recruiting	Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
NCT07361497	NSCLC	P3	recruiting	A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT04513925	SKYSCRAPER-03	P3	completed	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT03693300	—	P2	completed	A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Bile Duct Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT06274879	Ablatio	P2	recruiting	Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
NCT05655949	—	P2	recruiting	Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
NCT04298008	—	P2	unknown	AZD6738 Plus Durvalumab in Biliary Tract Cancer
NCT04298021	—	P2	unknown	DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Extensive Stage Lung Small Cell Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT06769126	—	P2	recruiting	Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
NCT06287775	—	P1/P2	recruiting	Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
NCT04728230	—	P1/P2	active not recruiting	Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
NCT05161533	—	P2	withdrawn	Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Small-cell Lung Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT07005128	DeLLphi-312	P3	recruiting	A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07174583	—	P1/P2	recruiting	A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT05068232	DARES	P2	recruiting	Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
NCT04951115	—	P2	terminated	A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Hepatocellular Carcinoma (HCC) (4)

NCT	Acronym	Phase	Status	Title
NCT06994299	PRISM	P2	withdrawn	A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
NCT06911255	MEDI4736	P1/P2	recruiting	Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
NCT07012798	MEDI4736	P2	recruiting	FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
NCT06040099	EMERALD-Y90	P2	active not recruiting	A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Non-small Cell Lung Cancer Stage III (4)

NCT	Acronym	Phase	Status	Title
NCT06908070	CROWD	P4	recruiting	Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
NCT06998719	ACCESS	P2	not yet recruiting	Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
NCT06634199	SIENNA	N/A	recruiting	Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
NCT04765709	BRIDGE	P2	terminated	Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Extensive-stage Small Cell Lung Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT04397003	MEDI4736	P2	active not recruiting	Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
NCT06719336	STONE-001	P3	not yet recruiting	Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)
NCT04774380	LUMINANCE	P3	completed	Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
NCT03085849	—	P1	completed	SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Mesothelioma (4)

NCT	Acronym	Phase	Status	Title
NCT05932199	—	P1/P2	recruiting	Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
NCT04334759	DREAM3R	P3	completed	DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT03075527	—	P2	terminated	A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
NCT02899195	PrE0505	P2	completed	Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Locally Advanced Lung Non-Small Cell Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT05624996	—	P3	recruiting	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05136846	—	P1	recruiting	Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
NCT03801902	IPH2201	P1	completed	Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
NCT04372927	—	P2	terminated	ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Urothelial Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT03317158	ADAPT-BLADDER	P1/P2	recruiting	Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT05137262	MEDI 4736	P2	active not recruiting	A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
NCT03871036	ICRA	P1/P2	completed	Improve Checkpoint-blockade Response in Advanced Urothelial Cancer
NCT04322643	—	P2	terminated	Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Solid Tumors (4)

NCT	Acronym	Phase	Status	Title
NCT04613492	—	P1	terminated	A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
NCT03946800	—	P1	completed	A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
NCT02503774	—	P1	completed	MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
NCT02556463	—	P1	terminated	A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Metastatic Colorectal Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT03982173	MATILDA	P2	withdrawn	Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
NCT03376659	—	P1/P2	terminated	Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
NCT03435107	—	P2	completed	Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
NCT03122509	—	P2	completed	A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Prostate Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT03385655	—	P2	active not recruiting	Prostate Cancer Biomarker Enrichment and Treatment Selection
NCT02788773	—	P2	completed	Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
NCT03810105	—	P2	terminated	A Study of Olaparib and Durvalumab in Prostate Cancer
NCT04089553	—	P2	completed	An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Squamous Cell Carcinoma of the Head and Neck (4)

NCT	Acronym	Phase	Status	Title
NCT03723967	FRAIL-IMMUNE	P2	completed	FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
NCT03624231	DURTRE-RAD	P2	completed	Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
NCT03635164	—	P1	completed	Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
NCT02882308	OPHELIA	P2	completed	Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.

Extensive-stage Small-cell Lung Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT07459634	—	P2	not yet recruiting	A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
NCT06223711	—	P2	recruiting	Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
NCT05403723	—	P1	suspended	Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Solid Tumor, Adult (3)

NCT	Acronym	Phase	Status	Title
NCT06824363	—	Early P1	not yet recruiting	ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
NCT03772561	MEDIPAC	P1	recruiting	Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
NCT03496519	MEDI4736	P1	withdrawn	Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Intrahepatic Cholangiocarcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT04238637	BTC	P2	active not recruiting	Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
NCT06728410	—	P2	recruiting	A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
NCT06375915	PM-CARE	P2	unknown	Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy

Advanced Biliary Tract Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT07229625	BTC	P3	recruiting	A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
NCT06708858	—	P2	recruiting	Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
NCT04781192	MEDI4736	P1/P2	active not recruiting	The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Triple Negative Breast Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT06954480	DIAMOND	P2	recruiting	Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
NCT03199040	—	P1	terminated	Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
NCT03167619	DORA	P2	completed	Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

Small Cell Lung Cancer Extensive Stage (3)

NCT	Acronym	Phase	Status	Title
NCT05856695	TAXIO	P2	active not recruiting	Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT03923270	—	P1	active not recruiting	Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
NCT06939036	SANTANA-225	P1/P2	terminated	Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

HCC - Hepatocellular Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06999694	Proton-STRIDE	P2	recruiting	Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
NCT06999707	Photon-STRIDE	P2	recruiting	Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
NCT06045975	DUMELEP	P2	active not recruiting	Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

Urinary Bladder Neoplasms (3)

NCT	Acronym	Phase	Status	Title
NCT06960577	NIAGARA-2	P3	recruiting	Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NCT03459846	BAYOU	P2	active not recruiting	A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
NCT03258593	BCG	P1	completed	Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Bladder Urothelial Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT03601455	—	P2	active not recruiting	Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
NCT04216290	—	P2	active not recruiting	A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
NCT06263153	—	P2	recruiting	Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Extensive-Stage Small-Cell Lung Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT06211036	DeLLphi-305	P3	active not recruiting	Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT05796089	CHEST RT	P2	active not recruiting	Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
NCT04985851	—	N/A	unknown	To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Metastatic Pancreatic Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT05927142	DURIPANC	P1/P2	recruiting	Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
NCT05659914	MEDI4736	P2	active not recruiting	Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations
NCT02734160	LY2157299	P1	completed	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

NSCLC (3)

NCT	Acronym	Phase	Status	Title
NCT05687266	AVANZAR	P3	active not recruiting	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT04716946	—	P2	active not recruiting	Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
NCT03955198	SILK BM	P2	completed	A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation

Advanced Solid Tumours (3)

NCT	Acronym	Phase	Status	Title
NCT05514132	—	P1	active not recruiting	A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
NCT03518606	MOVIE	P1/P2	completed	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
NCT03421353	—	P1	completed	AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Melanoma (3)

NCT	Acronym	Phase	Status	Title
NCT05061134	MONETTE	P2	active not recruiting	A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT04107168	—	N/A	unknown	Microbiome Immunotherapy Toxicity and Response Evaluation
NCT02027961	—	P1	completed	Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Gastric Adenocarcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT05034887	MEDI4736	P2	active not recruiting	Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
NCT03959293	—	P2	active not recruiting	Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT03780608	—	P2	unknown	This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Endometrial Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT05255653	RAINBO	P2/P3	recruiting	Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT03015129	—	P2	completed	A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
NCT04444193	Dulect2020-2	N/A	unknown	Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma

Muscle Invasive Bladder Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT04960709	VOLGA	P3	active not recruiting	Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT03732677	NIAGARA	P3	active not recruiting	Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03773666	BLASST-2	P1	completed	A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Anatomic Stage IV Breast Cancer AJCC v8 (3)

NCT	Acronym	Phase	Status	Title
NCT03606967	—	P2	recruiting	Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT03801369	AMTEC IIT	P2	terminated	AMTEC IIT: Phase 2 Multiarm Study in TNBC
NCT03544125	—	P1	completed	Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Gastric Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03539822	CAMILLA	P1/P2	recruiting	Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
NCT04379596	DG-03	P2	recruiting	Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04817826	INFINITY	P2	active not recruiting	TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Small Cell Lung Carcinoma Extensive Disease (3)

NCT	Acronym	Phase	Status	Title
NCT03043872	CASPIAN	P3	active not recruiting	Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT04712903	CANTABRICO	P3	completed	Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
NCT04449861	—	P3	completed	Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Rectal Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT04621370	PRIME-RT	P2	unknown	A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
NCT04293419	DUREC	P2	unknown	Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer
NCT03102047	MEDI4736	P2	completed	Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Colorectal Cancer Metastatic (3)

NCT	Acronym	Phase	Status	Title
NCT04108481	iRE-C	P1	terminated	Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
NCT03202758	MEDITREME	P1/P2	completed	Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC
NCT03007407	—	P2	completed	Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Renal Cell Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT03288532	RAMPART	P3	recruiting	Renal Adjuvant MultiPle Arm Randomised Trial
NCT03598816	PIVOT-RCC	P2	withdrawn	PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
NCT02762006	—	P1	completed	Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

HNSCC (3)

NCT	Acronym	Phase	Status	Title
NCT03726775	REWRITe	P2	active not recruiting	Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
NCT03292250	TRIUMPH	P2	completed	Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
NCT06446570	MEDI4736	P2	completed	Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Head and Neck Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03019003	ASTX727	P1	completed	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
NCT03829007	PINCH	P1/P2	completed	PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC
NCT03162224	HPV	P1/P2	completed	Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Urothelial Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT02516241	—	P3	active not recruiting	Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT03406650	SAKK 06/17	P2	completed	Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.
NCT02891161	DUART	P1/P2	terminated	Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Advanced Solid Malignancies (3)

NCT	Acronym	Phase	Status	Title
NCT02740985	—	P1	completed	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
NCT03084471	STRONG	P3	completed	An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
NCT03394144	—	P1	completed	Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Recurrent Squamous Cell Lung Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT02154490	—	N/A	completed	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
NCT03373760	—	P2	completed	Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
NCT02766335	—	P2/P3	completed	Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Metastatic Biliary Tract Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07107750	CA-4948	P1	recruiting	Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
NCT06548412	—	P1/P2	recruiting	CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Small Cell Lung Cancer (SCLC) (2)

NCT	Acronym	Phase	Status	Title
NCT07149363	—	P2	recruiting	Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
NCT04285866	S-REAL	N/A	completed	Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.

Hepatocellular Carcinoma Non-resectable (2)

NCT	Acronym	Phase	Status	Title
NCT07122089	IOSPHERE	P2	recruiting	Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
NCT04522544	—	P2	recruiting	Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Small Cell Lung Cancer Limited Stage (2)

NCT	Acronym	Phase	Status	Title
NCT07055581	—	P2	recruiting	Durvalumab as Consolidation for Patients LS-SCLC
NCT04602533	DOLPHIN	P2	active not recruiting	Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Advanced Biliary Tract Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07036380	TACTIC	P2	recruiting	MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
NCT03704480	IMMUNO-BIL	P2	active not recruiting	Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

HCC (2)

NCT	Acronym	Phase	Status	Title
NCT07168668	EXEPECT	P2	not yet recruiting	Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
NCT04988945	—	P2	recruiting	TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Non Small Cell Lung Cancer NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT06680050	AUSTRAL	P2	recruiting	Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
NCT03164616	POSEIDON	P3	active not recruiting	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Biliary Tract Cancers (2)

NCT	Acronym	Phase	Status	Title
NCT06564623	BTC	P1	recruiting	Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
NCT05924880	TopDouble	P3	completed	A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

Limited Stage Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06773910	TIGOS-LS	P2	recruiting	BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT05034133	—	P2	unknown	Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) (2)

NCT	Acronym	Phase	Status	Title
NCT06191250	—	P2	terminated	--SuPERIOR Trial--
NCT04026412	CheckMate73L	P3	completed	A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Advanced Solid Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT06302426	—	P1	recruiting	Trial of INI-4001 in Patients With Advanced Solid Tumours
NCT04705818	CAIRE	P2	completed	Combining Epigenetic And Immune Therapy to Beat Cancer.

Pancreatic Ductal Adenocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06060405	DORA	P2	recruiting	Durvalumab and Oleclumab in Resectable PDAC
NCT04262388	DOME	P2	withdrawn	A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

Anatomic Stage II Breast Cancer AJCC v8 (2)

NCT	Acronym	Phase	Status	Title
NCT06058377	—	P3	recruiting	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT03132467	—	Early P1	completed	Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Unresectable Hepatocellular Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06117891	REFINE-IO	N/A	active not recruiting	An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT05345678	—	N/A	approved for marketing	Himalaya Early Access Program

Advanced or Metastatic NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT05941897	LOTOS	P2	active not recruiting	A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
NCT04612751	TROPION-Lung04	P1	active not recruiting	Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05361395	ES-SCLC	P1	active not recruiting	First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT04699838	—	P2	recruiting	Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

NSCLC Stage IV (2)

NCT	Acronym	Phase	Status	Title
NCT03620669	—	P2	active not recruiting	1st Line Durvalumab in PS 2 NSCLC Patients
NCT05383001	—	P2	withdrawn	Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Epithelial Ovarian Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT04644289	WoO	P2	recruiting	WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
NCT04015739	BOLD	P2	unknown	Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse

Non-Small Cell Lung Cancer NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT04667312	CODAK	N/A	completed	Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom
NCT02879617	MEDI4736	P2	completed	A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Stage III Non-small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03822351	COAST	P2	completed	Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
NCT05157542	—	P1	unknown	Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Lung Neoplasms (2)

NCT	Acronym	Phase	Status	Title
NCT04380636	NSCLC	P3	active not recruiting	Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04230408	PACIFIC BRAZIL	P2	completed	Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers

Stage III Non-small-cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03589547	358	P2	completed	Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
NCT04441138	ESR1814205	P2	terminated	Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

Pancreatic Adenocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT03245541	—	P1/P2	active not recruiting	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
NCT02879318	—	P2	completed	Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Recurrent Lung Non-Small Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT04092283	—	P3	active not recruiting	Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT03581487	—	P1/P2	completed	Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Platinum-Resistant Fallopian Tube Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT03026062	—	P2	completed	Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT04019288	—	P1/P2	terminated	AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Esophageal Adenocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT02962063	—	P1/P2	active not recruiting	Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
NCT04159974	RICE	P2	unknown	RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

Sarcoma (2)

NCT	Acronym	Phase	Status	Title
NCT03802071	—	P1/P2	completed	A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma
NCT03798106	—	P2	completed	A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Head and Neck Neoplasms (2)

NCT	Acronym	Phase	Status	Title
NCT03051906	DUCRO-HN	P1/P2	unknown	Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
NCT03799744	—	P1	unknown	Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Breast Neoplasms (2)

NCT	Acronym	Phase	Status	Title
NCT01042379	I-SPY	P2	recruiting	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT03594396	—	P1/P2	active not recruiting	Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Carcinoma, Squamous Cell of Head and Neck (2)

NCT	Acronym	Phase	Status	Title
NCT03088059	UPSTREAM	P2	unknown	Biomarker-based Study in R/M SCCHN
NCT03509012	CLOVER	P1	completed	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Lymphoma, Large B-Cell, Diffuse (2)

NCT	Acronym	Phase	Status	Title
NCT03003520	—	P2	completed	A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
NCT03241017	IDA-D	P2	withdrawn	Durvalumab in DLBCL After Autologous Transplant

Metastatic Carcinoma in the Liver (2)

NCT	Acronym	Phase	Status	Title
NCT02754856	—	P1	completed	Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
NCT03005002	—	P1	completed	Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Germ Cell Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT03158064	MEDI4736	P2	active not recruiting	Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
NCT03081923	APACHE	P2	terminated	Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

Glioblastoma (2)

NCT	Acronym	Phase	Status	Title
NCT02866747	STERIMGLI	P1/P2	completed	A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
NCT02336165	MEDI4736	P2	completed	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Non Small Cell Lung Carcinoma NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT02542293	NEPTUNE	P3	active not recruiting	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT03003962	PEARL	P3	active not recruiting	Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Esophagogastric Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07507968	—	P2	not yet recruiting	TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Muscle Invasive Bladder Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07332351	TRIFECTA	P2	not yet recruiting	Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Small Cell Lung Cancer ( SCLC ) (1)

NCT	Acronym	Phase	Status	Title
NCT07339059	—	P2	recruiting	Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Combined Hepatocellular and Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06855225	—	P2	not yet recruiting	A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

MPNST (1)

NCT	Acronym	Phase	Status	Title
NCT05253131	—	P2	not yet recruiting	Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Advanced Unresectable Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07175441	—	P2	recruiting	Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Locally Advanced Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07511504	—	P2	not yet recruiting	Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Hepato Cellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07489976	—	P2	recruiting	IIT2025-03-YANG-LIFT-HCC

Solid Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT07391670	IMFINZI-subQ	P1	recruiting	A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

Hepato Cellular Carcinoma (HCC) (1)

NCT	Acronym	Phase	Status	Title
NCT06608940	STRIDE	P1/P2	withdrawn	BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Extensive Stage Lung Small Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07172412	—	P2	not yet recruiting	Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Gastroesophageal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05733689	—	P1	recruiting	Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Advanced Intrahepatic Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06858735	HYPERION CCA	P2	recruiting	HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc) (1)

NCT	Acronym	Phase	Status	Title
NCT06859684	HAIC-quad	P2	recruiting	Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Non-muscle Invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06503614	ENHANCE	P2	recruiting	A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Rare Tumour (1)

NCT	Acronym	Phase	Status	Title
NCT06692491	SPRING	P2	not yet recruiting	Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Borderline Resectable Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06017297	ESR-22-21719	P2	withdrawn	Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Advanced or Recurrent Endometrial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06746116	DUoENDE	P3	active not recruiting	A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT06501625	—	P1/P2	recruiting	Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Ovarian Cancer Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT06650709	NEOCATS	P2	not yet recruiting	NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

Gallbladder Cancer Unresectable (1)

NCT	Acronym	Phase	Status	Title
NCT06591650	GCND	P2	recruiting	Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer

Biliary Tract Cancers (BTC) (1)

NCT	Acronym	Phase	Status	Title
NCT06611345	—	N/A	recruiting	A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

Brain Metastases from Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04889066	MEDI4736	P2	withdrawn	Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT06551142	PanTumor-101	P1	recruiting	A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

Advanced Non-squamous Non-small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06463665	VIRO-25	P2	recruiting	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Extrahepatic Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06440993	ID-RFA	P2	recruiting	Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Biliary Tract Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06530823	—	P2	not yet recruiting	Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

Resectable Intrahepatic Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06050252	—	P2	recruiting	Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Hepatic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06492408	—	P2	recruiting	Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Large Cell Neuroendocrine Carcinoma of the Lung (1)

NCT	Acronym	Phase	Status	Title
NCT06393816	FIRST-NEC	P2	recruiting	FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Liver Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06482801	—	P2	recruiting	Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Locally Advanced Intrahepatic Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06058663	—	P1	recruiting	Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Lung Cancer Patients (1)

NCT	Acronym	Phase	Status	Title
NCT06331455	SUPER	P2	recruiting	Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

Hepatitis B, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT06245291	AB-729	P2	withdrawn	Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Gall Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06214572	RUGB	P2/P3	recruiting	Radiation Therapy in Unresectable Gall Bladder Cancer

Fibrolamellar Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06027086	FLC	P1/P2	recruiting	DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

TNBC - Triple-Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05209529	—	P2	withdrawn	Chemo-free BRCA-targeted Neoadjuvant Strategy

Extrapulmonary Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06464068	DURVASCC	P2	recruiting	AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Clinical Stage I Esophageal Adenocarcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT06078709	PHOX	P2	recruiting	Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

Gastrointestinal Neuroendocrine Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06070740	—	P2	recruiting	First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Oncology (1)

NCT	Acronym	Phase	Status	Title
NCT06031233	MINUTE	P4	recruiting	Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Esophagus Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05713838	—	P2	recruiting	Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Non-Muscle- Invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05943106	PATAPSCO	P3	active not recruiting	BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Nonsmall Cell Lung Cancer Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT05696782	—	P2	recruiting	Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT05194293	—	P2	active not recruiting	Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Unrescetable Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05864755	—	P2	unknown	HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

SCLC, Limited Stage (1)

NCT	Acronym	Phase	Status	Title
NCT06371482	—	P2	recruiting	Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Locally Advanced Pancreatic Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05411094	—	P1	suspended	Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Invasive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05795101	TRUDI	P2	recruiting	TRUDI: TDXD+Durva in HER2+/Low IBC

Resectable Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05701488	—	P1	recruiting	SIRT With Tremelimumab and Durvalumab for Resectable HCC

Durvalumab (1)

NCT	Acronym	Phase	Status	Title
NCT05672537	—	P2	unknown	Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Premenopausal Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05720260	—	P2	recruiting	Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT05388006	—	P2	recruiting	Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Stomach Cancer, Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05620628	MEDI4736	P2	recruiting	Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Nonsmall Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04625699	—	P2	withdrawn	Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Lung Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05198830	—	P2	recruiting	Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Triple Negative Breast Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT05582538	ATRiBRAVE	P2	recruiting	Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Resectable Biliary Tract Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05640791	—	P2	unknown	Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Adenocarcinoma of Lung (1)

NCT	Acronym	Phase	Status	Title
NCT04105270	—	P2	recruiting	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Advanced or Metastatic Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05450692	LATIFY	P3	active not recruiting	A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Locally Advanced Bladder Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04637594	IMAGINE	P3	active not recruiting	Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Pulmonary Large-cell Neuroendocrine Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06418087	DUPLE	P2	recruiting	Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

Biliary Tract Cancer (CCA) (1)

NCT	Acronym	Phase	Status	Title
NCT05239169	—	P2	completed	Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Mesothelioma, Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT05380713	—	P2	completed	......SMARTEST Trial......

Non-small-cell Lung Cancer Patients (1)

NCT	Acronym	Phase	Status	Title
NCT05568212	NSCLC	P2	recruiting	Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Colorectal Cancer Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT05382741	VIVA	P2	unknown	Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

Patients With Advanced Treatment Naive LCNEC (1)

NCT	Acronym	Phase	Status	Title
NCT05262985	MEDI4736	P2	unknown	Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study

Infiltrating Urothelial Carcinoma, Sarcomatoid Variant (1)

NCT	Acronym	Phase	Status	Title
NCT05154994	RESOLVE	P1	active not recruiting	Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

Locally Advanced or Metastatic Solid Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT04999969	—	P2	active not recruiting	Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Metastatic or Locally Advanced NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT05000710	CORAL-Lung	P2	active not recruiting	Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Early Small (cT1N0) Triple Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05215106	POP-DURVA	P2	recruiting	Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

Unresectable Non-small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT04416633	—	P4	completed	Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Renal Pelvis and Ureter Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04628767	—	P2/P3	recruiting	Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Papillary Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05043090	SAMETA	P3	active not recruiting	Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Borderline Resectable Pancreatic Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04940286	—	P2	active not recruiting	Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Unresectable Intrahepatic Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04301778	—	P2	completed	Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

BCLC Stage B Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04605731	—	P1	active not recruiting	Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Stage III Lung Cancer AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04892953	—	P2	recruiting	Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

EGFR-Mutated Non-Small-Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04538378	LYNPARZA	P2	terminated	Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Squamous Cell Head and Neck Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03673735	ADHERE	P3	withdrawn	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC

Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04800978	—	P2	unknown	Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy

Fallopian Tube Mucinous Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04739800	—	P2	active not recruiting	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Stomach Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04893252	—	P2	unknown	Vactosertib and Durvalumab in Gastric Cancer

SCLC, Extensive Stage (1)

NCT	Acronym	Phase	Status	Title
NCT04660097	—	P2	completed	Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Primary Central Nervous System Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04462328	—	P1	active not recruiting	Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

Advanced Bladder Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04902040	—	P1/P2	terminated	Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Biochemically Recurrent Prostate Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04336943	—	P2	terminated	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Hepatocellular Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03937830	TACE	P2	active not recruiting	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Stage IIIA Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04062708	—	P2	active not recruiting	CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04686305	DL03	P1	recruiting	Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Small-Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04745689	TAZMAN	P2	active not recruiting	Study of AZD2811 + Durvalumab in ES-SCLC

Unresectable Stage III NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT04982549	—	P2	unknown	A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Carcinoma, Non-Small Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT04499053	—	P2	recruiting	Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Metastatic Pancreatic Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04348045	MAZEPPA	P2	active not recruiting	Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

Platinum-Resistant Lung Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04607954	—	P2	active not recruiting	Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Epstein-Barr Virus Positive (1)

NCT	Acronym	Phase	Status	Title
NCT04231864	—	P2	withdrawn	Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

Carcinoma, Non- Small Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT04642469	MERMAID-2	P3	completed	Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Metastatic Angiosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT04668300	DOSa	P2	active not recruiting	Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Gastrointestinal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT04592913	—	P3	active not recruiting	Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT (1)

NCT	Acronym	Phase	Status	Title
NCT04517526	—	P2	unknown	Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Non-small Cell Lung Cancer Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT04108026	SAVIMMUNE	P2	completed	Immunotherapy in Patient With Poor General Condition

Microsatellite-stable Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04145193	—	P2	withdrawn	Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Liver Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04443322	Dulect2020-1	N/A	unknown	Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )

SCLC, Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT04525391	SUKSES-N5	P2	terminated	AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

Superior Sulcus Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04465968	DEEP_OCEAN	P3	not yet recruiting	Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Clear Cell Renal Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04504669	—	P1	completed	First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Malignant Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04223648	MEDI4736	Early P1	withdrawn	Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Advanced Malignant Skin Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04387084	—	P1	active not recruiting	Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Metastatic Malignant Female Reproductive System Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04395079	—	P2	active not recruiting	Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Progressive Metastatic Castrate-Resistant Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04495179	AARDVARC	P2	completed	A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Non Small Cell Lung Cancer Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT04672759	—	N/A	unknown	A Real-world Study of Durvalumab for Lung Cancer in China

Renal Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03741426	WIRE	P2	unknown	WIRE - Novel Treatments in Renal Cell Cancer

Leptomeningeal Metastasis (1)

NCT	Acronym	Phase	Status	Title
NCT04356222	—	P4	unknown	Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Non-Small Cell Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT04163432	STAGGER	P2	active not recruiting	Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

Nasopharyngeal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04447612	—	P2	unknown	Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Uveal Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04184518	CEDUVEAL-M	P2	withdrawn	Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

Pancreas Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04257448	SEPION	P1/P2	completed	Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04221555	—	P2	completed	Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Pancreatic Cancer Non-resectable (1)

NCT	Acronym	Phase	Status	Title
NCT04156087	MIMIPAC	P2	completed	Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Endometrial Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT04269200	DUO-E	P3	active not recruiting	Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Anlotinib (1)

NCT	Acronym	Phase	Status	Title
NCT04314297	—	P2	unknown	Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03878524	SMMART	P1	terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Immunotherapy (1)

NCT	Acronym	Phase	Status	Title
NCT04169841	GUIDE2REPAIR	P2	active not recruiting	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Anal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04230759	RADIANCE	P2	active not recruiting	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

RECTAL CANCER (1)

NCT	Acronym	Phase	Status	Title
NCT04083365	PANDORA	P2	unknown	Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT03991832	SOLID	P2	recruiting	Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

Urothelial Carcinoma Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT04064190	—	P2	withdrawn	Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

Gynaecological Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT04065269	ATARI	P2	active not recruiting	ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Advanced Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT03842228	COD	P1	active not recruiting	Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Luminal B (1)

NCT	Acronym	Phase	Status	Title
NCT03875573	Neo-CheckRay	P2	active not recruiting	Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:

Soft Tissue Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03784014	MULTISARC	P3	completed	Molecular Profiling of Advanced Soft-tissue Sarcomas

Breast Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT03740893	PHOENIX	P2	recruiting	PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

ER+ Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03983954	—	P1	active not recruiting	Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Larynx (1)

NCT	Acronym	Phase	Status	Title
NCT03529422	—	P2	active not recruiting	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Intermediate Stage of Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03638141	DEB-TACE	P2	completed	CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Breast Cancer Female (1)

NCT	Acronym	Phase	Status	Title
NCT04088032	—	Early P1	withdrawn	Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Bladder Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03824691	ARCADIA	P2	unknown	hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Stage III Hepatocellular Carcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT03942328	—	P1/P2	recruiting	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

HPV Positive Oropharyngeal Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04001413	—	P2	withdrawn	Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Metastatic Microsatellite-stable Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04068610	COLUMBIA-1	P1/P2	active not recruiting	COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04053322	DOLAF	P2	active not recruiting	Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03381183	—	P1	completed	IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Locally Advanced Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT03907475	—	P2	recruiting	Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Ovarian Cancer Stage IIIC (1)

NCT	Acronym	Phase	Status	Title
NCT03899610	KGOG3046	P2	unknown	A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

Stage IIB Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03916419	—	P2	completed	Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Tumor, Solid (1)

NCT	Acronym	Phase	Status	Title
NCT03911557	—	P2	completed	Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Bladder Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03912818	—	P2	terminated	Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Mismatch Repair Proficient Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03851614	DAPPER	P2	active not recruiting	Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

Metastatic Thyroid Papillary Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03753919	DUTHY	P2	terminated	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Node; Prostate (1)

NCT	Acronym	Phase	Status	Title
NCT03795207	POSTCARD	P2	active not recruiting	Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

Resectable (1)

NCT	Acronym	Phase	Status	Title
NCT03794544	—	P2	completed	Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Pediatric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03837899	—	P1/P2	active not recruiting	Durvalumab and Tremelimumab for Pediatric Malignancies

Locally Advanced Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03830866	CALLA	P3	completed	Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

Potentially Resectable Stage II/IIIa NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT03694236	MEDI4736	P1/P2	recruiting	Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03685344	—	P1	terminated	Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Clear Cell Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03682289	AZD6738	P2	active not recruiting	Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Advanced Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03737643	DUO-O	P3	active not recruiting	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Stage II-IVB Operable HNSCC Oral Cavity (1)

NCT	Acronym	Phase	Status	Title
NCT03737968	MEDI4736	P2	unknown	Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Stage III NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT04287894	Induction	P1	terminated	Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Metastatic Non-Small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT03819465	MAGELLAN	P1	active not recruiting	A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Triple Negative Breast Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT03742102	BEGONIA	P1/P2	active not recruiting	A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Non-small Cell Lung Cancer NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT03775486	ORION	P2	active not recruiting	Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Infiltrating Bladder Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03549715	NEMIO	P1/P2	unknown	NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Esophagus Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03777813	ARION	P2	completed	Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03739931	—	P1	completed	Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Platinum-resistant Recurrent Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03699449	AMBITION	P2	unknown	An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Advanced Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03579784	MEDI4736	P2	unknown	Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03702179	IMMUNOPRESERVE	P2	completed	Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach

Human Papillomavirus-16 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03439085	—	P2	terminated	DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Adenocarcinoma of the Pancreas (1)

NCT	Acronym	Phase	Status	Title
NCT03490760	—	P2	terminated	Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Squamous Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03319316	SOLUTION	P2	withdrawn	Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

Diffuse Large B Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03610061	RaDD	P1	completed	A Trial of Radiotherapy and Durvalumab in DLBCL and FL

Oesophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03653052	CALIBRATION	P2	active not recruiting	Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

Recurrent Head and Neck Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03691714	MEDI4736	P2	completed	Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

EGFR Mutant Advanced Non Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03994393	ILLUMINATE	P2	unknown	Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Pleura Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT04115111	Diadem	P2	completed	Diadem to Investigate the Activity and Safety of Durvalumab

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8 (1)

NCT	Acronym	Phase	Status	Title
NCT03618134	—	P1/P2	terminated	Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

High-Risk Resectable NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT03732664	—	P1	completed	ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Unresectable Locally Advanced Urothelial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03682068	NILE	P3	active not recruiting	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Endometrial Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03660826	—	P2	active not recruiting	Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Solid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03721679	—	P1/P2	terminated	Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Locally Advanced Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03426657	—	P2	completed	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

Oral Cavity Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03784066	DUTRELASCO	P1/P2	active not recruiting	Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Advanced Cervical Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03452332	—	P1	completed	Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Muscle-invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03234153	NITIMIB	P2	terminated	Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03611556	—	P1/P2	completed	MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Metastatic Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03751761	MEDI4736	P1/P2	completed	GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Recurrent Gynecological Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03277482	—	P1	terminated	Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03004105	NSCLC	P2	withdrawn	MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Lymphoma, T-Cell (1)

NCT	Acronym	Phase	Status	Title
NCT03161223	—	P1/P2	recruiting	Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Oropharyngeal Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03410615	—	P2	active not recruiting	Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

HER2-Negative Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03430518	—	P1	completed	Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Metastatic Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03522584	—	P1/P2	terminated	Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Castration Levels of Testosterone (1)

NCT	Acronym	Phase	Status	Title
NCT02966587	—	P2	withdrawn	Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Non-muscle-invasive Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03528694	POTOMAC	P3	active not recruiting	Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT03258554	—	P2/P3	completed	Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Malignant Neoplasms of Digestive Organs (1)

NCT	Acronym	Phase	Status	Title
NCT03428126	MEDI4736	P2	completed	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Cutaneous T Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03235869	—	Early P1	withdrawn	Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Extrahepatic Bile Duct Adenocarcinoma, Biliary Type (1)

NCT	Acronym	Phase	Status	Title
NCT03257761	—	P1	active not recruiting	Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Non-Transitional Cell Carcinoma of the Urothelial Tract (1)

NCT	Acronym	Phase	Status	Title
NCT03430895	MEDI4736	P2	completed	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Metastatic Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03164772	—	P1/P2	completed	Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

Lymphoma, Non-Hodgkin (1)

NCT	Acronym	Phase	Status	Title
NCT03310619	PLATFORM	P1/P2	completed	A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Carcinoma, Squamous Cell (1)

NCT	Acronym	Phase	Status	Title
NCT03174275	—	P2	active not recruiting	Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Advanced Kidney Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03308396	—	P1/P2	active not recruiting	Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Metastatic Adult Soft Tissue Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03317457	MEDISARC	P2	completed	Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

NSCLC, Stage I (1)

NCT	Acronym	Phase	Status	Title
NCT03446547	ASTEROID	P2	completed	Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

Squamous Cell Carcinoma, Head And Neck (1)

NCT	Acronym	Phase	Status	Title
NCT02993991	PRIMED-001	P1	withdrawn	Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Ovarian Clear Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03405454	—	P2	unknown	A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

EBV Related Non-Hodgkin's Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03212807	DuRIANS	P2	withdrawn	Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

Relapsed/Refractory Solid Tumor Malignancies or Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03323398	—	P1/P2	terminated	Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Metastatic Colorectal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02888743	—	P2	active not recruiting	Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Metastatic Pancreas Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02885727	Panc-Durval+RT	P2	withdrawn	Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)

LYMPHOMA (1)

NCT	Acronym	Phase	Status	Title
NCT03054532	—	P2	unknown	Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

Solitary Bone Plasmacytoma (1)

NCT	Acronym	Phase	Status	Title
NCT03196401	—	P1	withdrawn	A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

Castration-Resistant Prostate Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03204812	—	P2	completed	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 (1)

NCT	Acronym	Phase	Status	Title
NCT03144778	—	P1	completed	Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Thyroid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03215095	—	Early P1	active not recruiting	RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

BRCA1 Gene Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT02953457	—	P2	completed	Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT03022500	—	P2	completed	Pulmonary sarcomatoid_MEDI4736+Treme

Lung Cancer Stage II (1)

NCT	Acronym	Phase	Status	Title
NCT03141359	—	P2	active not recruiting	Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Ovarian Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03085225	TRAMUNE	P1	completed	Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Metastatic Anaplastic Thyroid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03122496	SBRT	P1	completed	Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

HIV (1)

NCT	Acronym	Phase	Status	Title
NCT03094286	—	P2	completed	Durvalumab in HIV-1 Patients With Solid Tumors

Neuroendocrine Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT03095274	DUNE	P2	completed	Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Head and Neck Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT02997332	MEDINDUCTION	P1	terminated	Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma

Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT03057106	—	P2	active not recruiting	Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Folliculotropic Mycosis Fungoides (1)

NCT	Acronym	Phase	Status	Title
NCT03011814	—	P1/P2	active not recruiting	Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Hydronephrosis (1)

NCT	Acronym	Phase	Status	Title
NCT02812420	—	Early P1	active not recruiting	Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Advanced Colorectal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02983578	—	P2	active not recruiting	Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Carcinoma in Situ of Bladder (1)

NCT	Acronym	Phase	Status	Title
NCT02901548	BCG	P2	terminated	Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Human Papillomavirus Infection (1)

NCT	Acronym	Phase	Status	Title
NCT02827838	—	Early P1	terminated	Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Advanced Rare Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT02879162	—	P2	completed	Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Advanced Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT02978482	MEDI4736	P1	completed	A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase (1)

NCT	Acronym	Phase	Status	Title
NCT02871323	—	P1	withdrawn	Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02937818	—	P2	completed	A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (1)

NCT	Acronym	Phase	Status	Title
NCT02706405	—	P1	terminated	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Malignant Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT02794883	—	P2	completed	Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Microsatellite Stable Colorectal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02811497	METADUR	P2	completed	Study of Azacitidine and Durvalumab in Advanced Solid Tumors

Advanced and/or Metastatic Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT02815995	—	P2	completed	Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Stage III Fallopian Tube Cancer AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT02726997	—	P1/P2	active not recruiting	Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Leukemia, Myeloid, Acute (1)

NCT	Acronym	Phase	Status	Title
NCT02775903	MEDI4736	P2	completed	An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Advanced Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02805660	—	P1/P2	terminated	Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02733042	FUSION NHL 001	P1/P2	completed	A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02701400	—	P2	completed	Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Select Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT02705482	—	P1	completed	A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Solid Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT02537418	—	P1	active not recruiting	Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Oropharyngeal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04116047	CompARE	P3	active not recruiting	CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Non-Small-Cell Lung Carcinoma NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02453282	MYSTIC	P3	active not recruiting	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Myelodysplastic Syndromes (1)

NCT	Acronym	Phase	Status	Title
NCT02281084	—	P2	completed	Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Colorectal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02484404	MEDI4736	P1/P2	active not recruiting	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Lung Non-Squamous Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02452463	—	P2	terminated	Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Pancreatic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02311361	—	P1/P2	completed	Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Adenocarcinoma of the Oesophagus (1)

NCT	Acronym	Phase	Status	Title
NCT02678182	PLATFORM	P2	active not recruiting	Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Non - Small Cell Lung Cancer NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02352948	ARCTIC	P3	completed	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02264678	—	P1	active not recruiting	Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Select Advanced Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT02118337	AMP-514	P1/P2	completed	A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Non-small Cell Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT02117167	SAFIR02_Lung	P2	completed	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Malignant Solid Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02029001	MOST plus	P2	recruiting	Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Stage II Non-Small Cell Lung Cancer AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT01993810	—	P3	active not recruiting	Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Durvalumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
MINUTE	NCT06031233	P4	recruiting	Oncology	776	—
CROWD	NCT06908070	P4	recruiting	Non-small Cell Lung Cancer Stage III	38	—
WAVE	NCT04078152	P4	completed	Solid Tumor	163	—
MK-1084	NCT07554339	P3	recruiting	Non-small Cell Lung Cancer	310	—
RAMPART	NCT03288532	P3	recruiting	Renal Cell Carcinoma	1,750	PMID 34538402
NSCLC	NCT07361497	P3	recruiting	Non-small Cell Lung Cancer (NSCLC)	850	—
NVALT28	NCT04597671	P3	active not recruiting	Carcinoma, Non-Small-Cell Lung	170	—
SUNRAY-02	NCT06890598	P3	recruiting	Carcinoma, Non-Small-Cell Lung	700	—
CompARE	NCT04116047	P3	active not recruiting	Oropharyngeal Cancer	785	—
PACIFIC-8	NCT05211895	P3	recruiting	Non-Small Cell Lung Cancer	860	—
IMAGINE	NCT04637594	P3	active not recruiting	Locally Advanced Bladder Urothelial Carcinoma	3	—
DEEP_OCEAN	NCT04465968	P3	not yet recruiting	Superior Sulcus Tumor	84	—
PACIFIC-9	NCT05221840	P3	active not recruiting	Non-Small Cell Lung Cancer	1,051	PMID 39023287
HORIZON 1	NCT05170204	P3	active not recruiting	Non-Small Cell Lung Cancer	68	—
ADOPT-lung	NCT06284317	P3	recruiting	Non Small Cell Lung Cancer	290	—
BTC	NCT07229625	P3	recruiting	Advanced Biliary Tract Cancer	604	—
DeLLphi-312	NCT07005128	P3	recruiting	Small-cell Lung Cancer	330	—
NSCLC	NCT04380636	P3	active not recruiting	Lung Neoplasms	870	PMID 35618629
AB02	NCT07221253	P3	recruiting	Biliary Tract Cancer	1,100	—
ALBORAN	NCT06992609	P3	recruiting	Small Cell Lung Carcinoma	70	—
DESTINY-BTC01	NCT06467357	P3	recruiting	Biliary Tract Cancer	620	—
STONE-001	NCT06719336	P3	not yet recruiting	Extensive-stage Small Cell Lung Cancer	182	—
DUoENDE	NCT06746116	P3	active not recruiting	Advanced or Recurrent Endometrial Cancer	45	—
NIAGARA-2	NCT06960577	P3	recruiting	Urinary Bladder Neoplasms	150	—
PACIFIC-4	NCT03833154	P3	active not recruiting	Carcinoma, Non-Small-Cell Lung	724	—
POTOMAC	NCT03528694	P3	active not recruiting	Non-muscle-invasive Bladder Cancer	1,018	PMID 41115436
DeLLphi-305	NCT06211036	P3	active not recruiting	Extensive-Stage Small-Cell Lung Cancer	563	PMID 40934933
AEGEAN	NCT03800134	P3	active not recruiting	Non-Small Cell Lung Cancer	825	PMID 40545237
VOLGA	NCT04960709	P3	active not recruiting	Muscle Invasive Bladder Cancer	712	—
LATIFY	NCT05450692	P3	active not recruiting	Advanced or Metastatic Non-Small Cell Lung Cancer	594	—
ADHERE	NCT03673735	P3	withdrawn	Squamous Cell Head and Neck Carcinoma	0	—
POSEIDON	NCT03164616	P3	active not recruiting	Non Small Cell Lung Cancer NSCLC	1,186	PMID 39243945
AVANZAR	NCT05687266	P3	active not recruiting	NSCLC	1,350	—
KUNLUN	NCT04550260	P3	active not recruiting	Esophageal Squamous Cell Carcinoma	640	—
NILE	NCT03682068	P3	active not recruiting	Unresectable Locally Advanced Urothelial Cancer	1,246	—
EMERALD-2	NCT03847428	P3	active not recruiting	Hepatocellular Carcinoma	908	—
TOPAZ-1	NCT03875235	P3	active not recruiting	Biliary Tract Neoplasms	810	PMID 38319896
DUO-E	NCT04269200	P3	active not recruiting	Endometrial Neoplasms	805	PMID 41943281
PATAPSCO	NCT05943106	P3	active not recruiting	Non-Muscle- Invasive Bladder Cancer	100	—
EMERALD-3	NCT05301842	P3	active not recruiting	Hepatocellular Carcinoma	760	—
PACIFIC-5	NCT03706690	P3	active not recruiting	Carcinoma, Non-Small-Cell Lung	407	PMID 41354932
SAMETA	NCT05043090	P3	active not recruiting	Papillary Renal Cell Carcinoma	148	PMID 41861260
ROSY-D	NCT05303532	P3	enrolling by invitation	Cancer	214	—
CASPIAN	NCT03043872	P3	active not recruiting	Small Cell Lung Carcinoma Extensive Disease	987	PMID 38811992
NEPTUNE	NCT02542293	P3	active not recruiting	Non Small Cell Lung Carcinoma NSCLC	953	PMID 36806898
MYSTIC	NCT02453282	P3	active not recruiting	Non-Small-Cell Lung Carcinoma NSCLC	1,118	PMID 32271377
DUO-O	NCT03737643	P3	active not recruiting	Advanced Ovarian Cancer	1,407	PMID 37185961
ADRIATIC	NCT03703297	P3	active not recruiting	Small Cell Lung Cancer	730	PMID 40976711
SIERRA	NCT05883644	P3	active not recruiting	Advanced Hepatocellular Carcinoma	111	—
TOURMALINE	NCT05771480	P3	active not recruiting	Biliary Tract Cancer	142	—
EMERALD-1	NCT03778957	P3	active not recruiting	Hepatocellular Carcinoma	724	PMID 39798579
HIMALAYA	NCT03298451	P3	active not recruiting	Hepatocellular Carcinoma	1,324	PMID 38805668
KEYVIBE-006	NCT05298423	P3	active not recruiting	Carcinoma, Non-Small-Cell Lung	611	—
NIAGARA	NCT03732677	P3	active not recruiting	Muscle Invasive Bladder Cancer	1,063	PMID 39282910
PEARL	NCT03003962	P3	active not recruiting	Non Small Cell Lung Carcinoma NSCLC	669	—
MULTISARC	NCT03784014	P3	completed	Soft Tissue Sarcoma	603	PMID 34740331
SKYSCRAPER-03	NCT04513925	P3	completed	Non-small Cell Lung Cancer (NSCLC)	829	—
DREAM3R	NCT04334759	P3	completed	Mesothelioma	214	PMID 33358660
TREMENDOUS	NCT05557838	P3	recruiting	Hepatocellular Carcinoma	210	—
TopDouble	NCT05924880	P3	completed	Biliary Tract Cancers	116	—
LUMINANCE	NCT04774380	P3	completed	Extensive-stage Small Cell Lung Cancer	152	—
CheckMate73L	NCT04026412	P3	completed	Non-Small Cell Lung Cancer (NSCLC)	925	PMID 42129521
MERMAID-2	NCT04642469	P3	completed	Carcinoma, Non- Small Cell Lung	30	—
MERMAID-1	NCT04385368	P3	completed	Carcinoma, Non-Small-Cell Lung	89	—
ARCTIC	NCT02352948	P3	completed	Non - Small Cell Lung Cancer NSCLC	597	PMID 32201234
CALLA	NCT03830866	P3	completed	Locally Advanced Cervical Cancer	770	PMID 38039991
CANTABRICO	NCT04712903	P3	completed	Small Cell Lung Carcinoma Extensive Disease	101	PMID 41033130
STRONG	NCT03084471	P3	completed	Advanced Solid Malignancies	867	PMID 35042068
Proton-STRIDE	NCT06999694	P2	recruiting	HCC - Hepatocellular Carcinoma	45	—
Photon-STRIDE	NCT06999707	P2	recruiting	HCC - Hepatocellular Carcinoma	45	—
DART	NCT04392505	P2	active not recruiting	Cancer	100	PMID 37476372
ENHANCE	NCT06503614	P2	recruiting	Non-muscle Invasive Bladder Cancer	60	—
TRUDI	NCT05795101	P2	recruiting	Invasive Breast Cancer	63	—
TIGOS-LS	NCT06773910	P2	recruiting	Limited Stage Small Cell Lung Cancer	250	—
SERPENTINE	NCT06680739	P2	recruiting	Colorectal Cancer	60	—
NSCLC	NCT04245514	P2	active not recruiting	Non-small Cell Lung Cancer	90	PMID 39349061
I-SPY	NCT01042379	P2	recruiting	Breast Neoplasms	5,000	PMID 21796368
MIGRANT	NCT07247786	P2	not yet recruiting	Non Small Cell Lung Cancer	68	—
DOVACC	NCT04742075	P2	active not recruiting	Ovarian Cancer	188	—
Ablatio	NCT06274879	P2	recruiting	Bile Duct Cancer	36	PMID 41816011
HYPERION CCA	NCT06858735	P2	recruiting	Advanced Intrahepatic Cholangiocarcinoma	60	—
MOZART	NCT05903092	P2	recruiting	Small Cell Lung Cancer	84	—
REVIVE	NCT07603856	P2	not yet recruiting	Non-Small Cell Lung Cancer	39	—
NeoCOAST-2	NCT05061550	P2	recruiting	Non-small Cell Lung Cancer	630	PMID 40450142
DIAMOND	NCT06954480	P2	recruiting	Triple Negative Breast Cancer	140	—
DURVALUNG	NCT05617963	P2	active not recruiting	Small Cell Lung Carcinoma	100	—
IOSPHERE	NCT07122089	P2	recruiting	Hepatocellular Carcinoma Non-resectable	80	—
SPRING	NCT06692491	P2	not yet recruiting	Rare Tumour	200	—
ATRiBRAVE	NCT05582538	P2	recruiting	Triple Negative Breast Cancer Metastatic	37	—
TACTIC	NCT07036380	P2	recruiting	Advanced Biliary Tract Carcinoma	75	—
BLOCKED	NCT05451043	P2	recruiting	Pancreatic Cancer	62	—
FIRST-NEC	NCT06393816	P2	recruiting	Large Cell Neuroendocrine Carcinoma of the Lung	80	—
MEDI4736	NCT04397003	P2	active not recruiting	Extensive-stage Small Cell Lung Cancer	6	—
Neo-CheckRay	NCT03875573	P2	active not recruiting	Luminal B	147	PMID 38056900
VIRO-25	NCT06463665	P2	recruiting	Advanced Non-squamous Non-small-cell Lung Cancer	142	—
PALEO	NCT06290505	P2	recruiting	Esophageal Cancer	54	—
PHOENIX	NCT03740893	P2	recruiting	Breast Neoplasm	119	—
MEDI4736	NCT05034887	P2	active not recruiting	Gastric Adenocarcinoma	64	—
SPRINT 2	NCT07146230	P2	not yet recruiting	Non-small Cell Lung Cancer	52	PMID 4612056
AUSTRAL	NCT06680050	P2	recruiting	Non Small Cell Lung Cancer NSCLC	21	PMID 40781023
SLIDE-HCC	NCT06880523	P2	recruiting	Hepatocellular Carcinoma	140	—
TREMENDOUS-2	NCT07081633	P2	active not recruiting	Hepatocellular Carcinoma	114	—
CONVERGE	NCT06667908	P2	recruiting	Carcinoma, Non-Small-Cell Lung	130	—
DTP	NCT03820141	P2	active not recruiting	Breast Cancer	51	—
NEOCATS	NCT06650709	P2	not yet recruiting	Ovarian Cancer Stage IV	40	—
L	NCT07288034	P2	recruiting	Lung Non-Small Cell Carcinoma	535	—
DUMELEP	NCT06045975	P2	active not recruiting	HCC - Hepatocellular Carcinoma	30	PMID 20060829
MEDI4736	NCT06441747	P2	recruiting	Cholangiocarcinoma	40	—
MEDI4736	NCT05206812	P2	active not recruiting	Non Small Cell Lung Cancer	25	—
PRISM	NCT06994299	P2	withdrawn	Hepatocellular Carcinoma (HCC)	0	—
RADITOP	NCT06502080	P2	not yet recruiting	Biliary Tract Cancer	128	—
WoO	NCT04644289	P2	recruiting	Epithelial Ovarian Cancer	60	—
UNICORN	NCT05845450	P2	recruiting	Colorectal Cancer	197	—
EXEPECT	NCT07168668	P2	not yet recruiting	HCC	90	—
ID-RFA	NCT06440993	P2	recruiting	Extrahepatic Cholangiocarcinoma	42	—
AZD6738	NCT03682289	P2	active not recruiting	Clear Cell Renal Cell Carcinoma	83	PMID 41686845
TAXIO	NCT05856695	P2	active not recruiting	Small Cell Lung Cancer Extensive Stage	67	—
CHEST RT	NCT05796089	P2	active not recruiting	Extensive-Stage Small-Cell Lung Cancer	35	PMID 40623886
DURVASCC	NCT06464068	P2	recruiting	Extrapulmonary Small Cell Carcinoma	66	PMID 41225446
ACCESS	NCT06998719	P2	not yet recruiting	Non-small Cell Lung Cancer Stage III	80	—
RESCUE	NCT05632809	P2	recruiting	Lung Cancer	39	—
ED-SCLC	NCT04472949	P2	active not recruiting	Small Cell Lung Cancer	46	—
TACE	NCT03937830	P2	active not recruiting	Hepatocellular Cancer	27	—
BTC	NCT04238637	P2	active not recruiting	Intrahepatic Cholangiocarcinoma	50	—
DRUP	NCT02925234	P2	recruiting	Cancer	1,550	PMID 37424386
POSTCARD	NCT03795207	P2	active not recruiting	Node; Prostate	96	—
TRITON	NCT06008093	P2	active not recruiting	Carcinoma, Non-Small-Cell Lung	100	PMID 41209621
MEDI4736	NCT06526104	P2	recruiting	Hepatocellular Carcinoma	32	—
MOST plus	NCT02029001	P2	recruiting	Malignant Solid Neoplasms	900	PMID 37444551
GCND	NCT06591650	P2	recruiting	Gallbladder Cancer Unresectable	33	—
DARES	NCT05068232	P2	recruiting	Small-cell Lung Cancer	49	—
DOLAF	NCT04053322	P2	active not recruiting	ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer	172	PMID 40986529
MDT-BRIDGE	NCT05925530	P2	active not recruiting	Non-small Cell Lung Cancer	142	—
GUIDE2REPAIR	NCT04169841	P2	active not recruiting	Immunotherapy	270	PMID 32778095
PANDoRA	NCT03872505	P2	withdrawn	Breast Cancer	0	—
ROWAN	NCT05063565	P2	active not recruiting	Hepatocellular Carcinoma	100	—
SCION	NCT04944173	P2	withdrawn	Non Small Cell Lung Cancer	0	—
MEDI4736	NCT05620628	P2	recruiting	Stomach Cancer, Adenocarcinoma	25	—
EP	NCT05092412	P2	active not recruiting	Lung Cancer	30	PMID 18500231
PLATFORM	NCT02678182	P2	active not recruiting	Adenocarcinoma of the Oesophagus	494	—
DG-03	NCT04379596	P2	recruiting	Gastric Cancer	450	PMID 40341124
NSCLC	NCT05568212	P2	recruiting	Non-small-cell Lung Cancer Patients	176	PMID 21233304
PHOX	NCT06078709	P2	recruiting	Clinical Stage I Esophageal Adenocarcinoma AJCC v8	99	—
ZENOBIA	NCT06698250	P2	recruiting	Hepatocellular Carcinoma	40	—
RADIANCE	NCT04230759	P2	active not recruiting	Anal Cancer	180	—
LADOGA	NCT06606847	P2	active not recruiting	Non-Small Cell Lung Cancer	30	—
HAIC-quad	NCT06859684	P2	recruiting	Intrahepatic Cholangiocarcinoma (Icc)	25	—
TRIFECTA	NCT07332351	P2	not yet recruiting	Muscle Invasive Bladder Urothelial Carcinoma	33	—
SOUND	NCT05374603	P2	active not recruiting	Lung Cancer	47	—
LOTOS	NCT05941897	P2	active not recruiting	Advanced or Metastatic NSCLC	39	—
DAPPER	NCT03851614	P2	active not recruiting	Mismatch Repair Proficient Colorectal Cancer	90	—
MEDI4736	NCT07012798	P2	recruiting	Hepatocellular Carcinoma (HCC)	30	—
GUIDANCE	NCT06419179	P2	enrolling by invitation	Small Cell Lung Carcinoma	29	—
MONTBLANC	NCT05844046	P2	recruiting	Hepatocellular Carcinoma	83	PMID 41732658
OlympiaN	NCT05498155	P2	active not recruiting	Breast Cancer	50	—
DUPLE	NCT06418087	P2	recruiting	Pulmonary Large-cell Neuroendocrine Carcinoma	49	—
IPROC	NCT04918186	P2	recruiting	Ovarian Cancer	60	—
CORAL-Lung	NCT05000710	P2	active not recruiting	Metastatic or Locally Advanced NSCLC	29	PMID 26541610
DOLPHIN	NCT04602533	P2	active not recruiting	Small Cell Lung Cancer Limited Stage	105	—
STAGGER	NCT04163432	P2	active not recruiting	Non-Small Cell Lung Cancer Metastatic	43	—
CHESS	NCT03965468	P2	active not recruiting	Non-small Cell Lung Cancer	96	PMID 21423255
BAYOU	NCT03459846	P2	active not recruiting	Urinary Bladder Neoplasms	154	PMID 35737919
OPTIMUM	NCT05222971	P2	recruiting	Biliary Tract Cancer	62	PMID 20375404
ADAPT-E	NCT04585477	P2	recruiting	Non-small Cell Lung Cancer	80	—
TAZMAN	NCT04745689	P2	active not recruiting	Small-Cell Lung Cancer	31	—
ESR-22-21719	NCT06017297	P2	withdrawn	Borderline Resectable Carcinoma	0	—
MEDI4736	NCT03158064	P2	active not recruiting	Germ Cell Tumor	30	—
MONETTE	NCT05061134	P2	active not recruiting	Melanoma	194	—
DORA	NCT06060405	P2	recruiting	Pancreatic Ductal Adenocarcinoma	22	—
MATISSE	NCT05742607	P2	recruiting	Non Small Cell Lung Cancer	70	—
ORION	NCT03775486	P2	active not recruiting	Non-small Cell Lung Cancer NSCLC	401	PMID 37390980
HUDSON	NCT03334617	P2	active not recruiting	Non-Small Cell Lung Cancer	528	PMID 38351187
MEDI 4736	NCT05137262	P2	active not recruiting	Urothelial Carcinoma	12	—
ATARI	NCT04065269	P2	active not recruiting	Gynaecological Cancers	174	—
REWRITe	NCT03726775	P2	active not recruiting	HNSCC	61	—
EMERALD-Y90	NCT06040099	P2	active not recruiting	Hepatocellular Carcinoma (HCC)	58	PMID 41903993
NEO-IMPACT	NCT06094140	P2	active not recruiting	Pancreatic Cancer	20	—
POP-DURVA	NCT05215106	P2	recruiting	Early Small (cT1N0) Triple Negative Breast Cancer	200	—
DOSa	NCT04668300	P2	active not recruiting	Metastatic Angiosarcoma	75	—
CALIBRATION	NCT03653052	P2	active not recruiting	Oesophageal Cancer	18	—
MEDI4736	NCT05659914	P2	active not recruiting	Metastatic Pancreatic Cancer	40	—
CHORUS	NCT04905316	P2	active not recruiting	Non-small Cell Lung Cancer	41	—
SUPER	NCT06331455	P2	recruiting	Lung Cancer Patients	12	—
INFINITY	NCT04817826	P2	active not recruiting	Gastric Cancer	31	PMID 40340830
MEDI4736	NCT03482102	P2	active not recruiting	Hepatocellular Carcinoma	37	—
BOLSTER	NCT05712356	P2	terminated	Cholangiocarcinoma	66	—
358	NCT03589547	P2	completed	Stage III Non-small-cell Lung Cancer	11	—
PM-CARE	NCT06375915	P2	unknown	Intrahepatic Cholangiocarcinoma	33	—
NSCLC	NCT06333678	P2	completed	Non-Small Cell Lung Cancer	10	—
TRADE-hypo	NCT04351256	P2	completed	NSCLC, Stage III	51	PMID 32842974
MAZEPPA	NCT04348045	P2	active not recruiting	Metastatic Pancreatic Adenocarcinoma	307	—
PRIME-RT	NCT04621370	P2	unknown	Rectal Cancer	48	PMID 34446053
IMMUNO-BIL	NCT03704480	P2	active not recruiting	Advanced Biliary Tract Carcinoma	106	PMID 33279854
UPSTREAM	NCT03088059	P2	unknown	Carcinoma, Squamous Cell of Head and Neck	340	PMID 30307465
DEBATE	NCT04308174	P2	active not recruiting	Biliary Tract Neoplasms	45	PMID 27664259
WIRE	NCT03741426	P2	unknown	Renal Cell Cancer	60	PMID 34794412
DEDALUS	NCT05128630	P2	unknown	NSCLC, Stage III	45	PMID 42093085
ASTEROID	NCT03446547	P2	completed	NSCLC, Stage I	106	—
SAVIMMUNE	NCT04108026	P2	completed	Non-small Cell Lung Cancer Stage IV	50	—
PANDORA	NCT04083365	P2	unknown	RECTAL CANCER	100	PMID 37774508
CAIRE	NCT04705818	P2	completed	Advanced Solid Tumor	164	—
ORCHARD	NCT03944772	P2	active not recruiting	Non-Small Cell Lung Cancer	247	PMID 34389237
ESPADURVA	NCT04202809	P2	unknown	NSCLC, Stage III	90	—
SOLID	NCT03991832	P2	recruiting	Glioma	58	—
DUREC	NCT04293419	P2	unknown	Rectal Cancer	58	—
PIONeeR	NCT03833440	P2	unknown	Non-small Cell Lung Cancer	114	—
MEDI4736	NCT04889066	P2	withdrawn	Brain Metastases from Non-small Cell Lung Cancer	0	—
SAKK 06/17	NCT03406650	P2	completed	Urothelial Cancer	61	—
BRIDGE	NCT04765709	P2	terminated	Non-small Cell Lung Cancer Stage III	10	PMID 18841514
MEDI4736	NCT05262985	P2	unknown	Patients With Advanced Treatment Naive LCNEC	22	—
MEDI4736	NCT03572400	P2	unknown	Pancreatic Cancer	71	—
MEDI4736	NCT03579784	P2	unknown	Advanced Gastric Cancer	40	—
LN-145	NCT03419559	P2	withdrawn	Non Small Cell Lung Cancer	0	—
MEDI4736	NCT03046862	P2	unknown	Biliary Tract Neoplasms	31	PMID 35278356
AMTEC IIT	NCT03801369	P2	terminated	Anatomic Stage IV Breast Cancer AJCC v8	24	PMID 32379297
PACIFIC BRAZIL	NCT04230408	P2	completed	Lung Neoplasms	48	—
MATILDA	NCT03982173	P2	withdrawn	Metastatic Colorectal Cancer	0	—
ARION	NCT03777813	P2	completed	Esophagus Cancer	112	—
MEDI4736	NCT03691714	P2	completed	Recurrent Head and Neck Cancer	35	—
RADIANT	NCT04543110	P2	unknown	Bladder Cancer	16	—
DUART	NCT04249362	P2	completed	Non-small Cell Lung Cancer	102	PMID 34775804
DUTHY	NCT03753919	P2	terminated	Metastatic Thyroid Papillary Carcinoma	79	PMID 41935063
MEDI4736	NCT05027425	P2	terminated	Hepatocellular Carcinoma	8	—
BOUNCE	NCT05718297	P2	withdrawn	NSCLC, Stage III	0	—
SILK BM	NCT03955198	P2	completed	NSCLC	4	—
DEB-TACE	NCT03638141	P2	completed	Intermediate Stage of Hepatocellular Carcinoma	21	—
AB-729	NCT06245291	P2	withdrawn	Hepatitis B, Chronic	0	—
HAIC	NCT04945720	P2	completed	Hepatocellular Carcinoma	30	PMID 42151180
RICE	NCT04159974	P2	unknown	Esophageal Adenocarcinoma	56	—
MILES-5	NCT03975114	P2	unknown	Carcinoma, Non-Small-Cell Lung	460	—
LURBIMUNE	NCT05572476	P2	withdrawn	Small Cell Lung Cancer	0	—
PIVOT-RCC	NCT03598816	P2	withdrawn	Renal Cell Carcinoma	0	—
NSCLC	NCT03004105	P2	withdrawn	Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma	0	—
ESR1814205	NCT04441138	P2	terminated	Stage III Non-small-cell Lung Cancer	10	PMID 28493811
FRAIL-IMMUNE	NCT03723967	P2	completed	Squamous Cell Carcinoma of the Head and Neck	104	—
VIVA	NCT05382741	P2	unknown	Colorectal Cancer Stage IV	182	—
LYNPARZA	NCT04538378	P2	terminated	EGFR-Mutated Non-Small-Cell Lung Carcinoma	4	—
DOMINATION	NCT04262375	P2	withdrawn	Non Small Cell Lung Cancer	0	—
ILLUMINATE	NCT03994393	P2	unknown	EGFR Mutant Advanced Non Small Cell Lung Cancer	100	PMID 39877028
MIMIPAC	NCT04156087	P2	completed	Pancreatic Cancer Non-resectable	12	—
BOLD	NCT04015739	P2	unknown	Epithelial Ovarian Cancer	74	—
SAFIR02_Lung	NCT02117167	P2	completed	Non-small Cell Lung Cancer Metastatic	999	—
MEDI4736	NCT05245994	P2	unknown	Lung Cancer	60	—
MEDI4736	NCT03737968	P2	unknown	Stage II-IVB Operable HNSCC Oral Cavity	48	PMID 38857913
SUKSES-N4	NCT04361825	P2	completed	Small Cell Lung Cancer	42	—
DuRIANS	NCT03212807	P2	withdrawn	EBV Related Non-Hodgkin's Lymphoma	0	—
DURTRE-RAD	NCT03624231	P2	completed	Squamous Cell Carcinoma of the Head and Neck	18	—
SBRT	NCT04255836	P2	unknown	Carcinoma, Non-Small-Cell Lung	35	—
COAST	NCT03822351	P2	completed	Stage III Non-small Cell Lung Cancer	189	PMID 35452273
PrE0505	NCT02899195	P2	completed	Mesothelioma	55	PMID 34750557
DUTRENEO	NCT03472274	P2	completed	Bladder Cancer	101	PMID 39864059
ARCADIA	NCT03824691	P2	unknown	Bladder Carcinoma	122	PMID 28481359
NSCLC	NCT03840902	P2	terminated	Non-small Cell Lung Cancer	153	PMID 36177913
DOME	NCT04262388	P2	withdrawn	Pancreatic Ductal Adenocarcinoma	0	—
DURATION	NCT03345810	P2	completed	Carcinoma, Non-Small-Cell Lung	200	PMID 32321565
Panc-Durval+RT	NCT02885727	P2	withdrawn	Metastatic Pancreas Cancer	0	—
HCC	NCT02821754	P2	completed	Biliary Tract Neoplasms	54	PMID 39965889
Donan	NCT03853187	P2	completed	Non-small Cell Lung Cancer	20	—
SOLUTION	NCT03319316	P2	withdrawn	Squamous Non-small Cell Lung Cancer	0	—
MEDI4736	NCT02904954	P2	completed	Carcinoma, Non-Small-Cell Lung	60	PMID 36028357
DESC	NCT04054518	P2	unknown	Esophageal Squamous Cell Carcinoma	22	—
AMBITION	NCT03699449	P2	unknown	Platinum-resistant Recurrent Ovarian Cancer	104	PMID 31671191
IMMUNOPRESERVE	NCT03702179	P2	completed	Invasive Bladder Cancer	32	—
MEDISARC	NCT03317457	P2	completed	Metastatic Adult Soft Tissue Sarcoma	103	—
AARDVARC	NCT04495179	P2	completed	Progressive Metastatic Castrate-Resistant Prostate Cancer	30	—
DORA	NCT03167619	P2	completed	Triple Negative Breast Cancer	45	PMID 38236575
MEDI4736	NCT02879617	P2	completed	Non-Small Cell Lung Cancer NSCLC	47	—
DUNE	NCT03095274	P2	completed	Neuroendocrine Tumors	126	PMID 37221181
MEDI4736	NCT03428126	P2	completed	Malignant Neoplasms of Digestive Organs	29	PMID 36007963
IMMUCHEC	NCT03473574	P2	completed	Cholangiocarcinoma	128	—
TRIUMPH	NCT03292250	P2	completed	HNSCC	180	PMID 37699162
ILOC	NCT03101475	P2	completed	Colorectal Cancer	22	—
SUKSES-N5	NCT04525391	P2	terminated	SCLC, Recurrent	4	—
FUSIONMM-003	NCT02807454	P2	terminated	Multiple Myeloma	37	—
CEDUVEAL-M	NCT04184518	P2	withdrawn	Uveal Melanoma	0	—
IDA-D	NCT03241017	P2	withdrawn	Lymphoma, Large B-Cell, Diffuse	0	—
MEDI4736	NCT03102047	P2	completed	Rectal Cancer	45	—
MEDI4736	NCT02775903	P2	completed	Leukemia, Myeloid, Acute	213	PMID 34972214
MEDI4736	NCT03608865	P2	completed	Metastatic Breast Cancer	30	—
BCG	NCT02901548	P2	terminated	Carcinoma in Situ of Bladder	17	—
MEDI4736	NCT02336165	P2	completed	Glioblastoma	159	PMID 26327487
MEDI4736	NCT02639065	P2	completed	Esophageal Cancer	39	PMID 34604072
MEDI4736	NCT06446570	P2	completed	HNSCC	18	—
KGOG3046	NCT03899610	P2	unknown	Ovarian Cancer Stage IIIC	24	PMID 37865397
MEDI4736	NCT03430895	P2	completed	Non-Transitional Cell Carcinoma of the Urothelial Tract	15	—
ULTIMATE	NCT02997995	P2	completed	Breast Cancer	61	—
METADUR	NCT02811497	P2	completed	Microsatellite Stable Colorectal Carcinoma	28	PMID 32753546
NITIMIB	NCT03234153	P2	terminated	Muscle-invasive Bladder Cancer	6	—
NEODURVARIB	NCT03534492	P2	completed	Bladder Cancer	29	—
OPHELIA	NCT02882308	P2	completed	Squamous Cell Carcinoma of the Head and Neck	41	PMID 33714009
APACHE	NCT03081923	P2	terminated	Germ Cell Tumor	36	PMID 30243800
IONESCO	NCT03030131	P2	terminated	Carcinoma, Non-Small-Cell Lung	50	PMID 36270733
Diadem	NCT04115111	P2	completed	Pleura Mesothelioma	57	PMID 36463732
FUSION-MM-005	NCT03000452	P2	completed	Multiple Myeloma	18	—

Terminated and withdrawn Durvalumab trials (118)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05209529withdrawnChemo-free BRCA-targeted Neoadjuvant Strategy
NCT06994299withdrawnA Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma
NCT05411094suspendedTesting the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT06963346suspendedStudy Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
NCT06608940withdrawnBC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
NCT03673735withdrawnMaintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
NCT05403723suspendedAdaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
NCT03872505withdrawnPre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
NCT04944173withdrawnSCION: SABR and Checkpoint Inhibition of NSCLC
NCT06017297withdrawnNeoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
NCT05383001withdrawnRandomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
NCT05712356terminatedA Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT04073160withdrawnTRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
NCT06083454terminatedAscorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
NCT06939036terminatedStudy of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
NCT05757843withdrawnUsing Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
NCT05443971terminatedDurvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen
NCT04748419terminatedSafety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
NCT02938793terminatedDurvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
NCT04336943terminatedDurvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
NCT04223648withdrawnProgrammed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
NCT05911308terminatedAbequolixron (RGX-104) and Durvalumab in Lung Cancer
NCT04902040terminatedPlinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
NCT04889066withdrawnDurvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
NCT04765709terminatedDurvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
NCT05161533withdrawnHypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
NCT03802747withdrawnImmunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
NCT03419559withdrawnStudy of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
NCT06191250terminated--SuPERIOR Trial--
NCT04064190withdrawnVactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
NCT03801369terminatedAMTEC IIT: Phase 2 Multiarm Study in TNBC
NCT03075527terminatedA Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
NCT03982173withdrawnBasket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
NCT03753919terminatedDurvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
NCT05027425terminatedDurvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
NCT04287894terminatedAssess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
NCT04019288terminatedAVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT05718297withdrawnBrigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
NCT03150836withdrawnRadiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
NCT06245291withdrawnStudy of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
NCT05572476withdrawnLurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
NCT04613492terminatedA Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
NCT03598816withdrawnPolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
NCT03004105withdrawnMEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
NCT03237377terminatedNeoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
NCT04231864withdrawnDurvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
NCT04441138terminatedChemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
NCT04145193withdrawnNovel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
NCT04538378terminatedOlaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
NCT04364048terminatedDurvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
NCT04262375withdrawnA Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
NCT04951115terminatedA Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
NCT05848843withdrawnA Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
NCT04625699withdrawnStudy of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
NCT04108481terminatedImmunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
NCT04866017terminatedA Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
NCT03212807withdrawnStudy Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
NCT04870112terminatedA Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer
NCT03376659terminatedDurvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
NCT03810105terminatedA Study of Olaparib and Durvalumab in Prostate Cancer
NCT03618134terminatedStereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
NCT02966587withdrawnDurvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT03199040terminatedNeoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
NCT04322643terminatedIntermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
NCT03970616terminatedA Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
NCT04696848terminatedThe Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
NCT03235869withdrawnRadiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
NCT03840902terminatedM7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
NCT04262388withdrawnA Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
NCT02885727withdrawnDurvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)
NCT02997332terminatedDurvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT03319316withdrawnCombination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
NCT04348292terminatedSirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
NCT03439085terminatedDNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
NCT03912818terminatedDurvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
NCT03277482terminatedDurvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
NCT04786093terminatedDurvalumab and Stereotactic Radiotherapy for Advanced NSCLC
NCT02891161terminatedDurvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
NCT04372927terminatedADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
NCT02827838terminatedDurvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
NCT03818776terminatedProton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC
NCT03522584terminatedDurvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04525391terminatedAZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer
NCT02807454terminatedA Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
NCT04184518withdrawnDurvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
NCT03241017withdrawnDurvalumab in DLBCL After Autologous Transplant
NCT03963414terminatedA Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
NCT03496519withdrawnAssessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
NCT04262869withdrawnPlatinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
NCT02901548terminatedPhase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
NCT03323398terminatedDose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
NCT04470674withdrawnStudy of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
NCT02706405terminatedJCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT04001413withdrawnTherapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
NCT04579133terminatedNeoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
NCT03665129terminatedIPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
NCT03721679terminatedPoly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
NCT03874325terminatedAromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
NCT04088032withdrawnNeoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT03685344terminatedSafety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
NCT03490760terminatedDurvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
NCT03275597terminatedPhase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
NCT03196401withdrawnA Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
NCT03234153terminatedNeoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
NCT02805660terminatedPhase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
NCT03081923terminatedDurvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
NCT03030131terminatedImmune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
NCT02452463terminatedNintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
NCT03038477withdrawnA Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
NCT02556463terminatedA Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
NCT02673814withdrawnPhase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
NCT02716805terminatedPhase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
NCT02993991withdrawnPre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
NCT03130764withdrawnDurvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
NCT02737072terminatedA Study of LY2510924 and Durvalumab in Participants With Solid Tumors
NCT02871323withdrawnDurvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
NCT02205333terminatedA Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

All Durvalumab trials (732)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT05155189		A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma	P1	recruiting	72	Zhejiang University	Feb 2022
NCT06498635		Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial	P3	recruiting	306	National Cancer Institute (NCI)	Apr 2025
NCT07554339	MK-1084	A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)	P3	recruiting	310	Merck Sharp & Dohme LLC	Jun 2026
NCT07195695		Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations	P3	recruiting	400	Boehringer Ingelheim	Jan 2026
NCT06492421		Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Jul 2024
NCT06482801		Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Jun 2024
NCT05187338		Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors	P1/P2	recruiting	100	Second Affiliated Hospital of Guangzhou Medical University	Nov 2021
NCT06694454	MEDI4736	Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)	P1/P2	recruiting	60	National Cancer Institute (NCI)	Jun 2026
NCT03288532	RAMPART	Renal Adjuvant MultiPle Arm Randomised Trial	P3	recruiting	1,750	University College, London	Jul 2018
NCT07361497	NSCLC	A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)	P3	recruiting	850	Bristol-Myers Squibb	Mar 2026
NCT06492408		Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Jul 2024
NCT06483347		Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Apr 2024
NCT06027086	FLC	DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)	P1/P2	recruiting	27	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Feb 2024
NCT06999694	Proton-STRIDE	Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	recruiting	45	Chang Gung Memorial Hospital	May 2025
NCT06999707	Photon-STRIDE	Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC	P2	recruiting	45	Chang Gung Memorial Hospital	May 2025
NCT04392505	DART	Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study	P2	active not recruiting	100	Oslo University Hospital	May 2020
NCT04597671	NVALT28	Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)	P3	active not recruiting	170	Association NVALT Studies	Dec 2021
NCT06503614	ENHANCE	A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer	P2	recruiting	60	John Sfakianos	Feb 2025
NCT05795101	TRUDI	TRUDI: TDXD+Durva in HER2+/Low IBC	P2	recruiting	63	Filipa Lynce, MD	May 2023
NCT06773910	TIGOS-LS	BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)	P2	recruiting	250	SCRI Development Innovations, LLC	Mar 2025
NCT04106115	DURANCE	DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr	P1/P2	recruiting	52	University College, London	Mar 2022
NCT06112379		A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer	P3	active not recruiting	1,902	AstraZeneca	Nov 2023
NCT06680739	SERPENTINE	Single cEll pRofiling PErsistaNce To ImmuNothErapy	P2	recruiting	60	Vall d'Hebron Institute of Oncology	Mar 2022
NCT07107750	CA-4948	Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer	P1	recruiting	48	Washington University School of Medicine	Mar 2026
NCT06058377		Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	P3	recruiting	3,680	National Cancer Institute (NCI)	Nov 2023
NCT05253131		Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas	P2	not yet recruiting	41	University of Alabama at Birmingham	May 2026
NCT06890598	SUNRAY-02	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer	P3	recruiting	700	Eli Lilly and Company	Mar 2025
NCT04245514	NSCLC	Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)	P2	active not recruiting	90	Swiss Cancer Institute	Jul 2020
NCT01042379	I-SPY	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	recruiting	5,000	QuantumLeap Healthcare Collaborative	Mar 2010
NCT07247786	MIGRANT	Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)	P2	not yet recruiting	68	Fundación GECP	Sep 2026
NCT05624996		Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer	P3	recruiting	474	NRG Oncology	Jul 2023
NCT06898957	(DeLLphi-310)	Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)	P1	active not recruiting	29	Amgen	May 2025
NCT07531095	DeLLphi-313	Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)	P1	recruiting	160	Amgen	Apr 2026
NCT04607954		Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer	P2	active not recruiting	29	Mayo Clinic	Dec 2020
NCT03847649		A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	P2	recruiting	60	Canadian Cancer Trials Group	Mar 2020
NCT07149363		Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer	P2	recruiting	65	Alliance Foundation Trials, LLC.	Feb 2026
NCT05255653	RAINBO	Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features	P2/P3	recruiting	1,615	Leiden University Medical Center	Nov 2021
NCT07489976		IIT2025-03-YANG-LIFT-HCC	P2	recruiting	41	Ju Dong Yang	Apr 2026
NCT04742075	DOVACC	Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer	P2	active not recruiting	188	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	Dec 2021
NCT03228667		QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	P2	active not recruiting	40	ImmunityBio, Inc.	Dec 2018
NCT04116047	CompARE	CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)	P3	active not recruiting	785	University of Birmingham	Jul 2015
NCT06274879	Ablatio	Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer	P2	recruiting	36	Insel Gruppe AG, University Hospital Bern	May 2026
NCT06858735	HYPERION CCA	HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma	P2	recruiting	60	M.D. Anderson Cancer Center	Jun 2025
NCT05903092	MOZART	MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer	P2	recruiting	84	Hirva Mamdani	Sep 2023
NCT05211895	PACIFIC-8	A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC	P3	recruiting	860	AstraZeneca	Feb 2022
NCT06904170	ALICE	Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma	P2/P3	recruiting	196	UNICANCER	Nov 2025
NCT06109272	LIVIGNO-2	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)	P2/P3	recruiting	660	AbbVie	Jan 2024
NCT06103864		A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	P3	recruiting	625	AstraZeneca	Nov 2023
NCT04637594	IMAGINE	Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy	P3	active not recruiting	3	Alliance for Clinical Trials in Oncology	May 2022
NCT04465968	DEEP_OCEAN	Efficacy and Safety of CRT, Durvalumab and Surgery for SST	P3	not yet recruiting	84	National Cancer Center Hospital East	Sep 2020
NCT05209529		Chemo-free BRCA-targeted Neoadjuvant Strategy	P2	withdrawn	0	European Organisation for Research and Treatment of Cancer - EORTC	Feb 2024
NCT05221840	PACIFIC-9	A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	P3	active not recruiting	1,051	AstraZeneca	Feb 2022
NCT07603856	REVIVE	A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer	P2	not yet recruiting	39	University of Chicago	Dec 2026
NCT05170204	HORIZON 1	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	P3	active not recruiting	68	Hoffmann-La Roche	Nov 2022
NCT05061550	NeoCOAST-2	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer	P2	recruiting	630	AstraZeneca	Apr 2022
NCT06282575		Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer	P3	recruiting	286	Jazz Pharmaceuticals	Jul 2024
NCT06284317	ADOPT-lung	A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.	P3	recruiting	290	ETOP IBCSG Partners Foundation	Jan 2025
NCT06954480	DIAMOND	Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	P2	recruiting	140	Queen Mary University of London	Oct 2025
NCT05617963	DURVALUNG	Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax	P2	active not recruiting	100	UNICANCER	Mar 2023
NCT07507968		TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma	P2	not yet recruiting	101	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Jul 2026
NCT04538742	DB-07	A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer	P1/P2	active not recruiting	245	AstraZeneca	Dec 2020
NCT05629585		A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)	P3	active not recruiting	1,174	AstraZeneca	Nov 2022
NCT06780137	MK-6070	A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)	P1/P2	recruiting	262	Merck Sharp & Dohme LLC	Feb 2025
NCT07122089	IOSPHERE	Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis	P2	recruiting	80	Center Eugene Marquis	Feb 2026
NCT07229625	BTC	A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)	P3	recruiting	604	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Jan 2026
NCT06769126		Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study	P2	recruiting	900	SWOG Cancer Research Network	Nov 2025
NCT06692491	SPRING	Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS	P2	not yet recruiting	200	Peking University Shenzhen Hospital	Jan 2025
NCT05582538	ATRiBRAVE	Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel	P2	recruiting	37	IFOM ETS - The AIRC Institute of Molecular Oncology	Dec 2022
NCT07339059		Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	P2	recruiting	35	Bindu R Potugari	Jun 2026
NCT07036380	TACTIC	MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma	P2	recruiting	75	Centre Hospitalier Universitaire de Besancon	Dec 2025
NCT05451043	BLOCKED	Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)	P2	recruiting	62	AHS Cancer Control Alberta	Jul 2023
NCT07269158		A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer	P1/P2	not yet recruiting	160	Yonsei University	Dec 2025
NCT06393816	FIRST-NEC	FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum	P2	recruiting	80	Centre Leon Berard	Jun 2024
NCT04397003	MEDI4736	Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer	P2	active not recruiting	6	Washington University School of Medicine	Mar 2022
NCT03875573	Neo-CheckRay	Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:	P2	active not recruiting	147	Jules Bordet Institute	Nov 2019
NCT03942328		Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	P1/P2	recruiting	85	Mayo Clinic	Sep 2019
NCT07055581		Durvalumab as Consolidation for Patients LS-SCLC	P2	recruiting	100	Qian Chu	Feb 2026
NCT06463665	VIRO-25	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer	P2	recruiting	142	Genelux Corporation	Sep 2024
NCT04430452		Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma	P2	recruiting	21	Mary Feng, MD	Feb 2022
NCT06290505	PALEO	A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study	P2	recruiting	54	Australasian Gastro-Intestinal Trials Group	Dec 2021
NCT06287775		Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer	P1/P2	recruiting	45	National Cancer Institute (NCI)	Apr 2025
NCT06214572	RUGB	Radiation Therapy in Unresectable Gall Bladder Cancer	P2/P3	recruiting	249	Tata Memorial Centre	Mar 2024
NCT07005128	DeLLphi-312	A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)	P3	recruiting	330	Amgen	Aug 2025
NCT04380636	NSCLC	Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)	P3	active not recruiting	870	Merck Sharp & Dohme LLC	Jul 2020
NCT07221253	AB02	A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)	P3	recruiting	1,100	AstraZeneca	Dec 2025
NCT06992609	ALBORAN	Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.	P3	recruiting	70	AstraZeneca	Sep 2025
NCT03740893	PHOENIX	PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer	P2	recruiting	119	Institute of Cancer Research, United Kingdom	Oct 2019
NCT03539822	CAMILLA	Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies	P1/P2	recruiting	117	Anwaar Saeed	Oct 2018
NCT06551142	PanTumor-101	A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)	P1	recruiting	845	GlaxoSmithKline	Sep 2024
NCT07174583		A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer	P1/P2	recruiting	208	IDEAYA Biosciences	Oct 2025
NCT06467357	DESTINY-BTC01	Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer	P3	recruiting	620	AstraZeneca	Aug 2024
NCT06548412		CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers	P1/P2	recruiting	50	M.D. Anderson Cancer Center	Jan 2025
NCT06564623	BTC	Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)	P1	recruiting	25	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	May 2025
NCT05034887	MEDI4736	Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma	P2	active not recruiting	64	National Cancer Center Hospital East	Jan 2022
NCT07166406		Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	P3	recruiting	226	NRG Oncology	Feb 2026
NCT07146230	SPRINT 2	The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2	P2	not yet recruiting	52	Montefiore Medical Center	Sep 2026
NCT06680050	AUSTRAL	Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen	P2	recruiting	21	Mario Negri Institute for Pharmacological Research	Aug 2025
NCT07172412		Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer	P2	not yet recruiting	165	Tianjin Medical University Cancer Institute and Hospital	Nov 2025
NCT06880523	SLIDE-HCC	STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma	P2	recruiting	140	Canadian Cancer Trials Group	Oct 2025
NCT07081633	TREMENDOUS-2	Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma	P2	active not recruiting	114	AstraZeneca	Aug 2025
NCT06667908	CONVERGE	A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)	P2	recruiting	130	Johnson & Johnson Enterprise Innovation Inc.	Dec 2024
NCT06546969		Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer	P1	recruiting	15	University of Maryland, Baltimore	Oct 2024
NCT06031233	MINUTE	Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	P4	recruiting	776	Isala	Sep 2023
NCT05713838		Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery	P2	recruiting	32	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Aug 2023
NCT03820141	DTP	Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer	P2	active not recruiting	51	The Methodist Hospital Research Institute	Jun 2020
NCT04092283		Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer	P3	active not recruiting	660	National Cancer Institute (NCI)	Apr 2020
NCT06908070	CROWD	Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab	P4	recruiting	38	Idris Bahce	Dec 2024
NCT06719336	STONE-001	Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)	P3	not yet recruiting	182	Anhui Shi, MD	Dec 2024
NCT05194293		Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer	P2	active not recruiting	4	Academic and Community Cancer Research United	Jul 2023
NCT06746116	DUoENDE	A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain	P3	active not recruiting	45	AstraZeneca	Dec 2024
NCT06058663		Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma	P1	recruiting	16	Mayo Clinic	Jun 2024
NCT01993810		Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer	P3	active not recruiting	330	Radiation Therapy Oncology Group	Jan 2014
NCT06650709	NEOCATS	NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study	P2	not yet recruiting	40	British Columbia Cancer Agency	Nov 2024
NCT06960577	NIAGARA-2	Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)	P3	recruiting	150	AstraZeneca	May 2025
NCT03833154	PACIFIC-4	Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation	P3	active not recruiting	724	AstraZeneca	Mar 2019
NCT07288034	L	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial	P2	recruiting	535	City of Hope Medical Center	Apr 2026
NCT03528694	POTOMAC	Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer	P3	active not recruiting	1,018	AstraZeneca	May 2018
NCT06484491	HyDose	IMPT Dose Escalation for NSCLC (HyDose)	N/A	recruiting	87	University Medical Center Groningen	Sep 2025
NCT06211036	DeLLphi-305	Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab	P3	active not recruiting	563	Amgen	Jun 2024
NCT06045975	DUMELEP	Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure	P2	active not recruiting	30	Assistance Publique - Hôpitaux de Paris	Mar 2024
NCT03800134	AEGEAN	A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer	P3	active not recruiting	825	AstraZeneca	Dec 2018
NCT04960709	VOLGA	Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin	P3	active not recruiting	712	AstraZeneca	Aug 2021
NCT07226063		Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer	P2	not yet recruiting	16	Amit Mahipal	May 2026
NCT06441747	MEDI4736	Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)	P2	recruiting	40	Australasian Gastro-Intestinal Trials Group	Sep 2024
NCT05361395	ES-SCLC	First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)	P1	active not recruiting	184	Amgen	Aug 2022
NCT06530823		Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma	P2	not yet recruiting	38	Eastern Hepatobiliary Surgery Hospital	Aug 2024
NCT06824363		ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu	Early P1	not yet recruiting	34	University of California, Irvine	Apr 2026
NCT05206812	MEDI4736	Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)	P2	active not recruiting	25	Yonsei University	Sep 2022
NCT06994299	PRISM	A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma	P2	withdrawn	0	Weill Medical College of Cornell University	Oct 2025
NCT05733598		Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	P2	recruiting	60	Replimune, Inc.	Aug 2024
NCT05411094		Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer	P1	suspended	18	National Cancer Institute (NCI)	May 2023
NCT06732401		Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer	P3	active not recruiting	630	National Cancer Institute (NCI)	Aug 2025
NCT06911255	MEDI4736	Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma	P1/P2	recruiting	24	Yoon Jun Kim	Apr 2025
NCT06502080	RADITOP	Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)	P2	not yet recruiting	128	Shanghai Zhongshan Hospital	Jul 2024
NCT04644289	WoO	WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC	P2	recruiting	60	AGO Research GmbH	May 2022
NCT06470256		Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma	P1	recruiting	50	Zhiyong Huang	Jun 2024
NCT06855225		A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma	P2	not yet recruiting	29	Mehmet Akce	May 2026
NCT05932199		Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma	P1/P2	recruiting	52	Baylor College of Medicine	Jul 2024
NCT05845450	UNICORN	Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)	P2	recruiting	197	Gruppo Oncologico del Nord-Ovest	May 2023
NCT04462328		Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma	P1	active not recruiting	25	Washington University School of Medicine	Apr 2021
NCT07168668	EXEPECT	Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment	P2	not yet recruiting	90	Chang Gung Memorial Hospital	Sep 2025
NCT05886439		LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer	P1/P2	recruiting	60	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	May 2023
NCT07459634		A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC	P2	not yet recruiting	50	Jazz Pharmaceuticals	Jun 2026
NCT06963346		Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents	P1	suspended	12	H. Lee Moffitt Cancer Center and Research Institute	Jun 2025
NCT06440993	ID-RFA	Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma	P2	recruiting	42	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Aug 2024
NCT04585490		Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	P3	recruiting	48	Maximilian Diehn	Aug 2021
NCT04550104	CONCORDE	A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC	P1	recruiting	200	University of Leeds	Mar 2021
NCT03682289	AZD6738	Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	P2	active not recruiting	83	Rahul Aggarwal	Jan 2019
NCT05856695	TAXIO	Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)	P2	active not recruiting	67	Intergroupe Francophone de Cancerologie Thoracique	Nov 2023
NCT05154994	RESOLVE	Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma	P1	active not recruiting	9	University of Utah	Jan 2022
NCT05796089	CHEST RT	Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy	P2	active not recruiting	35	Trans Tasman Radiation Oncology Group	Jan 2022
NCT04105270		RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	P2	recruiting	82	Masonic Cancer Center, University of Minnesota	Nov 2022
NCT03601455		Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer	P2	active not recruiting	13	Jonsson Comprehensive Cancer Center	Oct 2018
NCT06608940	STRIDE	BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma	P1/P2	withdrawn	0	Case Comprehensive Cancer Center	Nov 2025
NCT06464068	DURVASCC	AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA	P2	recruiting	66	Gruppo Oncologico Italiano di Ricerca Clinica	Jan 2024
NCT06998719	ACCESS	Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC	P2	not yet recruiting	80	Bi Nan	Jul 2025
NCT06591520		AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer	P3	active not recruiting	682	Akeso	Oct 2024
NCT06223711		Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC	P2	recruiting	43	Universität des Saarlandes	Oct 2023
NCT06371482		Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)	P2	recruiting	58	Hebei Medical University Fourth Hospital	Jun 2023
NCT05632809	RESCUE	REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)	P2	recruiting	39	M.D. Anderson Cancer Center	Jan 2023
NCT05450692	LATIFY	A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy	P3	active not recruiting	594	AstraZeneca	Sep 2022
NCT03673735	ADHERE	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC	P3	withdrawn	0	European Organisation for Research and Treatment of Cancer - EORTC	Jun 2021
NCT04900818		Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors	P1	recruiting	330	I-Mab Biopharma US Limited	Jun 2021
NCT04472949	ED-SCLC	Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).	P2	active not recruiting	46	Swiss Cancer Institute	Jun 2021
NCT03937830	TACE	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma	P2	active not recruiting	27	National Cancer Institute (NCI)	Mar 2021
NCT04728230		Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial	P1/P2	active not recruiting	63	M.D. Anderson Cancer Center	Jan 2021
NCT04522544		Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC	P2	recruiting	55	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Dec 2020
NCT04499053		Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer	P2	recruiting	18	Georgetown University	Dec 2020
NCT04238637	BTC	Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)	P2	active not recruiting	50	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Nov 2019
NCT03317158	ADAPT-BLADDER	Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder	P1/P2	recruiting	55	Noah Hahn, M.D.	Nov 2017
NCT02812420		Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery	Early P1	active not recruiting	54	M.D. Anderson Cancer Center	Mar 2017
NCT02925234	DRUP	The Drug Rediscovery Protocol (DRUP Trial)	P2	recruiting	1,550	The Netherlands Cancer Institute	Aug 2016
NCT02726997		Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)	P1/P2	active not recruiting	18	M.D. Anderson Cancer Center	Jul 2016
NCT06490107		Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC	P2	active not recruiting	40	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	May 2024
NCT03795207	POSTCARD	Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)	P2	active not recruiting	96	Institut Cancerologie de l'Ouest	Mar 2019
NCT06008093	TRITON	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS	P2	active not recruiting	100	AstraZeneca	Apr 2024
NCT06508216	COMPASS-TNBC	A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer	P1/P2	recruiting	50	Gustave Roussy, Cancer Campus, Grand Paris	Jul 2024
NCT06526104	MEDI4736	Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis	P2	recruiting	32	The University of Texas Health Science Center at San Antonio	Dec 2024
NCT05655949		Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio	P2	recruiting	30	Beth Israel Deaconess Medical Center	Feb 2024
NCT06124118	NOVOCURE	Tumor Treating Fields for Locally Advanced NSCLC	P1	recruiting	30	University of Utah	Apr 2024
NCT03164616	POSEIDON	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).	P3	active not recruiting	1,186	AstraZeneca	Jun 2017
NCT07174570		Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer	P2	recruiting	39	Emory University	Jan 2026
NCT06634199	SIENNA	Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients	—	recruiting	50	Fundación GECP	Oct 2024
NCT05687266	AVANZAR	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations	P3	active not recruiting	1,350	AstraZeneca	Dec 2022
NCT02029001	MOST plus	Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment	P2	recruiting	900	Centre Leon Berard	Mar 2014
NCT06591650	GCND	Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer	P2	recruiting	33	Fudan University	Oct 2024
NCT04940286		Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer	P2	active not recruiting	13	M.D. Anderson Cancer Center	Sep 2021
NCT02484404	MEDI4736	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...	P1/P2	active not recruiting	268	National Cancer Institute (NCI)	Jun 2015
NCT05068232	DARES	Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)	P2	recruiting	49	University of Chicago	Aug 2022
NCT04628767		Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer	P2/P3	recruiting	131	National Cancer Institute (NCI)	Nov 2021
NCT03620669		1st Line Durvalumab in PS 2 NSCLC Patients	P2	active not recruiting	48	Swiss Cancer Institute	Dec 2018
NCT02826434		Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer	P1	active not recruiting	22	Massachusetts General Hospital	Aug 2016
NCT04592913		Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer	P3	active not recruiting	957	AstraZeneca	Nov 2020
NCT06501625		Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation	P1/P2	recruiting	52	Institut de Recherches Internationales Servier	Dec 2024
NCT05403723		Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC	P1	suspended	50	University of Maryland, Baltimore	Jun 2026
NCT07175441		Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma	P2	recruiting	220	Riboscience, LLC.	Apr 2026
NCT04053322	DOLAF	Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.	P2	active not recruiting	172	UNICANCER	Aug 2019
NCT07391670	IMFINZI-subQ	A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab	P1	recruiting	40	AstraZeneca	Mar 2026
NCT05925530	MDT-BRIDGE	Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)	P2	active not recruiting	142	AstraZeneca	Feb 2024
NCT04387084		Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy	P1	active not recruiting	10	University of Southern California	Aug 2020
NCT04169841	GUIDE2REPAIR	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	P2	active not recruiting	270	Centre Georges Francois Leclerc	Feb 2020
NCT07511504		Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma	P2	not yet recruiting	40	OHSU Knight Cancer Institute	Apr 2026
NCT05484583		Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases	P2	not yet recruiting	58	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	Aug 2022
NCT06728410		A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement	P2	recruiting	38	Mehmet Akce	Jan 2026
NCT06708858		Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer	P2	recruiting	35	Dai, Guanghai	Aug 2024
NCT03872505	PANDoRA	Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer	P2	withdrawn	0	Cedars-Sinai Medical Center	Jul 2022
NCT03141359		Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC	P2	active not recruiting	61	Wake Forest University Health Sciences	May 2017
NCT05733689		Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)	P1	recruiting	20	University of California, Irvine	Jun 2025
NCT06710223		Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab	P1	recruiting	20	University of California, San Diego	Jan 2025
NCT05063565	ROWAN	TheraSphere With Durvalumab and Tremelimumab for HCC	P2	active not recruiting	100	Boston Scientific Corporation	Nov 2023
NCT04944173	SCION	SCION: SABR and Checkpoint Inhibition of NSCLC	P2	withdrawn	0	University of British Columbia	Aug 2023
NCT05620628	MEDI4736	Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)	P2	recruiting	25	Jeeyun Lee	Jan 2023
NCT05198830		Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer	P2	recruiting	42	National Cancer Institute (NCI)	Dec 2022
NCT05092412	EP	Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC	P2	active not recruiting	30	You Lu	Mar 2022
NCT04686305	DL03	Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	P1	recruiting	304	AstraZeneca	Mar 2021
NCT04550260	KUNLUN	Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC	P3	active not recruiting	640	AstraZeneca	Oct 2020
NCT02678182	PLATFORM	Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial	P2	active not recruiting	494	Royal Marsden NHS Foundation Trust	Feb 2015
NCT04379596	DG-03	Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)	P2	recruiting	450	AstraZeneca	Jun 2020
NCT03907475		Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial	P2	recruiting	115	National Cancer Institute (NCI)	Jul 2019
NCT03682068	NILE	Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer	P3	active not recruiting	1,246	AstraZeneca	Sep 2018
NCT03148327		Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy	P1/P2	active not recruiting	18	Jonsson Comprehensive Cancer Center	Oct 2017
NCT05568212	NSCLC	Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab	P2	recruiting	176	Fondazione Ricerca Traslazionale	May 2022
NCT03847428	EMERALD-2	Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment	P3	active not recruiting	908	AstraZeneca	Apr 2019
NCT03694236	MEDI4736	Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC	P1/P2	recruiting	39	Yonsei University	Feb 2019
NCT06078709	PHOX	Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma	P2	recruiting	99	Mayo Clinic	Nov 2023
NCT04216290		A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial	P2	active not recruiting	11	National Cancer Institute (NCI)	Mar 2021
NCT03875235	TOPAZ-1	Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)	P3	active not recruiting	810	AstraZeneca	Apr 2019
NCT06698250	ZENOBIA	Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)	P2	recruiting	40	Anwaar Saeed	Dec 2024
NCT05927142	DURIPANC	Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy	P1/P2	recruiting	43	Joachim Aerts, MD PhD	Jan 2024
NCT05696782		Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer	P2	recruiting	28	Wake Forest University Health Sciences	Jul 2023
NCT04269200	DUO-E	Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer	P3	active not recruiting	805	AstraZeneca	May 2020
NCT05943106	PATAPSCO	BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants	P3	active not recruiting	100	AstraZeneca	Aug 2023
NCT04230759	RADIANCE	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group	P2	active not recruiting	180	Goethe University	Jan 2020
NCT06611345		A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers	N/A	recruiting	60	Jiangsu Healthy Life Innovation Medical Technology Co., Ltd	Oct 2024
NCT06606847	LADOGA	A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)	P2	active not recruiting	30	AstraZeneca	Sep 2024
NCT06302426		Trial of INI-4001 in Patients With Advanced Solid Tumours	P1	recruiting	50	Inimmune Corporation	Jul 2024
NCT06859684	HAIC-quad	Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)	P2	recruiting	25	West China Hospital	Mar 2025
NCT04739800		Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	P2	active not recruiting	120	National Cancer Institute (NCI)	Jun 2021
NCT03660826		Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	P2	active not recruiting	288	National Cancer Institute (NCI)	Sep 2018
NCT05683977	ARSENAL	A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.	—	active not recruiting	254	AstraZeneca	Nov 2022
NCT03983954		Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.	P1	active not recruiting	120	NeoTX Therapeutics Ltd.	Oct 2019
NCT04716946		Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy	P2	active not recruiting	13	Memorial Sloan Kettering Cancer Center	Jan 2021
NCT05301842	EMERALD-3	Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC	P3	active not recruiting	760	AstraZeneca	Mar 2022
NCT03742102	BEGONIA	A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer	P1/P2	active not recruiting	243	AstraZeneca	Dec 2018
NCT03706690	PACIFIC-5	A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients	P3	active not recruiting	407	AstraZeneca	Nov 2018
NCT04605731		Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer	P1	active not recruiting	25	City of Hope Medical Center	Aug 2021
NCT05388006		Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P2	recruiting	27	Mayo Clinic	Jan 2023
NCT06050252		Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery	P2	recruiting	27	National Cancer Institute (NCI)	Jul 2024
NCT03174275		Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma	P2	active not recruiting	39	UNC Lineberger Comprehensive Cancer Center	Dec 2017
NCT07332351	TRIFECTA	Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial	P2	not yet recruiting	33	University of Washington	Sep 2026
NCT05043090	SAMETA	Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC	P3	active not recruiting	148	AstraZeneca	Oct 2021
NCT05720260		Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC	P2	recruiting	42	National Taiwan University Hospital	Jan 2023
NCT05374603	SOUND	Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC	P2	active not recruiting	47	AstraZeneca	Nov 2022
NCT02888743		Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer	P2	active not recruiting	110	National Cancer Institute (NCI)	Aug 2017
NCT05941897	LOTOS	A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy	P2	active not recruiting	39	AstraZeneca	Jun 2023
NCT03851614	DAPPER	Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors	P2	active not recruiting	90	University Health Network, Toronto	Apr 2019
NCT07012798	MEDI4736	FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma	P2	recruiting	30	Tianjin Medical University Cancer Institute and Hospital	Sep 2025
NCT06263153		Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy	P2	recruiting	24	Yuanquan Yang	Dec 2024
NCT06419179	GUIDANCE	Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)	P2	enrolling by invitation	29	University of Cologne	Oct 2024
NCT06070740		First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma	P2	recruiting	22	Peking Union Medical College Hospital	Nov 2023
NCT05844046	MONTBLANC	Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients	P2	recruiting	83	Enrico De Toni	Apr 2023
NCT05498155	OlympiaN	Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer	P2	active not recruiting	50	AstraZeneca	Nov 2022
NCT06418087	DUPLE	Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)	P2	recruiting	49	Gruppo Oncologico Italiano di Ricerca Clinica	May 2022
NCT04918186	IPROC	Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer	P2	recruiting	60	Canadian Cancer Trials Group	May 2022
NCT05303532	ROSY-D	Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab	P3	enrolling by invitation	214	AstraZeneca	Apr 2022
NCT04781192	MEDI4736	The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers	P1/P2	active not recruiting	40	University of Kansas Medical Center	Mar 2022
NCT05000710	CORAL-Lung	Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy	P2	active not recruiting	29	Sheba Medical Center	Dec 2021
NCT05136846		Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer	P1	recruiting	28	Ohio State University Comprehensive Cancer Center	Dec 2021
NCT04602533	DOLPHIN	Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)	P2	active not recruiting	105	Michael Hopp	Dec 2020
NCT04176848		CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer	P2	active not recruiting	15	Canadian Cancer Trials Group	Aug 2020
NCT04163432	STAGGER	Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC	P2	active not recruiting	43	University of Utah	Jun 2020
NCT03842228	COD	Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations	P1	active not recruiting	39	National Cancer Institute (NCI)	Nov 2019
NCT03965468	CHESS	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC	P2	active not recruiting	96	ETOP IBCSG Partners Foundation	Nov 2019
NCT03768570		Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer	P2	active not recruiting	82	Canadian Cancer Trials Group	Oct 2019
NCT03923270		Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer	P1	active not recruiting	25	H. Lee Moffitt Cancer Center and Research Institute	Jun 2019
NCT03837899		Durvalumab and Tremelimumab for Pediatric Malignancies	P1/P2	active not recruiting	50	AstraZeneca	Mar 2019
NCT03772561	MEDIPAC	Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies	P1	recruiting	40	National University Hospital, Singapore	Dec 2018
NCT03459846	BAYOU	A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)	P2	active not recruiting	154	AstraZeneca	Mar 2018
NCT03257761		Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer	P1	active not recruiting	55	University of Southern California	Feb 2018
NCT03043872	CASPIAN	Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)	P3	active not recruiting	987	AstraZeneca	Mar 2017
NCT02542293	NEPTUNE	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)	P3	active not recruiting	953	AstraZeneca	Nov 2015
NCT02516241		Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	P3	active not recruiting	1,126	AstraZeneca	Nov 2015
NCT02537418		Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens	P1	active not recruiting	153	Canadian Cancer Trials Group	Oct 2015
NCT02453282	MYSTIC	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)	P3	active not recruiting	1,118	AstraZeneca	Jul 2015
NCT07196384	GLOW	Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW	P1	not yet recruiting	15	University Medical Center Groningen	Dec 2025
NCT05222971	OPTIMUM	Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy	P2	recruiting	62	Asan Medical Center	Apr 2022
NCT03606967		Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	P2	recruiting	70	National Cancer Institute (NCI)	Apr 2021
NCT04585477	ADAPT-E	Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)	P2	recruiting	80	Stanford University	Apr 2021
NCT03737643	DUO-O	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients	P3	active not recruiting	1,407	AstraZeneca	Jan 2019
NCT02519348		A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma	P2	active not recruiting	433	MedImmune LLC	Oct 2015
NCT06117891	REFINE-IO	An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery	—	active not recruiting	300	Bayer	Nov 2023
NCT04745689	TAZMAN	Study of AZD2811 + Durvalumab in ES-SCLC	P2	active not recruiting	31	AstraZeneca	Feb 2021
NCT04988945		TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma	P2	recruiting	33	The University of Hong Kong	Dec 2020
NCT04395079		Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies	P2	active not recruiting	9	Jonsson Comprehensive Cancer Center	Aug 2020
NCT06017297	ESR-22-21719	Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma	P2	withdrawn	0	Georgetown University	Dec 2024
NCT06218511		A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)	P1	active not recruiting	10	National Cancer Institute, Naples	Nov 2022
NCT04711824	SOLARA	Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases	P1/P2	recruiting	41	Colette Shen	Mar 2022
NCT04699838		Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer	P2	recruiting	30	Muhammad Furqan	Apr 2021
NCT03158064	MEDI4736	Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors	P2	active not recruiting	30	Memorial Sloan Kettering Cancer Center	May 2017
NCT02962063		Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	P1/P2	active not recruiting	64	Memorial Sloan Kettering Cancer Center	Nov 2016
NCT04068610	COLUMBIA-1	COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC	P1/P2	active not recruiting	61	MedImmune LLC	Sep 2019
NCT05061134	MONETTE	A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition	P2	active not recruiting	194	AstraZeneca	Aug 2022
NCT06060405	DORA	Durvalumab and Oleclumab in Resectable PDAC	P2	recruiting	22	University Health Network, Toronto	Nov 2023
NCT03703297	ADRIATIC	Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy	P3	active not recruiting	730	AstraZeneca	Sep 2018
NCT05701488		SIRT With Tremelimumab and Durvalumab for Resectable HCC	P1	recruiting	20	Jiping Wang, MD, PhD	Apr 2023
NCT05883644	SIERRA	Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)	P3	active not recruiting	111	AstraZeneca	Jun 2023
NCT05742607	MATISSE	IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)	P2	recruiting	70	Innate Pharma	Jun 2023
NCT04892953		Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy	P2	recruiting	51	M.D. Anderson Cancer Center	Jul 2021
NCT03245541		Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	P1/P2	active not recruiting	18	Memorial Sloan Kettering Cancer Center	Aug 2020
NCT03775486	ORION	Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)	P2	active not recruiting	401	AstraZeneca	Dec 2018
NCT05771480	TOURMALINE	Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)	P3	active not recruiting	142	AstraZeneca	Aug 2023
NCT03334617	HUDSON	Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy	P2	active not recruiting	528	AstraZeneca	Dec 2017
NCT04294498		Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection	P2	active not recruiting	30	National Taiwan University Hospital	Nov 2020
NCT05137262	MEDI 4736	A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder	P2	active not recruiting	12	M.D. Anderson Cancer Center	Oct 2021
NCT04065269	ATARI	ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss	P2	active not recruiting	174	Institute of Cancer Research, United Kingdom	Nov 2019
NCT03726775	REWRITe	Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN	P2	active not recruiting	61	Groupe Oncologie Radiotherapie Tete et Cou	Jul 2019
NCT03778957	EMERALD-1	A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma	P3	active not recruiting	724	AstraZeneca	Nov 2018
NCT03011814		Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma	P1/P2	active not recruiting	38	City of Hope Medical Center	Mar 2017
NCT03298451	HIMALAYA	Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	P3	active not recruiting	1,324	AstraZeneca	Oct 2017
NCT05298423	KEYVIBE-006	Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)	P3	active not recruiting	611	Merck Sharp & Dohme LLC	May 2022
NCT04062708		CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer	P2	active not recruiting	38	Alliance Foundation Trials, LLC.	Mar 2021
NCT03999710		Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	P2	active not recruiting	61	Memorial Sloan Kettering Cancer Center	Jul 2019
NCT03410615		Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC	P2	active not recruiting	129	Canadian Cancer Trials Group	May 2018
NCT03215095		RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers	Early P1	active not recruiting	11	Memorial Sloan Kettering Cancer Center	Jul 2017
NCT06040099	EMERALD-Y90	A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE	P2	active not recruiting	58	AstraZeneca	Feb 2024
NCT03819465	MAGELLAN	A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC	P1	active not recruiting	175	AstraZeneca	Dec 2018
NCT05809869		Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma	P2	recruiting	25	The University of Hong Kong	Feb 2023
NCT06094140	NEO-IMPACT	NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer	P2	active not recruiting	20	Australasian Gastro-Intestinal Trials Group	May 2022
NCT04999969		Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours	P2	active not recruiting	126	AstraZeneca	Dec 2021
NCT05215106	POP-DURVA	Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)	P2	recruiting	200	Gustave Roussy, Cancer Campus, Grand Paris	Dec 2021
NCT04668300	DOSa	Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma	P2	active not recruiting	75	M.D. Anderson Cancer Center	Nov 2020
NCT03732677	NIAGARA	Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC	P3	active not recruiting	1,063	AstraZeneca	Nov 2018
NCT03653052	CALIBRATION	Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab	P2	active not recruiting	18	Simon C Pacey, MD	Oct 2018
NCT03057106		Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC	P2	active not recruiting	301	Canadian Cancer Trials Group	Mar 2017
NCT03003962	PEARL	Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)	P3	active not recruiting	669	AstraZeneca	Jan 2017
NCT02264678		Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents	P1	active not recruiting	354	AstraZeneca	Oct 2014
NCT04556773	DB-08	A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer	P1	active not recruiting	138	AstraZeneca	Dec 2020
NCT05659914	MEDI4736	Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations	P2	active not recruiting	40	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Nov 2022
NCT06111326		BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma	P1/P2	unknown	83	Biocity Biopharmaceutics Co., Ltd.	Oct 2023
NCT05383001		Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)	P2	withdrawn	0	AIO-Studien-gGmbH	May 2022
NCT04905316	CHORUS	A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer	P2	active not recruiting	41	Memorial Sloan Kettering Cancer Center	May 2021
NCT04521686		Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	P1	active not recruiting	200	Eli Lilly and Company	Oct 2020
NCT03529422		Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	P2	active not recruiting	18	UNC Lineberger Comprehensive Cancer Center	Oct 2019
NCT04612751	TROPION-Lung04	Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer	P1	active not recruiting	155	AstraZeneca	Feb 2021
NCT06331455	SUPER	Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection	P2	recruiting	12	Marc de Perrot	May 2024
NCT04817826	INFINITY	TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.	P2	active not recruiting	31	Gruppo Oncologico del Nord-Ovest	Apr 2021
NCT03482102	MEDI4736	Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer	P2	active not recruiting	37	Massachusetts General Hospital	May 2018
NCT05712356	BOLSTER	A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors	P2	terminated	66	Lisata Therapeutics, Inc.	May 2023
NCT05514132		A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours	P1	active not recruiting	14	AstraZeneca	Sep 2022
NCT03784066	DUTRELASCO	Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity	P1/P2	active not recruiting	21	Universitaire Ziekenhuizen KU Leuven	Aug 2018
NCT03589547	358	Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung	P2	completed	11	Brown University	May 2019
NCT06375915	PM-CARE	Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy	P2	unknown	33	Francesco De Cobelli	May 2024
NCT04073160	TRIO Bladder	TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer	P1	withdrawn	0	Daniel George, MD	Jun 2020
NCT06333678	NSCLC	A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)	P2	completed	10	Memorial Sloan Kettering Cancer Center	Mar 2024
NCT04351256	TRADE-hypo	Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy	P2	completed	51	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	May 2020
NCT03784014	MULTISARC	Molecular Profiling of Advanced Soft-tissue Sarcomas	P3	completed	603	Institut National de la Santé Et de la Recherche Médicale, France	Oct 2019
NCT06083454	NSCLC	Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)	P1	terminated	1	William Zeitler	Oct 2023
NCT06939036	SANTANA-225	Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )	P1/P2	terminated	2	Ariceum Therapeutics GmbH	Jul 2025
NCT05757843		Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	P2	withdrawn	0	Indiana University	Sep 2024
NCT06255262		Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer	P1/P2	unknown	30	China Medical University, China	Feb 2024
NCT05451173		Combining ICI With SBRT or HypoFrx-RT for ES NSCLC	P1/P2	unknown	83	Alexander Chi	Oct 2023
NCT05864755		HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma	P2	unknown	30	Tianjin Medical University Cancer Institute and Hospital	Jun 2023
NCT05672537		Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk	P2	unknown	70	Tianjin Medical University Cancer Institute and Hospital	Jan 2023
NCT04348045	MAZEPPA	Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.	P2	active not recruiting	307	GERCOR - Multidisciplinary Oncology Cooperative Group	Dec 2020
NCT04621370	PRIME-RT	A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer	P2	unknown	48	Liz-Anne Lewsley	Dec 2020
NCT04443322	Dulect2020-1	Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )	N/A	unknown	20	RenJi Hospital	Sep 2020
NCT04298008		AZD6738 Plus Durvalumab in Biliary Tract Cancer	P2	unknown	26	Seoul National University Hospital	Jun 2020
NCT03899428		Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC	P2	recruiting	30	Humanity & Health Medical Group Limited	May 2019
NCT03704480	IMMUNO-BIL	Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.	P2	active not recruiting	106	GERCOR - Multidisciplinary Oncology Cooperative Group	Nov 2018
NCT03385655		Prostate Cancer Biomarker Enrichment and Treatment Selection	P2	active not recruiting	200	Canadian Cancer Trials Group	Aug 2018
NCT03594396		Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer	P1/P2	active not recruiting	54	Seoul National University Hospital	Jun 2018
NCT03088059	UPSTREAM	Biomarker-based Study in R/M SCCHN	P2	unknown	340	European Organisation for Research and Treatment of Cancer - EORTC	Nov 2017
NCT04762030		Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study	P2	unknown	39	Shanghai Pulmonary Hospital, Shanghai, China	Feb 2021
NCT04308174	DEBATE	Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer	P2	active not recruiting	45	Asan Medical Center	May 2020
NCT05380713		......SMARTEST Trial......	P2	completed	30	University Health Network, Toronto	May 2022
NCT05443971		Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen	P1	terminated	4	Mayo Clinic	Jan 2024
NCT03519971		Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer	P3	active not recruiting	328	AstraZeneca	Mar 2018
NCT03741426	WIRE	WIRE - Novel Treatments in Renal Cell Cancer	P2	unknown	60	CCTU- Cancer Theme	Jul 2020
NCT05128630	DEDALUS	Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.	P2	unknown	45	Fondazione IRCCS Policlinico San Matteo di Pavia	Oct 2021
NCT04895579	LCD	Lung Cancer With Copanlisib and Durvalumab	P1	completed	11	Zhonglin Hao	May 2021
NCT04517227	TAD	The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)	N/A	unknown	30	Fudan University	Jul 2021
NCT03581487		Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer	P1/P2	completed	40	M.D. Anderson Cancer Center	Apr 2019
NCT03911557		Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors	P2	completed	14	John L. Villano, MD, PhD	Jun 2019
NCT03446547	ASTEROID	Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)	P2	completed	106	Vastra Gotaland Region	Dec 2017
NCT06341764		Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma	P2	recruiting	38	National Cancer Institute, Naples	Sep 2023
NCT03549715	NEMIO	NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma	P1/P2	unknown	121	Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie	Dec 2018
NCT03916419		Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer	P2	completed	26	Washington University School of Medicine	Jun 2019
NCT04748419		Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab	P1/P2	terminated	6	University of Nebraska	Jul 2021
NCT04108026	SAVIMMUNE	Immunotherapy in Patient With Poor General Condition	P2	completed	50	Intergroupe Francophone de Cancerologie Thoracique	Oct 2020
NCT02938793		Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors	P2	terminated	92	Prisma Health-Upstate	Dec 2016
NCT03026062		Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	P2	completed	100	M.D. Anderson Cancer Center	May 2017
NCT03801902	IPH2201	Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial	P1	completed	26	National Cancer Institute (NCI)	Oct 2019
NCT03258554		Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin	P2/P3	completed	196	National Cancer Institute (NCI)	Apr 2018
NCT02671435	MEDI4736	A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors	P1/P2	active not recruiting	383	MedImmune LLC	Feb 2016
NCT04083365	PANDORA	Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer	P2	unknown	100	AUSL Romagna Rimini	Jan 2020
NCT02983578		Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer	P2	active not recruiting	39	M.D. Anderson Cancer Center	Mar 2017
NCT03739931		Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies	P1	completed	134	ModernaTX, Inc.	Nov 2018
NCT04513925	SKYSCRAPER-03	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	P3	completed	829	Hoffmann-La Roche	Aug 2020
NCT04705818	CAIRE	Combining Epigenetic And Immune Therapy to Beat Cancer.	P2	completed	164	Institut Bergonié	Jul 2021
NCT04107168		Microbiome Immunotherapy Toxicity and Response Evaluation	—	unknown	1,800	CCTU- Cancer Theme	Jul 2020
NCT04334759	DREAM3R	DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma	P3	completed	214	PrECOG, LLC.	Feb 2021
NCT04336943		Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	P2	terminated	6	University of Washington	Apr 2021
NCT04224337		Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma	P2	completed	16	Seoul National University Hospital	Jun 2020
NCT03944772	ORCHARD	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)	P2	active not recruiting	247	AstraZeneca	Jun 2019
NCT02788773		Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer	P2	completed	52	Canadian Cancer Trials Group	Dec 2016
NCT04202809	ESPADURVA	Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.	P2	unknown	90	University Hospital, Essen	Jan 2020
NCT04221555		Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma	P2	completed	68	Asan Medical Center	May 2020
NCT05557838	TREMENDOUS	Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma	P3	recruiting	210	AstraZeneca	Feb 2023
NCT04646837		Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models	P1/P2	unknown	20	Peking Union Medical College Hospital	May 2021
NCT03991832	SOLID	Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors	P2	recruiting	58	University Health Network, Toronto	Dec 2019
NCT02879318		Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma	P2	completed	180	Canadian Cancer Trials Group	Nov 2016
NCT04293419	DUREC	Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer	P2	unknown	58	Grupo Espanol Multidisciplinario del Cancer Digestivo	Dec 2019
NCT04223648	MEDI4736	Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma	Early P1	withdrawn	0	Yale University	Aug 2020
NCT03833440	PIONeeR	Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance	P2	unknown	114	Assistance Publique Hopitaux De Marseille	Oct 2019
NCT05911308	RGX-104	Abequolixron (RGX-104) and Durvalumab in Lung Cancer	P1	terminated	1	UNC Lineberger Comprehensive Cancer Center	Apr 2024
NCT04902040		Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies	P1/P2	terminated	19	M.D. Anderson Cancer Center	Apr 2021
NCT03212469	ABIMMUNE	A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer	P1/P2	completed	54	Gustave Roussy, Cancer Campus, Grand Paris	Jun 2017
NCT05239169		Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer	P2	completed	40	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	May 2022
NCT05924880	TopDouble	A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)	P3	completed	116	AstraZeneca	Jul 2023
NCT04889066	MEDI4736	Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases	P2	withdrawn	0	University of Texas Southwestern Medical Center	Oct 2024
NCT03406650	SAKK 06/17	Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.	P2	completed	61	Swiss Cancer Institute	May 2018
NCT03051906	DUCRO-HN	Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer	P1/P2	unknown	69	Azienda Ospedaliero-Universitaria Careggi	Jan 2018
NCT04765709	BRIDGE	Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC	P2	terminated	10	Mario Negri Institute for Pharmacological Research	Sep 2021
NCT02879162		Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours	P2	completed	140	Canadian Cancer Trials Group	Dec 2016
NCT06826677	ARAL	REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER	—	completed	71	AstraZeneca	Jul 2024
NCT03871036	ICRA	Improve Checkpoint-blockade Response in Advanced Urothelial Cancer	P1/P2	completed	53	The Netherlands Cancer Institute	May 2019
NCT03509012	CLOVER	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors	P1	completed	105	AstraZeneca	May 2018
NCT04774380	LUMINANCE	Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer	P3	completed	152	AstraZeneca	Nov 2021
NCT05262985	MEDI4736	Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study	P2	unknown	22	Elizabeth Dudnik	Jan 2022
NCT05161533		Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial	P2	withdrawn	0	University of Washington	Oct 2023
NCT05640791		Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer	P2	unknown	40	Tianjin Medical University Cancer Institute and Hospital	Dec 2022
NCT04913480		SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma	P2	unknown	37	The University of Hong Kong	Oct 2020
NCT04298021		DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer	P2	unknown	74	Seoul National University Hospital	Jun 2020
NCT04447612		Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma	P2	unknown	118	The University of Hong Kong	Jun 2020
NCT03802747		Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases	P1	withdrawn	0	University of Colorado, Denver	Aug 2019
NCT03572400	MEDI4736	Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer	P2	unknown	71	Do-Youn Oh	Nov 2018
NCT03579784	MEDI4736	Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer	P2	unknown	40	Do-Youn Oh	Nov 2018
NCT03283605		Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	P1/P2	active not recruiting	45	Centre hospitalier de l'Université de Montréal (CHUM)	Jul 2018
NCT03419559	LN-145	Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer	P2	withdrawn	0	Iovance Biotherapeutics, Inc.	Feb 2018
NCT03249142	INeOV	Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer	P1/P2	completed	69	ARCAGY/ GINECO GROUP	Oct 2017
NCT03046862	MEDI4736	Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer	P2	unknown	31	Seoul National University Hospital	Feb 2017
NCT06191250		--SuPERIOR Trial--	P2	terminated	10	University Health Network, Toronto	Sep 2024
NCT05935579		Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer	P2	unknown	40	Peking Union Medical College Hospital	Dec 2022
NCT04064190		Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition	P2	withdrawn	0	MedPacto, Inc.	Dec 2019
NCT03801369	AMTEC IIT	AMTEC IIT: Phase 2 Multiarm Study in TNBC	P2	terminated	24	Gordon Mills, MD, PhD	Dec 2018
NCT04230408	PACIFIC BRAZIL	Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers	P2	completed	48	Latin American Cooperative Oncology Group	Mar 2021
NCT03518606	MOVIE	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours	P1/P2	completed	126	UNICANCER	Jun 2018
NCT03075527		A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma	P2	terminated	19	Dana-Farber Cancer Institute	Apr 2017
NCT04364776		Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.	—	unknown	100	Fondazione IRCCS Policlinico San Matteo di Pavia	Jan 2020
NCT03982173	MATILDA	Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	P2	withdrawn	0	Gustave Roussy, Cancer Campus, Grand Paris	Sep 2020
NCT05450484	OPTIC	Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer	P1	completed	21	University Medical Center Groningen	Apr 2023
NCT04985851		To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.	N/A	unknown	90	Shanghai Chest Hospital	Sep 2021
NCT03777813	ARION	Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer	P2	completed	112	UNICANCER	Dec 2018
NCT03691714	MEDI4736	Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	P2	completed	35	Trisha Wise-Draper	Oct 2018
NCT04543110	RADIANT	Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC	P2	unknown	16	Ottawa Hospital Research Institute	Jan 2021
NCT03959293		Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma	P2	active not recruiting	107	Federation Francophone de Cancerologie Digestive	Jul 2019
NCT04026412	CheckMate73L	A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery	P3	completed	925	Bristol-Myers Squibb	Oct 2019
NCT04249362	DUART	Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy	P2	completed	102	AstraZeneca	Nov 2020
NCT03753919	DUTHY	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial	P2	terminated	79	Grupo Espanol de Tumores Neuroendocrinos	Apr 2019
NCT05027425	MEDI4736	Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant	P2	terminated	8	University of Cincinnati	Dec 2021
NCT04003246		Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer	P2	completed	10	University of Texas Southwestern Medical Center	Apr 2020
NCT04287894	Induction	Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment	P1	terminated	18	The Netherlands Cancer Institute	Dec 2018
NCT02866747	STERIMGLI	A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma	P1/P2	completed	108	Institut Claudius Regaud	Jan 2017
NCT04672759		A Real-world Study of Durvalumab for Lung Cancer in China	—	unknown	100	Peking Union Medical College Hospital	Jul 2020
NCT04078152	WAVE	Durvalumab Long-Term Safety and Efficacy Study	P4	completed	163	AstraZeneca	Sep 2019
NCT04019288		AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P1/P2	terminated	12	M.D. Anderson Cancer Center	Dec 2019
NCT04504669		First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours	P1	completed	60	AstraZeneca	Aug 2020
NCT05718297	BOUNCE	Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer	P2	withdrawn	0	ETOP IBCSG Partners Foundation	Jun 2024
NCT03019003	ASTX727	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients	P1	completed	13	Massachusetts General Hospital	Mar 2017
NCT03150836		Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer	P2	withdrawn	0	Terence Friedlander, MD	Oct 2017
NCT05034133		Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer	P2	unknown	20	Beijing Haidian Hospital	Sep 2021
NCT04800978		Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy	P2	unknown	37	Samsung Medical Center	Jun 2021
NCT03955198	SILK BM	A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation	P2	completed	4	Institut Claudius Regaud	May 2021
NCT03638141	DEB-TACE	CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab	P2	completed	21	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Oct 2019
NCT02953457		Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	P2	completed	40	Roswell Park Cancer Institute	Jun 2017
NCT06245291	AB-729	Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection	P2	withdrawn	0	Arbutus Biopharma Corporation	May 2024
NCT02616640		A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma	P1	completed	114	Celgene	Jan 2016
NCT04945720	HAIC	Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma	P2	completed	30	Sun Yat-sen University	Apr 2022
NCT04257448	SEPION	Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer	P1/P2	completed	75	GWT-TUD GmbH	May 2020
NCT05312216		Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma	P2	unknown	25	Zhejiang University	Apr 2023
NCT04660097		Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer	P2	completed	34	Henan Cancer Hospital	May 2021
NCT04159974	RICE	RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus	P2	unknown	56	University of Cologne	Sep 2019
NCT03975114	MILES-5	A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)	P2	unknown	460	National Cancer Institute, Naples	Dec 2018
NCT02815995		Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes	P2	completed	57	M.D. Anderson Cancer Center	Aug 2016
NCT05572476	LURBIMUNE	Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer	P2	withdrawn	0	Institut Bergonié	Oct 2023
NCT04613492		A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors	P1	terminated	40	AstraZeneca	Dec 2020
NCT03598816	PIVOT-RCC	PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma	P2	withdrawn	0	Washington University School of Medicine	Aug 2020
NCT03004105	NSCLC	MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)	P2	withdrawn	0	M.D. Anderson Cancer Center	May 2018
NCT03237377		Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer	P2	terminated	9	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Dec 2017
NCT03132467		Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer	Early P1	completed	16	M.D. Anderson Cancer Center	Jun 2017
NCT05327582		An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC	P1/P2	unknown	65	Chinese PLA General Hospital	Apr 2022
NCT03610061	RaDD	A Trial of Radiotherapy and Durvalumab in DLBCL and FL	P1	completed	34	Austin Health	Nov 2018
NCT04231864		Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer	P2	withdrawn	0	Alain Algazi	Dec 2020
NCT04441138	ESR1814205	Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC	P2	terminated	10	Rush University Medical Center	Feb 2021
NCT03421353		AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer	P1	completed	76	AstraZeneca	Feb 2018
NCT04145193		Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC	P2	withdrawn	0	MedImmune LLC	Oct 2020
NCT03723967	FRAIL-IMMUNE	FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel	P2	completed	104	Centre Leon Berard	May 2019
NCT05382741	VIVA	Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial	P2	unknown	182	Ospedale Policlinico San Martino	Mar 2022
NCT03426657		Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	P2	completed	120	University of Erlangen-Nürnberg Medical School	Sep 2018
NCT04538378	LYNPARZA	Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors	P2	terminated	4	National Cancer Institute (NCI)	Jul 2021
NCT04301778		Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	P2	completed	5	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Aug 2021
NCT04364048		Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer	P2	terminated	10	Rachel Sanborn	Jun 2020
NCT05267392	IDEAR	Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy	P1/P2	unknown	30	Instituto Portugues de Oncologia, Francisco Gentil, Porto	Feb 2021
NCT04262375	DOMINATION	A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION	P2	withdrawn	0	University Health Network, Toronto	Jan 2021
NCT03994393	ILLUMINATE	Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.	P2	unknown	100	University of Sydney	Oct 2018
NCT04156087	MIMIPAC	Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer	P2	completed	12	Baki Topal	May 2020
NCT04015739	BOLD	Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse	P2	unknown	74	ARCAGY/ GINECO GROUP	Mar 2019
NCT04951115		A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer	P2	terminated	6	Weill Medical College of Cornell University	Jul 2021
NCT05848843		A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations	P1	withdrawn	0	M.D. Anderson Cancer Center	Apr 2023
NCT04642469	MERMAID-2	Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.	P3	completed	30	AstraZeneca	Nov 2020
NCT04568200		Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma	P2	completed	60	Peking Union Medical College Hospital	Jun 2020
NCT04625699		Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment	P2	withdrawn	0	Catherine Shu	Dec 2022
NCT04893252		Vactosertib and Durvalumab in Gastric Cancer	P2	unknown	55	Hark Kyun Kim	Jun 2021
NCT03308396		Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer	P1/P2	active not recruiting	57	Ajjai Alva, MD	Dec 2017
NCT03356860	B-IMMUNE	Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.	P1/P2	completed	57	Grand Hôpital de Charleroi	Apr 2017
NCT02117167	SAFIR02_Lung	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients	P2	completed	999	UNICANCER	Apr 2014
NCT03780608		This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)	P2	unknown	61	Samsung Medical Center	Jul 2019
NCT05245994	MEDI4736	An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese	P2	unknown	60	Li Zhang, MD	Aug 2021
NCT02664935		National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	P2	completed	423	University of Birmingham	May 2015
NCT02937818		A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer	P2	completed	72	AstraZeneca	Nov 2016
NCT04108481	iRE-C	Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	P1	terminated	5	University of Iowa	Oct 2020
NCT03737968	MEDI4736	Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.	P2	unknown	48	Yonsei University	Jan 2019
NCT04416633		Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC	P4	completed	100	AstraZeneca	Nov 2021
NCT04361825	SUKSES-N4	Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects	P2	completed	42	Se-Hoon Lee	Jun 2020
NCT04866017		A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer	P3	terminated	63	BeiGene	Jun 2021
NCT02281084		Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes	P2	completed	65	Celgene	Jul 2015
NCT04385368	MERMAID-1	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)	P3	completed	89	AstraZeneca	Jul 2020
NCT03212807	DuRIANS	Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL	P2	withdrawn	0	Singapore General Hospital	Aug 2017
NCT04870112	SCope-D1	A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer	P1	terminated	18	AstraZeneca	Jun 2021
NCT03751761	MEDI4736	GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study	P1/P2	completed	58	Asan Medical Center	Jun 2018
NCT02352948	ARCTIC	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer	P3	completed	597	AstraZeneca	Jan 2015
NCT03946800		A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors	P1	completed	61	MedImmune LLC	May 2019
NCT03624231	DURTRE-RAD	Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC	P2	completed	18	Ulrich Keilholz	Aug 2018
NCT03452332		Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers	P1	completed	20	M.D. Anderson Cancer Center	Jul 2018
NCT03376659		Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma	P1/P2	terminated	8	Georgetown University	Aug 2018
NCT04255836	SBRT	Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)	P2	unknown	35	Zhejiang Cancer Hospital	Sep 2020
NCT03822351	COAST	Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC	P2	completed	189	MedImmune LLC	Dec 2018
NCT03810105		A Study of Olaparib and Durvalumab in Prostate Cancer	P2	terminated	5	Memorial Sloan Kettering Cancer Center	Mar 2019
NCT03830866	CALLA	Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)	P3	completed	770	AstraZeneca	Feb 2019
NCT04851132		Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma	N/A	unknown	33	Chinese Academy of Medical Sciences	Mar 2021
NCT04356222		Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis	P4	unknown	30	Hui Bu	Jun 2020
NCT03381183		IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma	P1	completed	19	H. Lee Moffitt Cancer Center and Research Institute	Aug 2019
NCT03618134		Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner	P1/P2	terminated	19	Jonsson Comprehensive Cancer Center	Oct 2018
NCT02899195	PrE0505	Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma	P2	completed	55	PrECOG, LLC.	Jun 2017
NCT04712903	CANTABRICO	Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer	P3	completed	101	AstraZeneca	Dec 2020
NCT05157542		Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC	P1	unknown	9	Juan LI, MD	Jun 2021
NCT02966587		Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	P2	withdrawn	0	University of Washington	May 2018
NCT03635164		Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma	P1	completed	21	University of Colorado, Denver	Nov 2018
NCT03199040		Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy	P1	terminated	18	Washington University School of Medicine	Jul 2019
NCT02793466		Durvalumab in Pediatric and Adolescent Patients	P1	completed	15	Leo Mascarenhas	Jul 2016
NCT03435107		Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	P2	completed	33	Asan Medical Center	Apr 2018
NCT03693300		A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer	P2	completed	117	AstraZeneca	Apr 2019
NCT04322643		Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma	P2	terminated	4	Case Comprehensive Cancer Center	Mar 2020
NCT03472274	DUTRENEO	Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)	P2	completed	101	Fundacion CRIS de Investigación para Vencer el Cáncer	Oct 2018
NCT04089553		An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer	P2	completed	59	AstraZeneca	Aug 2019
NCT03970616	DEDUCTIVE	A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma	P1/P2	terminated	27	AVEO Pharmaceuticals, Inc.	Sep 2019
NCT02740985		A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	P1	completed	313	AstraZeneca	Jun 2016
NCT04449861		Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)	P3	completed	166	AstraZeneca	Dec 2020
NCT03732664		ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer	P1	completed	27	Second Affiliated Hospital, School of Medicine, Zhejiang University	Oct 2018
NCT04696848		The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors	P1/P2	terminated	25	Tae Won Kim	Feb 2021
NCT02503774		MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.	P1	completed	192	MedImmune LLC	Jul 2015
NCT04982549		A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC	P2	unknown	35	Shandong Cancer Hospital and Institute	Jan 2021
NCT03235869		Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma	Early P1	withdrawn	0	University of Michigan Rogel Cancer Center	Mar 2018
NCT03824691	ARCADIA	hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"	P2	unknown	122	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Sep 2019
NCT03161223		Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma	P1/P2	recruiting	148	University of Virginia	May 2018
NCT03840902	NSCLC	M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)	P2	terminated	153	EMD Serono Research & Development Institute, Inc.	Apr 2019
NCT03310619	PLATFORM	A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies	P1/P2	completed	62	Celgene	Dec 2017
NCT04262388	DOME	A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation	P2	withdrawn	0	University Health Network, Toronto	Jan 2021
NCT03799744		Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma	P1	unknown	20	Institut Català d'Oncologia	Mar 2019
NCT02754856		Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery	P1	completed	24	M.D. Anderson Cancer Center	Aug 2016
NCT03202758	MEDITREME	Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC	P1/P2	completed	57	Centre Georges Francois Leclerc	Aug 2017
NCT03759496		Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer	P2	unknown	39	Hellenic GenitoUrinary Cancer Group	Nov 2018
NCT03345810	DURATION	Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)	P2	completed	200	AIO-Studien-gGmbH	Dec 2017
NCT02885727	Panc-Durval+RT	Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)	P2	withdrawn	0	University of Maryland, Baltimore	Jul 2017
NCT02821754	HCC	A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)	P2	completed	54	National Cancer Institute (NCI)	Jul 2016
NCT03015129		A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer	P2	completed	80	Memorial Sloan Kettering Cancer Center	Jan 2017
NCT03084471	STRONG	An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.	P3	completed	867	AstraZeneca	Jun 2017
NCT03889275		A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors	P1	completed	39	MedImmune LLC	Oct 2019
NCT03618654		Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma	Early P1	completed	38	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Nov 2018
NCT03853187	Donan	Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer	P2	completed	20	Radboud University Medical Center	Sep 2019
NCT04517526		Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study	P2	unknown	60	Shanghai Cancer Hospital, China	Nov 2020
NCT02997332	MEDINDUCTION	Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma	P1	terminated	14	Gustave Roussy, Cancer Campus, Grand Paris	Mar 2017
NCT03319316	SOLUTION	Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)	P2	withdrawn	0	European Organisation for Research and Treatment of Cancer - EORTC	Nov 2018
NCT04348292		Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer	P1	terminated	3	Emory University	Jan 2021
NCT03258593	BCG	Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)	P1	completed	15	National Cancer Institute (NCI)	Jun 2018
NCT02904954	MEDI4736	Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer	P2	completed	60	Weill Medical College of Cornell University	Dec 2016
NCT04054518	DESC	Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma	P2	unknown	22	Tiago Biachi	Oct 2019
NCT03699449	AMBITION	An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)	P2	unknown	104	Yonsei University	Nov 2018
NCT04667312	CODAK	Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom	—	completed	115	AstraZeneca	Jun 2021
NCT03439085		DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers	P2	terminated	41	M.D. Anderson Cancer Center	Nov 2018
NCT02685826		A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma	P1/P2	completed	56	Celgene	Apr 2016
NCT05933044	RELEVANCE	RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada	—	completed	662	AstraZeneca	Nov 2021
NCT02733042	FUSION NHL 001	A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia	P1/P2	completed	106	Celgene	May 2016
NCT03702179	IMMUNOPRESERVE	Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach	P2	completed	32	Spanish Oncology Genito-Urinary Group	Nov 2018
NCT03317457	MEDISARC	Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma	P2	completed	103	AIO-Studien-gGmbH	Dec 2017
NCT03912818		Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer	P2	terminated	7	Stanford University	Apr 2019
NCT03802071		A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma	P1/P2	completed	44	Yonsei University	Sep 2019
NCT03798106		A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma	P2	completed	46	Yonsei University	Apr 2019
NCT04495179	AARDVARC	A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.	P2	completed	30	AstraZeneca	Aug 2020
NCT04124991	SOLID	Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC	P1/P2	completed	24	Seoul National University Hospital	Jun 2020
NCT03611556		MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.	P1/P2	completed	213	MedImmune LLC	Jun 2018
NCT03277482		Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer	P1	terminated	16	Dana-Farber Cancer Institute	Jun 2018
NCT03167619	DORA	Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)	P2	completed	45	Duke University	Oct 2018
NCT03206073		A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer	P1/P2	completed	34	National Cancer Institute (NCI)	Dec 2017
NCT02963831		A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies	P1/P2	completed	67	Ludwig Institute for Cancer Research	Sep 2017
NCT04261075		IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.	P1	completed	57	MedImmune LLC	Mar 2020
NCT02735239		Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer	P1/P2	completed	73	Ludwig Institute for Cancer Research	Jun 2016
NCT04786093		Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC	P2	terminated	1	University of Texas Southwestern Medical Center	Jul 2021
NCT02870920		Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer	P2	completed	180	Canadian Cancer Trials Group	Oct 2016
NCT02879617	MEDI4736	A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients	P2	completed	47	Academic Thoracic Oncology Medical Investigators Consortium	Apr 2017
NCT03122496	SBRT	Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer	P1	completed	13	Memorial Sloan Kettering Cancer Center	Apr 2017
NCT03095274	DUNE	Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin	P2	completed	126	Grupo Espanol de Tumores Neuroendocrinos	Apr 2017
NCT03428126	MEDI4736	Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer	P2	completed	29	M.D. Anderson Cancer Center	Mar 2018
NCT02891161	DUART	Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder	P1/P2	terminated	26	Monika Joshi, MD	Nov 2016
NCT05345678		Himalaya Early Access Program	—	approved for marketing	0	AstraZeneca	—
NCT03003520		A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma	P2	completed	46	Celgene	Feb 2017
NCT04372927		ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy	P2	terminated	1	University of Washington	Dec 2021
NCT02827838		Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer	Early P1	terminated	17	Wake Forest University Health Sciences	Jan 2017
NCT02492867		A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	N/A	completed	49	University of Michigan Rogel Cancer Center	Jan 2016
NCT02154490		Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	—	completed	1,864	SWOG Cancer Research Network	Jul 2014
NCT03450967		Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC	P2	unknown	31	Samsung Medical Center	Apr 2018
NCT03373760		Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer	P2	completed	67	SWOG Cancer Research Network	Nov 2017
NCT03094286		Durvalumab in HIV-1 Patients With Solid Tumors	P2	completed	20	Spanish Lung Cancer Group	Apr 2017
NCT03473574	IMMUCHEC	Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients	P2	completed	128	AIO-Studien-gGmbH	May 2018
NCT03405454		A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas	P2	unknown	46	National University Hospital, Singapore	Oct 2017
NCT03292250	TRIUMPH	Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]	P2	completed	180	Seoul National University Hospital	Sep 2017
NCT04314297		Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study	P2	unknown	33	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Apr 2020
NCT03101475	ILOC	Synergism of Immunomodulation and Tumor Ablation	P2	completed	22	European Organisation for Research and Treatment of Cancer - EORTC	Nov 2018
NCT02643303		A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers	P1/P2	completed	58	Ludwig Institute for Cancer Research	Dec 2016
NCT03818776		Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC	Early P1	terminated	7	Case Comprehensive Cancer Center	Aug 2019
NCT03522584		Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	P1/P2	terminated	6	University of Washington	May 2018
NCT04525391	SUKSES-N5	AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer	P2	terminated	4	Se-Hoon Lee	Sep 2020
NCT03085225	TRAMUNE	Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.	P1	completed	40	Institut Bergonié	May 2017
NCT02807454	FUSIONMM-003	A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma	P2	terminated	37	Celgene	Jul 2016
NCT04184518	CEDUVEAL-M	Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma	P2	withdrawn	0	Grupo Español Multidisciplinar de Melanoma	May 2020
NCT04285866	S-REAL	Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.	—	completed	245	Fundación GECP	May 2020
NCT03241017	IDA-D	Durvalumab in DLBCL After Autologous Transplant	P2	withdrawn	0	Insel Gruppe AG, University Hospital Bern	Oct 2017
NCT02520453		Adjuvant Durvalumab for Esophageal Cancer	P2	unknown	86	Samsung Medical Center	Feb 2016
NCT03102047	MEDI4736	Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer	P2	completed	45	NSABP Foundation Inc	May 2018
NCT03377400		Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer	P2	unknown	40	Samsung Medical Center	Dec 2017
NCT02775903	MEDI4736	An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)	P2	completed	213	Celgene	Jun 2016
NCT03585998		Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer	P2	unknown	51	Samsung Medical Center	Jun 2018
NCT03963414		A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC	P1	terminated	1	University of Nebraska	Sep 2020
NCT03829007	PINCH	PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC	P1/P2	completed	33	Radboud University Medical Center	Apr 2019
NCT03608865	MEDI4736	Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing	P2	completed	30	Yonsei University	Sep 2017
NCT03496519	MEDI4736	Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors	P1	withdrawn	0	University of Colorado, Denver	Oct 2018
NCT03164772		Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC	P1/P2	completed	61	Ludwig Institute for Cancer Research	Dec 2017
NCT03267589		Trial in Patients With Relapsed Ovarian Cancer	P2	completed	25	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	May 2018
NCT04262869		Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer	P2	withdrawn	0	Emory University	Mar 2020
NCT02901548	BCG	Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder	P2	terminated	17	H. Lee Moffitt Cancer Center and Research Institute	Feb 2017
NCT03323398		Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies	P1/P2	terminated	79	ModernaTX, Inc.	Aug 2017
NCT03773666	BLASST-2	A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)	P1	completed	12	Dana-Farber Cancer Institute	Feb 2019
NCT03054532		Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma	P2	unknown	22	Singapore General Hospital	Jul 2017
NCT02563925		Brain Irradiation and Tremelimumab in Metastatic Breast Cancer	N/A	completed	28	Memorial Sloan Kettering Cancer Center	Sep 2015
NCT02336165	MEDI4736	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	P2	completed	159	Ludwig Institute for Cancer Research	Feb 2015
NCT01975831		A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab	P1	completed	104	Ludwig Institute for Cancer Research	Dec 2013
NCT02431559		Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer	P1/P2	completed	53	Ludwig Institute for Cancer Research	Dec 2015
NCT02639065	MEDI4736	A Study of Durvalumab (MEDI4736) in Esophageal Cancer	P2	completed	39	Shadia Jalal, MD	Apr 2016
NCT04470674		Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients	P2	withdrawn	0	Shirish M Gadgeel	Apr 2021
NCT06446570	MEDI4736	Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma	P2	completed	18	Seoul National University Hospital	Sep 2017
NCT04444193	Dulect2020-2	Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma	N/A	unknown	20	Shanghai First Maternity and Infant Hospital	Aug 2020
NCT03899610	KGOG3046	A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)	P2	unknown	24	Yonsei University	Jul 2019
NCT02706405		JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	P1	terminated	30	Fred Hutchinson Cancer Center	Nov 2016
NCT03122509		A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer	P2	completed	25	Memorial Sloan Kettering Cancer Center	Apr 2017
NCT03204812		Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	P2	completed	31	M.D. Anderson Cancer Center	Jul 2017
NCT04001413		Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients	P2	withdrawn	0	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Sep 2019
NCT03162224	HPV	Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer	P1/P2	completed	35	MedImmune LLC	Jun 2017
NCT03144778		Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer	P1	completed	39	M.D. Anderson Cancer Center	Jul 2017
NCT04579133		Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy	P2	terminated	140	Latin American Cooperative Oncology Group	Mar 2021
NCT03665129	STELLAR-001	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	P1	terminated	73	Innate Pharma	Sep 2018
NCT03430895	MEDI4736	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract	P2	completed	15	Memorial Sloan Kettering Cancer Center	Jan 2018
NCT03721679		Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1	P1/P2	terminated	7	Oncovir, Inc.	Sep 2018
NCT02764333		TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer	P2	completed	29	Memorial Sloan Kettering Cancer Center	May 2016
NCT03794544		Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer	P2	completed	84	MedImmune LLC	Mar 2019
NCT03874325		Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer	P2	terminated	17	H. Lee Moffitt Cancer Center and Research Institute	Apr 2019
NCT04088032		Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer	Early P1	withdrawn	0	Alison Stopeck	Oct 2019
NCT02311361		Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer	P1/P2	completed	65	National Cancer Institute (NCI)	Mar 2015
NCT03283943		PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.	P1	unknown	22	British Columbia Cancer Agency	Apr 2018
NCT03878524	SMMART	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	P1	terminated	2	OHSU Knight Cancer Institute	Apr 2020
NCT02725489		Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers	P2	completed	13	Mary Crowley Medical Research Center	Jun 2016
NCT02978482	MEDI4736	A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies	P1	completed	26	AstraZeneca	Dec 2016
NCT03238027		A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors	P1	completed	45	Syndax Pharmaceuticals	Sep 2017
NCT03544125		Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer	P1	completed	3	OHSU Knight Cancer Institute	May 2018
NCT02762006		Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma	P1	completed	29	Moshe Ornstein	Dec 2016
NCT03685344		Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma	P1	terminated	13	ADC Therapeutics S.A.	Feb 2019
NCT02766335		Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers	P2/P3	completed	116	SWOG Cancer Research Network	Jul 2014
NCT02997995	ULTIMATE	Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure	P2	completed	61	UNICANCER	Feb 2017
NCT02701400		Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer	P2	completed	18	Emory University	Apr 2016
NCT02811497	METADUR	Study of Azacitidine and Durvalumab in Advanced Solid Tumors	P2	completed	28	University Health Network, Toronto	Sep 2016
NCT03490760		Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas	P2	terminated	9	Baptist Health South Florida	Nov 2018
NCT03275597	SBRT	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition	P1	terminated	17	University of Wisconsin, Madison	Feb 2018
NCT03196401		A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma	P1	withdrawn	0	Memorial Sloan Kettering Cancer Center	Jul 2017
NCT03089645		MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.	P1	completed	39	MedImmune LLC	Mar 2017
NCT02794883		Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma	P2	completed	36	Northwestern University	Nov 2016
NCT03234153	NITIMIB	Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin	P2	terminated	6	Insel Gruppe AG, University Hospital Bern	Jul 2018
NCT02628132		Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients	P1/P2	completed	22	King Faisal Specialist Hospital & Research Center	Nov 2016
NCT02118337	AMP-514	A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies	P1/P2	completed	97	MedImmune LLC	May 2014
NCT03534492	NEODURVARIB	Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)	P2	completed	29	Spanish Oncology Genito-Urinary Group	Nov 2018
NCT03430518		Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer	P1	completed	9	Amy Tiersten	May 2018
NCT02900157		Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors	P1	completed	42	MedImmune LLC	Aug 2016
NCT02882308	OPHELIA	Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.	P2	completed	41	Hellenic Cooperative Oncology Group	Oct 2016
NCT02777710	MEDIPLEX	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers	P1	completed	48	Centre Leon Berard	Jun 2016
NCT02805660		Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC	P1/P2	terminated	83	Mirati Therapeutics Inc.	Jun 2016
NCT03081923	APACHE	Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors	P2	terminated	36	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Feb 2017
NCT03022500		Pulmonary sarcomatoid_MEDI4736+Treme	P2	completed	32	Seoul National University Hospital	May 2017
NCT03005002		Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver	P1	completed	9	City of Hope Medical Center	Jun 2017
NCT02658214		Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors	P1	completed	32	AstraZeneca	Apr 2016
NCT02649686		Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab	P1	completed	15	Canadian Cancer Trials Group	May 2016
NCT03030131	IONESCO	Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer	P2	terminated	50	Intergroupe Francophone de Cancerologie Thoracique	Jan 2017
NCT03007407		Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy	P2	completed	33	NSABP Foundation Inc	Jul 2017
NCT02705482		A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors	P1	completed	58	MedImmune LLC	Mar 2016
NCT02802098		Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer	Early P1	completed	25	Centro Nacional de Investigaciones Oncologicas CARLOS III	May 2016
NCT02452463		Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy	P2	terminated	8	Roswell Park Cancer Institute	Jun 2015
NCT04115111	Diadem	Diadem to Investigate the Activity and Safety of Durvalumab	P2	completed	57	Mario Negri Institute for Pharmacological Research	Oct 2018
NCT02734160	LY2157299	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	P1	completed	37	Eli Lilly and Company	Jun 2016
NCT03394144		Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies	P1	completed	11	AstraZeneca	Jan 2018
NCT03038477		A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection	P2	withdrawn	0	University of Colorado, Denver	Jun 2017
NCT02718911		A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors	P1	completed	72	Eli Lilly and Company	Jun 2016
NCT03085849		SGI-110 Plus Durvalumab/Tremelimumab in SCLC	P1	completed	2	Catherine Shu	Dec 2017
NCT02556463		A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors	P1	terminated	53	MedImmune LLC	Nov 2015
NCT02673814		Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer	P2	withdrawn	0	Peregrine Pharmaceuticals	Feb 2016
NCT02027961		Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone	P1	completed	68	MedImmune LLC	Dec 2013
NCT02301130		Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors	P1	completed	64	Kyowa Kirin, Inc.	Nov 2014
NCT02716805		Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant	P1	terminated	6	Ludwig Institute for Cancer Research	Dec 2016
NCT02993991	PRIMED-001	Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity	P1	withdrawn	0	University Health Network, Toronto	Oct 2017
NCT03000452	FUSION-MM-005	A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)	P2	completed	18	Celgene	Mar 2017
NCT03130764		Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC	P2	withdrawn	0	Columbia University	Mar 2017
NCT02737072		A Study of LY2510924 and Durvalumab in Participants With Solid Tumors	P1	terminated	9	Eli Lilly and Company	Sep 2016
NCT02403271		A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors	P1/P2	completed	124	Pharmacyclics LLC.	Mar 2015
NCT02898116		Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer	P1/P2	completed	2	Ludwig Institute for Cancer Research	May 2017
NCT02871323		Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis	P1	withdrawn	0	Northwestern University	Nov 2016
NCT02205333	MEDI6469	A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies	P1/P2	terminated	48	MedImmune LLC	Aug 2014

Durvalumab clinical trials: frequently asked questions

How many Durvalumab clinical trials are there?: 732 Durvalumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 162 are actively recruiting participants. 189 are marked completed.
Are Durvalumab clinical trials recruiting in 2026?: Yes — 162 Durvalumab trials are actively recruiting in 2026, with 2298 U.S. sites across 49 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Durvalumab being studied for?: Durvalumab is being studied for Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Lung Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung and 1041 more. The trials are grouped by indication on this page.
What phase is Durvalumab in?: Durvalumab clinical trials span 5 Phase 4, 84 Phase 3, 397 Phase 2, 117 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Durvalumab clinical trials?: The lead sponsor across the most Durvalumab trials is AstraZeneca, with 303 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Durvalumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Durvalumab overview Durvalumab evidence & publications